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 Biomedical researchers, government agencies, and the pharmaceutical 
industry increasingly use the term metabolic syndrome to define the observed co-
occurrence of the major biological risk markers for heart disease, type II diabetes, and 
stroke. The metabolic syndrome is a new feature in what I call the politics of 
metabolism, or the discourses, social processes, and institutional relationships that 
governs the metabolism of individuals and groups.  The emergence of the metabolic 
syndrome reflects a growing network of scientific, state, and corporate actors and 
institutions that are invested in studying, regulating, and profiting from control over 
metabolism.  Drawing on insights from critical race theory, science and technology 
studies, and Foucauldian studies of biopower, I analyze the metabolic syndrome as a 
new discourse about metabolism that continually draws upon racial meanings to 
construct individual and group differences in different kinds of metabolic risk.    
  
 The metabolic syndrome not only constitutes a new way of constructing, 
studying, and treating metabolic health problems, it also constitutes an emerging site 
for the production of racial meanings.  Researchers use race in metabolic syndrome 
research and to study, prescribe, and label prescription drugs that may be related to 
the metabolic syndrome.  I investigate the use of race and the metabolic syndrome in 
biomedical research on prescription drugs and African Americans. I develop the 
metaphor of killer applications to examine how prescription drugs operate in the 
politics of metabolism.  A killer application is a superior technology that combines 
human and non-human elements that structure bodily practices in a wide range of 
social, commercial, and scientific contexts—prescription drugs have become the new 
killer applications in biomedicine.  I argue that the search for killer applications has 
transformed the ways that pharmaceutical corporations study prescription drugs, 
metabolism, and race.  I compare how drug researchers use race and the metabolic 
syndrome to study antipsychotics and statins in African Americans, how physicians’ 
race-based diagnoses of schizophrenia and high cholesterol structure the prescribing 
patterns of antipsychotics and statins, and how scientists’ assumptions about the 
genetic basis of racial differences in drug metabolism structure the debate about race-
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Chapter 1: Introduction 
 According to the National Library of Medicine, the central library of the 
National Institutes of Health (NIH), metabolism encompasses all the physical and 
chemical processes within the body that create and use energy.1  While metabolism 
encompasses a litany of bodily processes that are linked to the development of poor 
health, a particular cadre of metabolic problems has increasingly assumed a new 
spotlight in the biomedical research community.  Heart disease, type II diabetes, and 
obesity have all become predominant health problems and constitute the leading 
causes of death in the contemporary United States.   
 An expanding set of descriptions connects these problems of human 
metabolism to the social and economic conditions of modernity, like increasing 
leisure time and more widespread economic prosperity.  Some have called these 
metabolic conditions diseases of comfort, referring to the observation that these 
conditions are increasingly prevalent among the populations of Western nations that 
enjoy an overabundance of food and leisure (Choi, Hunter, Tsou, and Sainsbury 
2005).   Others have called these conditions diseases of affluence, a label that 
emphasizes the positive statistical correlations between social class and metabolic 
illness (Ezzati, Vander Hoorn, Lawes, Leach, James, Lopez, Rodgers, and Murray 
2005).   This shift from infectious and communicable diseases to chronic metabolic 
conditions as leading causes of death has been called “the epidemiologic transition” 
(Olshansky and Ault 1986; Omran 1971; Omran 2005).  
 Since 1956 biomedical researchers, government agencies, and the 




describe the observed co-morbidity of metabolic conditions linked to heart disease, 
diabetes, and obesity.2 The metabolic syndrome is metabolic because it concerns the 
biological processes by which bodies metabolize nutrients derived from food and 
describes these processes in terms of physiological or biochemical indicators of 
disease processes that are measured at the level of an individual’s 
biology/biochemistry.  Specifically, the metabolic syndrome is comprised of so-called 
abnormal levels of several clinical and laboratory measurements that represent the 
development of metabolic health problems: elevated blood pressure, elevated 
cholesterol, elevated blood sugar, and elevated weight.  Elevated blood pressure, or 
hypertension, is defined as having systolic pressure of at least 140 mmHg and 
diastolic pressure of at least 90 mmHg. Elevated cholesterol, or dyslipidemia, is 
defined as having total serum cholesterol higher than 240. Elevated blood sugar, or 
hyperglycemia, is defined as having fasting blood glucose of at least 126 mg/dL.  
Elevated weight, or obesity, is defined as having a body mass index (BMI) greater 
than 30.    
 The metabolic syndrome is a syndrome precisely because it is an aggregation 
of clinical and laboratory measurements that has not yet reached designation as a 
disease (Hall et al 2003:414).  The metabolic syndrome represents the collection of 
measurements of hypertension, dyslipidemia, hyperglycemia, and obesity, each of 
which biomedical researchers and epidemiologists have identified as major so-called 
risk factors for heart disease, diabetes, and stroke.  According to an analysis of the 
1988-1994 National Health and Nutrition Examination Survey (NHANES), a 




of 4 (23.7%), over 60 million people, could potentially be classified with the 
metabolic syndrome (Ford, Giles, and Dietz 2002).3 
 The fact that high proportions of Americans can be classified with the 
metabolic syndrome has helped to establish a context where a range of biomedical, 
government, and corporate social actors has taken up the metabolic syndrome in their 
programs and protocols.   For example, in 2000, an iteration of the metabolic 
syndrome (then named dysmetabolic syndrome X) was given a diagnostic code in the 
World Health Organization’s International Classification of Disease (ICD-9).  In 
2002, a group of biomedical researchers started The Metabolic Syndrome Institute, an 
independent and not-for-profit organization that is the first organization dedicated to 
the dissemination of knowledge about the metabolic syndrome.4   In 2003, a new 
academic journal was established to publish research articles specifically on the 
metabolic syndrome (Metabolic Syndrome and Related Disorders).  The metabolic 
syndrome is also the subject of numerous medical books and monographs intended 
for the lay public (Reaven, Strom, and Fox 2000), physicians (Grundy 2005), mental 
health professionals (Mendelson 2008), and animal and biomedical researchers 
(Hansen and Bray 2008). 
 The metabolic syndrome is a discursive formation whose meanings and 
applications vary widely across biomedical, political, and commercial contexts.  
Foucault defines a discursive formation as a series of regularities or patterns in 
statements in terms of the objects to which they refer, the concepts used, and the 
thematic choices that circumscribe them over time (Foucault 1972, p. 38).  While 




research on the metabolic syndrome began to accelerate in the 1990s and into the 
millennium for a host of reasons I will explore in this study.  The volume of 
published biomedical research literature on the metabolic syndrome is substantial and 
the rate of new publications has steadily increased in recent years.5  In 1989, as Figure 
1.1 shows, there was only one article published on the metabolic syndrome.  
However, by 2008, 2,613 articles were published on the metabolic syndrome, 
representing a two thousand percent increase in publications over a 20-year time 
period.   
 
[Figure 1.1 The number of scientific studies published on the metabolic syndrome, 
1989-2008]. 
 
Despite the increasing visibility of the metabolic syndrome, it would be a mistake to 
assume that the name, definition, and purpose of the syndrome have been consistent 
within this exponentially growing body of biomedical literature.    
 Scientists from across biomedicine, the government, and pharmaceutical 
corporations are using the discourse of metabolic syndrome as a new way to describe 
and respond to the increasing challenge that having multiple chronic metabolic 
conditions presents to Americans’ health.  Using widely accepted statistical 
techniques like factor analysis and linear regression, biomedical researchers have 
correlated the metabolic syndrome with an impressive and sobering array of health 
conditions including stroke, kidney failure6, polycystic ovarian syndrome7, cancer8, 




the metabolic processes that encompass the metabolic syndrome unfold via every 
biological system of the body.   Cardiologists and endocrinologists use the syndrome 
as a statistical predictor of who is most likely to develop heart disease and type II 
diabetes.11  Psychiatrists and mental health researchers have noted the associations 
between the metabolic syndrome and mental disorders, like schizophrenia, bipolar 
disorder, and depression.12   
In addition to biomedical researchers, government institutions that conduct 
and regulate biomedical research, such as the National Institutes of Health and the 
Food and Drug Administration, have also focused on the metabolic syndrome.  In 
2001, the National Cholesterol Education Program (NCEP) of the National Institute 
of Heart, Lung, and Blood Disorders (NHLBI), one of the National Institutes of 
Health, defined the metabolic syndrome as a potential target of biomedical 
intervention in its landmark guidelines on how to address the problem of high 
cholesterol among Americans.13  The federal government also coordinates clinical 
trials for prescription drugs that might be associated with the metabolic syndrome.   A 
search of the clinicaltrials.gov website that solicits research subjects for federally 
regulated clinical trials and found 180 studies that list the metabolic syndrome as a 
condition under study.  Twenty percent of these trials (36 studies) are funded by 
pharmecutical industry; the federal government is the sponsor of the remaining 150 
studies.  Figure 1.2 shows a geopolitical map of these studies. The vast majority of 





[Insert Figure 1.2 Global map of clinical trials recruiting for the metabolic syndrome, 
April 2009] 
 
Ninety percent of the global market for prescription drugs is in the United States, 
Europe, and Japan.  However, given the deepening global recession, patented 
prescription drug sales are at 30-year lows (adjusted for inflation) due to the 
increasing market share of generic medications, slower FDA approval processes, and 
fewer blockbuster drugs.14    
In this context, pharmaceutical corporations are interested in developing 
prescription drugs that could be sold to people who might be classified with the 
metabolic syndrome.  Indeed, the health problems encapsulated by the metabolic 
syndrome currently account for one fifth of health care spending in the United States 
and much of that money is spent on prescription drugs.  In 2005, Americans spent 
$200.3 billion dollars on prescription drugs, five times more than they spent in 1990 
(KFF 2007).  In 2004, four of the ten most dispensed prescriptions manage 
hypertension or dyslipidemia, two core components of the metabolic syndrome (KFF 
2007).15  For example, Lipitor and Zocor, which manage hypertension and high blood 
pressure, respectively, were the two biggest prescription drugs sold in 2004, bringing 
in $7.7 and $4.6 billion in sales.  Any prescription drugs that treat hypertension, 
dyslipidemia, hyperglycemia, and obesity are all potentially useful in treating patients 





The Politics of Metabolism 
 Collectively, these increases in biomedical, government, and pharmaceutical 
attention on the metabolic syndrome reflect a growing apparatus of scientific, 
government, and corporate actors and institutions that are deeply invested in studying, 
regulating, and profiting from problems associated with metabolism.  French social 
philosopher Michel Foucault defined the apparatus as the heterogeneous network of 
power and knowledge that can be established between discourses (including 
scientific, philosophic, moral, and philanthropic statements), institutions, structural 
arrangements, policy decisions, laws, and administrative measures (Rabinow and 
Rose 2003).  An apparatus forms as a strategic response to a specific scientific 
discovery, political crisis, or economic opportunity (Rabinow and Rose in Foucault 
2003: xvi).   
 In this context, the metabolic syndrome is a new discourse in the apparatus I 
call the politics of metabolism, which I define as the discourses, social processes, and 
institutional relationships that govern the metabolic health of individuals and groups.  
These relationships operate on several different levels of analysis.  At the macro 
level, big social institutions like government health research institutions, 
pharmaceutical corporations, and professional medical doctors represent the three 
groups of social actors who are produce discourses of the metabolic syndrome and 
race.  At the micro level, these discourses, technologies, and practices operate at the 





The Metabolic Syndrome and Race in the Politics of Metabolism 
The metabolic syndrome not only constitutes a new way of constructing, 
studying, and treating human metabolism, it may also constitute an emerging site for 
the construction of new racial meanings in the politics of metabolism.   Specifically, 
the metabolic syndrome may draw upon and extend knowledge-making practices that 
have long constructed race as natural, biological, and genetic.   In the contemporary 
politics of metabolism, the metabolic syndrome draws upon and extends scientific 
practices that have long used race to categorize individuals into groups.  To document 
and understand the relationships between the metabolic syndrome and race, and to 
analyze the racial meanings produced through the science of the metabolic syndrome, 
this study focuses on the use of racial and ethnic categories in metabolic syndrome 
research and research on prescription drugs that may be related to the metabolic 
syndrome.  
The first set of relationships that might link the metabolic syndrome to race 
concern the specific constructions of race, and relatedly, ethnicity, that are used in 
metabolic syndrome research.  Race and ethnicity are both socially constructed 
systems of categorization that are used to identify, group, and rank human beings, 
albeit based on different criteria.  Race is a socially constructed category that emerged 
in the 1700s to classify individuals into so-called races based on presumed biological 
differences between population groups.  Ethnicity is a socially constructed category 
that emerged in the 1920 to classify individuals into so-called ethnic groups based on 
presumed differences in culture, geographic origin, and ancestry.  Race and ethnicity 




notions of race.  Given this historical relationship, race and ethnicity are not 
interchangeable systems of categorization.  However, there is meaningful overlap 
between what are considered racial and ethnic groups.   For example, African 
Americans are considered to be both a racial and an ethnic group.    Race and 
ethnicity are both controversial systems of categorization especially in the context of 
biomedical research because individual biological and genetic differences do not fall 
neatly along racial and ethnic lines.  In other words, despite their shared origins in 
response to biological interpretations of individual and group differences, race and 
ethnicity are social constructions.   
Because of historical and current federal research policies that regulate 
demographic data collection, statistical information about a research subject’s race 
and/or ethnicity is routinely collected along with anthropomorphic, molecular, and 
genetic information about a subject’s metabolism.16  Therefore, the sampling frame, 
analytic strategy, and research findings of metabolic syndrome research studies are 
often framed using these racial and ethnic categories.  In this regulated scientific 
environment, it is also common to see published review articles that are focused 
exclusively on particular racial and ethnic minority groups.17  In this context, many 
researchers also frame their research on OMB racial groups as ethnic instead 
seemingly to avoid talking explicitly about race in ways that could be interpreted as 
racial bias, or worse, scientific racism.  
 A second set of relationships that might link the metabolic syndrome to race 
concern the use of race to study, prescribe, and label drugs that may be related to the 




individuals who seemingly have the metabolic syndrome in their clinical research. 
For example, the African American Rosuvastatin Investigation and Efficacy Study 
(or, ARIES Study) investigated the ability of Crestor, a powerful new member of the 
statin class, to lower both blood pressure and cholesterol in a self-identified African 
American population (Flack, Victor, Watson, Ferdinand, Saunders, Tarasenko, 
Jamieson, Shi, and Bruschi 2008).   A second recent study, the Clinical Utility of 
Caduet in Simultaneously Achieving Blood Pressure and Lipid Endpoints in a 
Specific Patient Population (or, CAPABLE Study) investigated whether Caduet, a 
combination of two drugs Lipitor and Norvasc, was effective at lowering African 
Americans’ blood pressure and cholesterol (Flack et al. 2008).  Both of these 
prescription drug studies were conducted in a manner similar to the way that African 
Americans were targeted in the research and marketing of BiDil, an anti-hypertensive 
medication that is the first drug approved by the FDA for specific use in a specific so-
called ethnic group: African Americans (Duster 2005; Kahn 2006; Sankar and Kahn 
2005).  Yet, coupled with recent research findings that suggest that members of 
racially and ethnically categorized groups might require different medications, 
dosages, and routes of administration of prescription drugs trials and because of new 
federal guidelines about the inclusion of racial and ethnic minorities in clinical trials, 
this research has a new racial dimension.19 
 Through these practices, the metabolic syndrome may have become a new 
discursive tool used to produce new meanings of race in the politics of metabolism.  
The overarching theoretical challenge of understanding the possible linkages between 




called a polyvalent manner.  Foucault used the term polyvalence to describe how 
discourses can be used as both a technique and an outcome of power (Foucault 1978: 
101-102).  For example, laws are both produced by and constitute state power.  In 
other words, discourse is not only the documented effect of power relations, as in the 
case of the legal discourse that is produced by the state (discourse as an effect of 
power), discourse can also be used to mark its own material effects on bodies 
themselves by virtue of an existing set of power relations (discourse as a technique of 
power). Understood in this context of polyvalence, discourses establish the scientific 
knowledges that are used to justify unequal power arrangements.  In turn, these 
arrangements structure the production and content of scientific knowledge.   
 Therefore, this study explores how the metabolic syndrome and race may 
operate together as polyvalent forms of power and knowledge in the politics of 
metabolism.  Three questions guide the study.  First, how did the metabolic syndrome 
emerge as a new discursive formation in the politics of metabolism?  Second, how are 
current conceptions and meanings of race constructed through the discourses of the 
metabolic syndrome?  Third, what are the implications of this emerging relationship 
between the metabolic syndrome and race for understanding the construction of racial 
meanings in the politics of metabolism?  
 
Research Methods: Genealogy and Discourse Analysis 
Foucault’s genealogy serves as the central methodology for this study of the 
relationship between current constructions and practices of race and the emergence of 




syndrome and race in the United States.   I ground my articulation and execution of 
genealogy based upon what Foucault wrote in books, essays, and lectures, as well as 
secondary interpretations of key Foucauldian scholars.20  One of the main practical 
challenges of executing this study was how to transform the seemingly obtuse method 
of genealogy into a set of procedures that I could follow consistently to analyze 
different kinds of documents and construct a critical narrative that challenge the 
relationships between the metabolic syndrome and race.   Any reasonable 
interpretation of genealogy is complicated by the fact that Foucault never codified 
specifically how he believed genealogies ought to be carried out in various 
disciplines, and when he did state his method in recognizable terms, these definitions 
shifted over time in various contexts. Indeed, Foucault was not forthcoming with a 
codified checklist of procedures a researcher might follow to conduct a genealogy, 
and since his death, his interpreters have continued to struggled to do the same.21  To 
this point, leading Foucault scholars Nikolas Rose and Paul Rabinow argue that the 
methodological construct of genealogy might need to be re-imagined through the 
lenses of comparative or ethnographic research methods, depending on how social 
arrangements unfold in the contemporary moment (Rabinow and Rose 2003).  
Despite the spirited debates about Foucault’s codification of a genealogical method, 
and disagreement about how these methods ought to be deployed, this study attempts 
to utilize a grounded interpretation of what genealogy entails. 
Genealogy is a historical methodology that traces the emergence and descent 
of technologies and practices used to produce discourses about the body and the 




natural and universal.  Genealogy is also a form of political critique that diagnoses 
how such discourses, practices, and technologies are embedded in and rationalize 
unequal power arrangements.   The intellectual and political intent of genealogy, 
therefore, is to contest discourses that are used to instantiate, enable, and support 
repressive and/or productive forms of modern social power by showing how those 
discourses have determined (in a limited way) what constitutes our present 
understanding of ourselves, our social world and the social relationships therein.   It is 
in this sense that Foucault and others have referred to genealogy as a “history of the 
present.”  There are two intertwined analyses that comprise genealogy, namely, the 
analyses of descent and emergence.  Because the analyses of descent and emergence 
helped me specify the data sources that I analyze with discourse analysis, I will 
briefly summarize these important components of the genealogical method. 
 
The analysis of descent and emergence 
 The analysis of descent documents the heterogeneous sites of knowledge 
production by tracing the actual research techniques and procedures used in scientific 
practice (Foucault 2003 [1971]; Foucault 2003 [1976]; May 1993).  The analysis of 
descent shows how these techniques and procedures structure what kinds of scientific 
practices are acceptable and how social arrangements shape the production of 
scientific knowledge (Foucault 2003 [1978]).22   In this Foucauldian sense, practices 
can be defined as “places where what is said and what is done, rules imposed and 
reasons given, the planned and the taken-for-granted meet and interconnect” 




where the objects of genealogical analysis are inscribed by particular constellations of 
discourses, techniques, and practices.   
 However, in contrast to a more conventional form of historiography that might 
produce a linear and modern history of these technologies and practices, the analysis 
of descent highlights what I call the disjunctures that are central to the inscription of 
power/knowledge relationships.  A disjuncture is an accident, error, shift, or deviation 
that challenges the assumption that historical events are homogeneous and represent 
self-evident truths.   Disjunctures represent distinctive moments where the structure 
of discursive possibilities either opens up or contracts depending on the particular 
configuration of the field of power and knowledge in play in that moment.   
Foucault’s approach to analyzing the disjunctures of modern history is directly linked 
to one of the central epistemological aims of genealogy; namely, to challenge self-
evident discourses and practices that justify unequal social arrangements.   Foucault 
worked to carry out this aim without resorting to presentism, which Foucault 
interpreter Mitchell Dean defines as “the unwitting projection of a structure of 
interpretation that arises from the historian’s own experience or context onto aspect of 
the past under study” (Dean 1994: 28).  Based on this understanding, I use the 
construct of disjunctures to work against the notion that this study is a modern history 
of ideas and to highlight the multiple open-ended processes that undergird the 
production of the metabolic syndrome and race as taken-for-granted truths.   
 In conjunction with the analysis of descent, the analysis of emergence situates 
the emergence of a practice or discourse within in a broader network of institutionally 




emergence should avoid describing the causes, motives, or perceived intent of a given 
social practice as self-evident, natural, and universal.  To the contrary, practices can 
emerge in multiple sites of power, can take radically different forms in different 
historical moments, and do not result from one unitary cause.  For example, drawing 
upon an analysis of Foucault’s The Birth of the Clinic: An Archeology of Medical 
Perception (1975), Foucauldian scholar Todd May (2003) argues that it was not 
always self-evident that individual bodies required examination to determine the 
cause of illness.  May argues that genealogy challenges three epistemological 
assumptions about the search for the emergence of a discourse or practice.  The first 
assumption that genealogy challenges is that there is an essence behind a discourse or 
practice of interest, that there is “a being behind the becoming” (May 2003: 74).   The 
second assumption is that the beginning of a discourse or practice is a highly visible 
social production when they are just as likely to be hidden from plain sight.  Third, 
the concept of origins assumes a foundational notion of truth, that the origin is the 
“pristine instant” or “moment of pure communication [of a discourse or practice] with 
itself” (p. 74) (May 1993)  Thus, this analysis recognizes that social practices are 
historically structured in a multiplicity of institutional and discursive contexts and 
that no single institution or individual is ever solely responsible for the emergence of 
a practice or discourse.   
 Foucault’s treatment of the body illustrates these dual concepts of descent and 
emergence.  For instance, again in The Birth of the Clinic: An Archeology of Medical 
Perception (1975), Foucault argued that the surveillance of the body was historically 




sought to rationalize the space-time between life and death by classifying and 
organizing the body scientifically (Foucault 1975b).   Foucault argued that 
genealogies should make an ascending analysis of power that traces the descent and 
emergence of the technologies used in the scientific study of the body and the social 
regulations of institutional power (Foucault 2003[1976]: 30).  In this way, the 
analysis of descent should reveal how the body itself becomes inscribed through the 
production of discourses that are produced in service of power arrangements 
(Foucault 2003 [1971]).  In other words, Foucault believed that the body was the 
canvas upon which power paints history.  The analysis of emergence investigates 
what Foucault called the hazardous play of dominations, which represents the 
practices, theories, and regulations of social institutions that impose various rights, 
obligations, and practices on the body (Foucault 2003 [1971]).  Taken together, these 
components of genealogy examine the polyvalent ways in which the body, the spaces 
around it, and the materials inside of it became both the object of knowledge and 
subject to new forms of social power. 
 Understanding the politics of metabolism requires a methodological 
framework that can analyze the relationships between power and knowledge, which I 
believe lies at the heart of my core questions about the metabolic syndrome and race.  
I have selected this method because I see genealogy as a necessary methodological 
alternative to conducting a standard quantitative analysis of racial health inequality 
and the metabolic syndrome that often aims to produce truth claims about the 
metabolic syndrome and race.  In contrast, a genealogical account of the relationships 




any so-called scientific hypotheses about the metabolic syndrome and race.   Rather, a 
genealogical account would examine the social structures of power and knowledge 
that made it epistemologically possible for biomedical scientists to produce scientific 
claims about the metabolic syndrome and race in the first instance.  
 
Discourse analysis 
 Drawing on this notion of genealogy as a form of social historiography and 
political critique, I also rely heavily on the tools of discourse analysis as a method for 
analyzing my documents.24  Rather than only analyzing the meaning of a discourse, 
discourse analysis also analyzes the structure of the discursive themes by which a 
particular discourse is produced.  Specifically, discourse analysis asks three core 
questions about the production of discourses: (1) who produced the discourses and 
with what resources? (2) Under what political, economic, and historical conditions 
were the discourses produced? (3) How are the meanings of the discourse shaped by 
these economic, political, and historical conditions?  Thus, my discourse analysis 
aims to interpret how the discourse of metabolic syndrome emerged in ways that 
draw upon constructions of race in service of producing new meanings of race.  I 
analyze the explicit and implicit assumptions about race that structured the 
discourses, practices, and technologies of the metabolic syndrome.    




Data sources and procedures 
The methods of genealogy and discourse analysis bring into focus the types of 
documentary evidence required to analyze the relationships between race and the 
metabolic syndrome.  Each of these documents contains specific information about 
the discourses, techniques, and practices used in the scientific study of the body.   
This study analyzes three types of documents: (a) published research, commentaries, 
and editorials on the metabolic syndrome and race in professional and academic 
biomedical journals; (b) corporate documents from pharmaceutical companies 
including yearly reports, regulatory submissions to the FDA, and clinical trial 
documentation; and (c) government documents including NIH and FDA regulatory 
guidelines on the collection of data on race and ethnicity in U.S. biomedical research 
and clinical trials, published reports and scientific documents from the NIH and its 
institutes, and other relevant government agencies.  More information on my data 
sources and procedures can be located in the Appendix. 
My data collection proceeded as follows.  I employed three basic strategies to 
traverse and circumscribe the universe of documents about the metabolic syndrome 
and race.  As I demonstrated earlier, thousands of research articles have been 
published on the metabolic syndrome, and while it was not possible to analyze all of 
the documents about the metabolic syndrome in this study, it was important to 
establish a subset of this universe of documents to analyze.  The overall purpose of 
this three-step process was to identify the primary documents that formed the 




First, I conducted extensive searches of multiple biomedical research 
databases in order to compile a comprehensive bibliography of documents pertaining 
to the metabolic syndrome and race.  Specifically, I repeatedly searched three 
prominent databases in this first strategy: (1) www.science.gov, the federal 
government’s central search engine for published scientific research both within and 
outside the purview of the government and its scientific agencies; (2) Medline and 
PubMed™ Central, the premier bibliographic databases for the National Library of 
Medicine of the National Institutes of Health; and (3) ISI Web of Science, Science 
Citation Index.  
A second strategy was to use the ISI Web of Science cited citations index to 
conduct citation counts on the published documents I found on the metabolic 
syndrome and race to determine the extent to which a particular document has 
traveled and gained scientific currency throughout biomedicine.  I employed this 
strategy in the full recognition that some sites of biomedical knowledge production 
have more political and scientific influence than others.  For instance, a document 
published by one of the National Institutes of Health wields more influence than a 
document published in a relatively obscure biomedical journal that deals with a 
narrow subject matter.  When appropriate, I make reference to this information 
throughout the study.  
A third strategy was to place special emphasis on the relatively smaller 
number of government and corporate documents pertaining to the metabolic 
syndrome and race.  The fact that governments and corporations publish documents 




institutional relationships between social power and biomedical knowledge that have 
converged around the metabolic syndrome and race.   
 
Organization of the Study  
 
  Recall the three questions guide the study.  First, how did the metabolic 
syndrome emerge as a new discursive formation in the politics of metabolism?  
Second, how are current conceptions and meanings of race constructed through the 
discourses of the metabolic syndrome?  Third, what are the implications of this 
emerging relationship between the metabolic syndrome and race for understanding 
the construction of racial meanings in the politics of metabolism?   
 To investigate these questions, this study proceeds as follows.   In chapter two 
(Theorizing Race, Biomedicine, and Power), I outline the theoretical frameworks that 
I use to explain the relationships between the metabolic syndrome and race by 
drawing on ideas from three bodies of scholarship: critical race theory, 
biomedicalization, and the social theory of Michel Foucault, especially his framework 
of biopower. Each of these frameworks provides a unique perspective on the 
relationships between the metabolic syndrome and race, but together they provide a 
power and nuanced interpretive framework through which to articulate a genealogy of 
the metabolic syndrome and race.   
 In chapter three (Disciplining Bodies & Regulating Populations: The Racial 
Formation of the Metabolic Syndrome), I analyze the emergence of the metabolic 
syndrome, highlighting some of what has made it controversial, and analyze some of 




race was central to the emergence of the metabolic syndrome and that the metabolic 
syndrome, in turn, serves as dynamic new site for the production of race.  This 
chapter is divided into two main sections.  In Part I, I trace the emergence of the 
metabolic syndrome across three historical periods in American biomedicine: 
Technical and Conceptual Foundations (1947-1986); From Syndrome X to 
Dysmetabolic Syndrome X  (1987-2000); and The Ascendance of the Metabolic 
Syndrome (2001-present). Each of these periods represents a distinct conceptual 
moment in the attempt to establish the metabolic syndrome as a biological clinical 
disease as a legitimate object of biomedical knowledge production.  Across these 
periods, I demonstrate that the metabolic syndrome has had several different names 
and empirical definitions that each has different implications for how the syndrome 
constructs racial meanings and explains racial inequality.  In the second part of the 
chapter, I trace the different racial meanings that are produced during the three 
conceptual periods. In some contexts, this racial production is explicit and in others it 
is implicitly woven into the everyday practice of doing biomedical science.  In Part II 
of the chapter, I trace the production of racial meaning during the three conceptual 
periods of the emergence of the metabolic syndrome: Sampling Normal Subjects, 
1956-1987; Is Race Really To Blame? 1988-2000; and The New Special Populations, 
2001-present. 
In chapter three (Killer Applications: The Racial Pharmacology of Metabolic 
Syndrome), I use the ideas developed in the preceding chapters to analyze one site of 
genealogical descent of the metabolic syndrome into biomedical research on 




interpret these two cases as part of a new racial pharmacology, or the scientific study 
of prescription drugs in racially categorized bodies and populations, that is a central 
feature of the politics of metabolism.  I divide this chapter into four sections. In the 
first section, I develop the metaphor of killer applications to examine how 
prescription drugs operate in the new racial pharmacology.  This metaphor is 
especially well suited for examining prescription drugs and for exploring the new 
ways that biotechnologies are involved in the production of racial meaning in the 
politics of metabolism.  In the third and fourth sections, I compare the different ways 
that conceptions of race (and ethnicity) and the metabolic syndrome are used in the 
racial pharmacology25 of two potential killer applications: antipsychotics and statins.  
I argue that race and the metabolic syndrome intersect in unique ways in the racial 
pharmacology of these two potential killer applications.  The case of antipsychotics 
involves the pharmacokinetic effects that “atypical” antipsychotics have on the 
development of the metabolic syndrome, explicitly in populations with schizophrenia.  
The case of statins involves the development and marketing of statins, explicitly in 
populations with high cholesterol.  
 In the concluding chapter of the study (The Politics of Metabolism), I 
summarize the study’s main interpretations, outline the implications of the study for 
critical social theory, and elaborate on the broader sociological significance of the 





















Chapter 2: Theorizing Race, Biomedicine, and Power 
  
 This study investigates the relationships between the emergence of the 
discourses and practices of the metabolic syndrome and current conceptions of race in 
the U.S.  Three questions guide this study.  First, how did the metabolic syndrome 
become a discourse and a technique for producing biomedical knowledge?  Second, 
how are current conceptions and meanings of race and racial difference forged 
through the discourses and practices of the metabolic syndrome?  Third, what are the 
implications of this emerging relationship between the metabolic syndrome and race 
for understanding the construction of racial meaning in the politics of metabolism?
 To situate these questions in a broader theoretical context, I draw upon core 
themes across three related bodies of scholarship: critical race theory, 
biomedicalization, and the social theory of Michel Foucault, especially his framework 
of biopower.  In this chapter, I first develop these frameworks to provide the 
theoretical vocabulary for the second and third chapters of this study.  Then, I 
consider how each framework sheds light on different aspects of the relationships 
between race, biomedicine, and power, which together form an important context 
through which the politics of metabolism play out in the United States.  I conclude the 
chapter by outlining some of the areas of convergence and divergence across these 
theoretical frameworks.  
The Framework of Critical Race Theory 
  Because critical race theory provides a framework for analyzing the 




racial meaning in the United States, it is important to outline some of its 
distinguishing features.   Critical race theory refers to a historical and contemporary 
body of scholarship that aims to interrogate the discourses, ideologies, and social 
structures that produce and maintain conditions of racial injustice.  At the most 
general level, critical race theories analyze how race and racism are structural 
elements of global, national, and local social organizations and in the life experiences 
of people living in racialized social orders.  In particular, critical race theories have 
analyzed how race and racism were produced as elements of social structure in earlier 
periods and continue to be reproduced through contemporary social arrangements.   
 Critical race theories understand race as a constitutive feature of global social, 
political, economic, and cultural organization since the 1600s and not as a naturalized 
system of biological essences.  Critical race theorists Michael Omi and Howard 
Winant defined race as “a concept that signifies and symbolizes sociopolitical 
conflicts and interests in reference to different types of human bodies” (Omi and 
Winant 1994: 55).   This definition reflects the centrality of the body to critical racial 
theories, because black and brown bodies have born the brunt of racism.  Race 
concepts and their accompanying racisms were used to establish colonial social 
systems (McClintock 1995; Stoler 1995), modern nation states and global political 
economies (Goldberg 2002; Omi and Winant 1994; Winant 2001), and the human 
biological sciences and medicine of the eighteenth, nineteenth, and twentieth 
centuries (Barkan 1992; Duster 2003a; Graves 2001; Reardon 2005; Stephan 1982). 
 Critical race theories understand racism as a vast and complicated system of 




political power in unjust and racially coded ways.  While some race theorists have 
examined racism as a form of maligned individual prejudice, critical race theorists 
tend to embrace a more institutional understanding of racism that aims to identify 
how racism is embedded in the racially patterned practices of social institutions 
(Bonilla-Silva 1997; Bonilla-Silva 2003; Carmichael and Hamilton 1967).  In 
examining the institutionalized aspects of racism, critical race theorists challenge the 
idea that people of color are responsible for their own oppression (Brown, Carnoy, 
Currie, Duster, Oppennheimer, Shultz, and Wellman 2003). These theories continue 
to challenge entrenched racial inequalities in health, education, criminal injustice, 
political representation, and social class (Brown et al. 2003; Guiner and Torres 2002; 
Shapiro 2004).  The body of knowledge is too broad to review in great detail here, so 
in the section that follows, I develop four central themes from critical race theory that 
inform this study.  These core themes are: 1) racial formation and racial projects; 2) 
science and medicine as sites of racial formation and racial projects; 3) scientific 
racisms and essentialisms; 4) the nation state as a sites of racial formation in the 
context of biomedical research.   
 The first core idea from critical race theory that is germane to this study is 
racial formation, which refers to the social and historical process by which racial 
categories are created, transformed, and destroyed (Omi and Winant 1994).  Racial 
formation theory emerged in the 1990s in response to contemporaneous theories of 
race that viewed race as an epiphenomenon of ethnicity, social class, and/or 
nationality.  From this perspective, interpreting the meaning of race analytically in the 




racial dimensions in social structures (Omi and Winant 1994: 57).  For example, 
analyzing race in the context of criminal justice would involve examining how the 
laws and practices of social institutions structure the unequal treatment of racially 
categorized individuals, not just comparing statistical rates of incarceration across 
groups or conducing psychological experiments to determine the inherent criminality 
of raced inmates.   Race and racism, then, must always be understood in the context 
of the institutional relationships that are brought to bear in shaping racial conflicts 
and interests.   
 In this way, the notion of racial projects is also central to racial formation 
theory because it articulates how discursive and institutional elements of race work 
together in the process of racial formation.  According to Omi and Winant (1994), a 
racial project is “simultaneously an interpretation, representation, or explanation of 
racial dynamics, and an effort to organize and distribute resources along particular 
racial lines” (Omi and Winant 1994: 56).   Racial projects combine what race means 
in a particular discursive practice and the ways in which both social structures and 
everyday experiences are racially organized based upon that meaning (Winant 2001; 
Winant 2004).    
 A second core theme of critical race theory that is germane to this study is that 
critical race theory has long recognized the centrality of science and medicine to the 
construction of racial concepts and meanings that in turn influence the practices of 
social institutions, multiple levels of society, as well as the changing meaning of race 
over time.    In other words, science and medicine are primary sites of racial 




context of science and medicine has shifted dramatically over the past 100 years.26  In 
the wake of World War I, scientific conceptions of race began to shift from the so-
called “typological view” to a population-based conception of race that has 
dominated biological theory in the post-war period (Barkan 1992; Gannett 2001).27  In 
the typological approach to race, every conceivable physical and mental characteristic 
of the human body was measured and compared across racial types, in an effort to 
validate pre-existing racial taxonomies. In a population approach to race, 
anthropomorphic, mental, and social characteristics were compared across groups 
classified into races to perform the same ideological work, to confirm the hardness 
and impermeability of racial categories.   
 The population approach to race did not replace the typological approach, nor 
did the concept of population first emerge during this period following WWII, rather 
race was increasingly conceptualized as a population phenomenon, a new way to talk 
about presumably different populations.  However, typological and population-based 
explanations of racial inequality can both draw upon essentialist understandings of 
race.   By the 1950s, the UNESCO statements on race signaled the emerging 
scientific consensus that race concepts were socially constructed and were without 
foundation in human biology or nature (Reardon 2005).  However, in contemporary 
biomedical theory and practice, racial categories are still assumed to be proxies for 
genetic or biological variation (IOM 2002).  
 A third core theme that is germane to this study is that critical race theories 
have challenged scientific racial projects that were used to create racial hierarchies 




scientific racism.   Scientific racism consists of meanings of race based on presumed 
physiological, biological, and/or genetic differences and the practices of deploying 
such ideas as explanations for racial stratification and oppression.  Scientific racism 
emerged as an ad hoc justification of colonial subjugation and slavery in the 
eighteenth century and is most easily associated with the social practices of eugenics 
and Nazi racial hygiene in the nineteenth and early-to-mid twentieth centuries.   
Racial formation theorist Howard Winant argues that scientific racism functions by 
severing the effects of racism from the causes of white capitalist supremacy by 
attributing systematic racial inequalities to the nature of things, namely, to science 
(Winant 2001: 296).  
 Critical race theories have refuted scientific racism as a racial project by 
dismantling one of its core philosophical ideas: racial essentialism.  Racial projects 
can be defined as racist if they create or reproduce structures of racial oppression 
based on essentialist understandings of race.  Racial essentialism is the assumption 
that race categories reflect some inherent hierarchical organization of human bodies 
based on essences.  Racial essentialism is the philosophical underpinning of scientific 
racism because the presumptive essential differences between bodies are 1) permanent 
and 2) cannot be caused by social forces.  Racial essentialisms disallow institutional 
explanations of racism because.  In his analysis of how European nation states used 
race to justify colonial domination and European expansion during the 19th and 20th 
centuries, philosopher of race David Theo Goldberg articulates a useful philosophical 




illustrates how different racial essentialisms operated in the context of modern 
government formation.  
 Racial naturalism is the view that racial inequalities are the outcome of natural 
law and racially subjected peoples are considered to be objective features of the 
natural environment meant for political appropriation and economic exploitation.  
Through the racial naturalism, race is the conduit for collapsing what is social and 
historical into and upon what is considered natural (Goldberg 2002).   For Goldberg, 
primitivism emerges during the mid-twentieth century as a discursive bridge for racial 
essentialisms, as the forms of racial rule began to shift from racial naturalism towards 
historicism.  As Goldberg writes, the logic of primitivism was to transform the 
subjects of colonial subjugation into idealized versions of themselves, frozen-in-time 
and taken-for-granted (Goldberg 2002: 93).28  In contrast to naturalism and 
primitivism where non-Europeans are naturally inferior, through the racial historicism, 
racially subjugated peoples are historically immature and are thus subject to the 
civilizing process that constituted Manifest Destiny. Thus, racial historicism views 
racial inequality as the outcome of history, a history guided by the hidden hand of 
Enlightenment progress and modernity, the production of the “facts” of European 
racial superiority. 
 A fourth core theme of critical race theory that is germane to this study is the 
recognition that the US government is a central site of racial formation, especially in 
terms of the knowledge production apparatuses of the government that produce and 
enforce racial classification.29   Since the taking of the first federal census in 1790, 




The 1790 census measured the numbers of “free white males” as well as the “the 
number of slaves.”30  For centuries, the standard practice was for the census taker to 
make a determination as to the racial classification of individual members of the 
population.  The federal government has employed numerous taxonomies of race in 
the Census.  In response to the changing terms and meanings of race and ethnicity 
used in federal data collection, in 1997, the Office of Management and Budget issued 
new regulations on maintaining, collecting, and presenting federal data on race and 
ethnicity in the United States. The minimum categories for data on race and ethnicity 
for Federal statistics, program administrative reporting, and civil rights compliance 
reporting are defined as follows in Table 2.1: 
 
[Insert Table 2.1. Office of Management and Budget racial and ethnic categories, 
1997] 
 
These federal regulations were intended to provide a standardized and universal 
language for defining the major population groups of the country and applies to all 
federal data collection efforts, including all clinical and biomedical research funded 
by the government (Office of Management and Budget 1997).  According to these 
regulations, the U.S. government and its agencies consider self-identification as the 
preferred means of obtaining information about an individual’s race and/or ethnicity.   
 Nonetheless, the implementation of standardized federal racial and ethnic 
categories, and the technique of self-identification, permitted the continued expansion 




Evelyn, Toigo, Banks, Pohl, Gray, Robins, and Ernat 2001; Stevens 2003).  This 
represents a substantive shift from earlier forms of racial knowledge that were 
grounded in the institutions of science and medicine.  Yet, the OMB states that its 
racial and ethnic categories were developed to represent social-political constructs, 
and are not anthropologically or scientifically based (OMB 1997).31  In other words, 
the federally mandated racial and ethnic categories are intended to be interpreted and 
applied in administrative and legal contexts, not scientific and biomedical contexts. 
 Sociologist Steve Epstein (2007) examined these and other recent changes in 
US biomedical research policies and practices in the mid-1990s regarding the 
inclusion of racial and ethnic groups and women in clinical research and trials.   
Drawing on racial formation theory, Epstein analyzes the US government’s regulation 
of racial categories in biomedical and clinical trials research.  As of 1994, the 
National Institutes of Health policy was that women and members of minority groups 
and their subpopulation must be included in all NIH-supported biomedical and 
behavioral research projects involving human subjects (NIH 1994).32  Epstein’s 
analysis raises important questions about what types of bodily difference the 
government should measure, how this measurement should be carried out, and how 
such differences should be interpreted. 
Critical race theorists have focused explicitly on illuminating and contesting 
the social, economic, and political arrangements that undergird racism as a system of 
oppression.   The core themes I have outlined provide a sense of critical race theory’s 
multiple interventions into these arrangements.  Critical race theory provides an 




with the social reproduction of race and racism, particularly in American society. As I 
have argued, critical race theory has long recognized the centrality of science and 
medicine to the construction of racial concepts and meanings that in turn influence 
the practices of social institutions.  Drawing on this critical race framework, I argue 
that the metabolic syndrome is an emerging site for the reproduction of race and 
racism in American society.  
In the next section, I turn to the framework of biomedicalization to understand 
how recent shifts within science, medicine, and technology can help to account for 
the relationships between the metabolic syndrome and race.  
 
The Framework of Biomedicalization 
The framework of biomedicalization constitutes a second important 
theoretical framework shaping this project.  Biomedicalization is a historical and 
analytic framework for understanding the series of institutional, scientific, and 
technological processes that have transformed American biomedicine on multiple 
levels of social organization, especially since the mid-1980s (Clarke, Mamo, 
Fishman, Shim, and Fosket 2003).  Whereas medicalization refers to a process 
whereby social practices, bodily processes, and bodily materials were subsumed 
under the jurisdiction of clinical medicine (Starr 1982), biomedicalization refers to 
the ways that medicalization is shaped by the powerful intersection of medicine, 
biology, and technology.   Biomedicalization has been theorized from within a 
broader interdisciplinary body of knowledge called science and technology studies 




that are especially relevant for this study: 1) technoscience; 2) molecularization; 4) 
the increased importance of risk; 5) the development of biomedical capitalism; and 6) 
stratified biomedicalization. 
The first core theme of biomedicalization is technoscience, which is a way of 
understanding these increasingly technological and biological aspects of the practice 
of medicine in the contemporary world (Haraway 1997; Latour 1987).  This framing 
of the relationship between biology and technology requires analyzing the practices 
by which scientific discourses about the body are culturally and collectively produced 
by scientists and their technologies (Haraway 1997; Jasanoff 2004; Oudshoorn 2002).  
Stated differently, bodies have to be manipulated to make them produce biomedical 
knowledge.  This bodily manipulation occurs through the use of biotechnologies such 
as diagnostic tools, screening tests, drugs, and other regulatory devices.  Thus, an 
important understanding of technoscience, and one shared by many scholars in the 
field known as science and technology studies (STS), is that biomedical scientists 
gain cultural authority and produce scientific objectivity by concealing the 
institutional practices that construct and constitute such knowledges and the unequal 
power relationships in which those practices are embedded.  
For example, in her Foucauldian-inspired archaeology of sex hormones, STS 
scholar Nelly Oudshoorn shows how cultural norms and ideas about sex difference 
shape the institutional practices that produce knowledge about masculine and 
feminine sex hormones.  Whereas once the essential nature of femininity had been 
located in specific organs especially the uterus and the ovaries, Oudshoorn argues that 




femininity increasingly became associated not with specific organs, but their 
chemical substances.   Oudshoorn argues that prescientific ideas about sex difference 
influenced the interpretation of which hormones were labeled as male and female.    
However, the social and cultural contexts in which these ideas about sex difference 
influenced knowledge production do not become part of the record of so-called 
scientific truth. The epistemology of technoscience recognizes the seamless 
relationships between biomedical technologies, their bodily applications, and the 
scientific knowledge they are used to manufacture (Oudshoorn 2002).  “Science,” 
feminist technoscience scholar Nelly Oudshoorn states plainly, “is not just words” 
(Oudshoorn 2002: 13). 
 As Oudshoorn’s work demonstrates, a second core theme of biomedicalization 
is molecularization or the emergence and dominance of scientific practices, 
technologies, and theories that conceptualize and conduct surveillance of human life 
at the molecular level (Kay 1993; Rose 2001; Shostak 2004).  Molecularization 
encompasses processes of institutional and structural reorganization, the creation and 
application of new technologies, and the production of new theoretical ideas about 
molecules and their relationship to human disease.  Beginning in the late 1800s and 
continuing to the present, molecularization was a central feature of the ways that the 
biological sciences conceptualized the body and its processes.    
 More recently, STS scholars have examined how scientists construct 
meanings of race at the molecular level.  For instance, Sara Shostak (2004) analyzes 
two trends in genomic research on racial differences in environmental health that 




toxicogenomics are measuring the effects of environmental exposures at the 
molecular level, i.e. on DNA, genes, and gene expression.  Second, scientists are 
using race to search for genetic differences that may shape individual and population 
responses to environmental exposures.   On one hand, these new molecular tools are 
viewed as enabling new strategies of disease prevention that might help to interrupt 
the process from environmental exposure to illness.  On the other hand, these 
molecular techniques might be used to create new scientific conceptions of race that 
sustain “a new era of molecularized scientific racism” (Shostak 2004: 547). 
A third core theme of biomedicalization that emerges out of a technoscientific 
approach to studying life at the molecular level is an increasing emphasis on risk in 
biomedicine.   The so called risk factor paradigm has been the dominant theoretical 
framework for chronic disease epidemiology in the second half of the twentieth 
century (Susser 1998; Susser and Susser 1996a; Susser and Susser 1996b).  This 
methodological focus on risk in epidemiology reflects a influence of the dominant 
biomedical theory that human illness is caused by an interaction of environmental, 
physiological, and behavioral factors: so-called risk factors.   In the risk factor 
paradigm, researchers produce risk statistics from population-level surveillance data 
that show that particular variables, often conceptualized at the molecular level are 
statistically associated with an undesirable health outcome.  Analysts then interpret 
these population-level risk statistics as individual-level risk factors that, by virtue of 
their expression of molecular processes, become transformed into biologically 




Sociologist Janet Shim’s analysis of the implications of this risk factor 
paradigm for constructions and meanings of race illustrates this third core theme of 
biomedicalization.  Shim’s research illustrates how practices of surveillance and 
discourses of risk are coproduced, which means that scientists use practices of 
surveillance to produce knowledge about risks, and then risks are used to justify 
further practices of surveillance (Clarke et al. 2003: 172). For example, as biomedical 
researchers analyze population surveillance data collected using race categories, these 
practices contribute to the construction of race as an individual-level cause of disease.  
In practice, race variables are often statistically associated with undesirable health 
outcomes, and in this context race is often interpreted as an individual-level risk 
factor.  In this context, bodies marked with risk as race suggests that race itself 
becomes an indicator of risk.  
A fourth theme of biomedicalization that is relevant to this study is that 
biomedicine is a profitable global capitalist system that exploits human health as a 
commodity, especially the pharmaceutical industry(Hegecoe 2004; Kremer and 
Glennerster 2004; Moynihan, Heath, and Henry 2002).  Drawing on Marxist social 
theory, scholars Catherine Waldby and Nikolas Rose argue that contemporary 
biomedicine is increasingly driven and organized by the search for biovalue, or the 
production of a surplus out of life itself (Rose 2006; Waldby 2000).  Feminist science 
studies scholar Charis Thompson takes this argument one step further to argue that 
biomedicine has helped to establish a new mode of capitalism in the United States—




Thompson identifies five distinguishing features of the biomedical model of 
reproduction that comprise biomedicalization as a capitalist system.   First, whereas 
traditional forms of capitalism have focused on modes of production, biomedical 
capitalism has shifted to a focus on reproduction through the deployment of 
biotechnology.   Second, as I suggested earlier, whereas traditional forms of 
capitalism produced profit through the extraction of surplus labor, biomedical 
capitalism has shifted to the extraction and maximization of profit out of bodies and 
their bodily products.  Third, whereas traditional forms of capitalism alienated 
workers from their labor and the products of their labor, biomedical capitalism has 
shifted to a situation where bodies are alienated from the profits of their own 
reproduction.  Fourth, whereas traditional capitalism is premised on the accumulation 
of capital in the present moment, biomedical capitalism is characterized by the 
success of procedures and processes that lead to promised future returns (i.e. 
developing future cures).  Fifth, and finally, whereas traditional capitalism produced 
by-products or externalities that require disposal, the by-products of biomedical 
capitalism are often ethically sensitive materials (such as embros) or are desirable in 
themselves (such as donated organs).   
One central feature of the rise of biomedical capitalism is new biomedical-
government-industry collaborations that involve the production, legitimation, and 
commercialization of biomedical knowledge (Etzkowitz, Healey, and Webster 1998; 
Swann 1988; Teeling-Smith 1965).    These new relationships form the institutional 
bases out of which growing volumes of research are produced.  For example, 




trials for their new investigational drugs, and then pay federal drug regulators at the 
Food and Drug Administration to review their drug for regulatory approval.   
In the context of a biomedical mode of capitalism and new ways of producing 
profitable biomedical knowledge, Sandra Soo-Jin Lee investigates the corporate 
research, development, and marketing of pharmaceutical drugs targeted toward 
specific racial groups.33  In the context of pharmaceuticals, Lee outlines what she 
calls an infrastructure for racialization, a set of scientific and institutional practices 
that inscribe bodies and their bodily products with racial meaning.  These practices 
consist of (1) new research on human genetic variation that overlays genetic data onto 
social categories of race; (2) the continued and widespread use of race as a proxy for 
risk in clinical medicine; and (3) the commercial development of racially inscribed 
niche markets by the pharmaceutical industry (Lee 2005).    
Collectively, the scholarship of Sara Shostak, Janet Shim, Charis Thompson, 
and Sandra Soo-Jin Lee suggests that the scientific, technological and economic 
processes that encompass biomedicalization do not operate uniformly on all social 
groups.  Thus, a fifth core theme is that biomedicalization is a stratified and 
stratifying social process.   Clarke et al (2003) define cooptative biomedicalization 
and exclusionary disciplining as two oppositional processes within biomedicalization 
that target and exclude particular bodies and populations, respectively.  Drawing on 
the framework of medicalization, cooptative biomedicalization entails the expansion 
of medical jurisdiction over areas previously not deemed medical in terms of 
interventions targeted towards particular social groups.  For example, Sandra Soo-Jin 




through the cooptation of race in biomedical research.  Exclusionary disciplining 
refers to the institutionalized practices that erect barriers to the social process of 
biomedicalization for selected social groups.  For instance, drawing on my earlier 
example, members of racial and ethnic population groups who lack prescription drug 
coverage are excluded from the cooptative practices of pharmaceutical companies.  
The framework of biomedicalization provides a set of powerful analytic tools 
through which to analyze the relationships of the metabolic syndrome and race.  In 
the next section, I turn to Foucault’s framework of biopower.  I argue that biopower 
provides a synthetic conceptual framework for this study that views racial formation 
and biomedicalization as part of the same apparatus of power/knowledge.   
 
The Framework of Biopower 
The social theory of Michel Foucault, especially his analytic framework of 
biopower, provides a third and synthetic theoretical lens shaping this study. In this 
section, I will define Foucault’s framework of biopower as a theory of power and 
knowledge, and then outline the core themes from which I draw upon to analyze the 
relationships between the metabolic syndrome and race.   Foucault uses the concept 
of biopower as a way of understanding the transitional period beginning in the 
seventeenth century when modern institutions of power began to take human life as 
their objective and target.  The framework of biopower focuses on the relationships 
through which the life and health of bodies and populations become the objects of 




Foucault conceived of biopower as the convergence of disciplinary power and a new 
kind of regulatory power over the life processes of entire populations, two “poles” of 
power that converge at the level of concrete arrangements (Foucault 1978: 140).  
These concrete arrangements were bodies and populations themselves.  
The first core theme of biopower that is relevant to this study is that the two 
technologies of biopower, disciplinary power and regulatory power, represent distinct 
institutional locations for the operation of power and the production of knowledge.  
Disciplinary power is the means to extract political and economic productivity from 
individual bodies and the use of tactical procedures used to observe, judge, and 
examine bodies.  Achieving the disciplining of the body requires hierarchical 
observation, normalizing judgment, and the physical examination (Foucault 1975a).  
Through these techniques and practices, disciplinary power establishes the relations 
of docility and utility of the body—this is how discipline makes docile bodies 
(Foucault 1975b).  Hierarchical observation involves the continuous and uniform 
monitoring of the processes of the body, in order to achieve its maximal productive 
efficiency.  Normalizing judgment involves the introduction of a system of rewards 
and punishments whose goal was to induce the body to conform to the laws of 
efficient movement corresponding to the activity it was being asked to perform under 
disciplinary conditions.  The examination is the recurrent and culminating event in 
the disciplinary process through which the body is gazed upon as “both a ritual of 
power and a procedure for the establishment of truth” (May 1992: 43).  Disciplinary 
knowledges are the scientific truths about the body produced through the observation, 




Whereas disciplinary powers operates through strategies that target the 
individual body, regulatory power operates through “massifying” strategies that deal 
strictly with populations as “a political problem, as a biological problem, and as 
power’s problem” (Foucault 2003[1976]: 245).   Regulatory power gained increasing 
prominence in the nineteenth century with the rise of demography, epidemiology, and 
sociology.  The primary techniques of regulatory power involve the use of 
demographic averages, comprehensive and comparative measures, and statistical 
assessments that are derived from the surveillance of populations.  Foucault provides 
the familiar example of the birth rate as such a measure.   The birth rate is a statistical 
measurement of the population that used to evaluate the relative health of the 
population.  In a recursive fashion, these measures are then used to establish further 
regulations that are intended to act on the population as a whole.   If the birth rate is 
low, interventions are required to improve the population’s health.  Whereas 
disciplinary power makes docile bodies so as to increase utility, regulatory power 
constructs populations more regulated so as to maximize health and life.   
A second important theme of the framework of biopower is that governments 
and corporations create and use the disciplines and regulations to conform bodies and 
populations to unequal political and economic arrangements.  With its explicit focus 
on the life processes of human populations, Foucault articulates biopower as a 
critique and synthesis of the liberal-juridical and Marxist conceptions of power.  The 
juridical or liberal conception of power maintains that the governments exercise the 
Law and threat of death to rule over its subjects.  Indeed, the institution of the nation 




individuals, citizens.   Foucault argues that governments had historically exercised 
their right to kill their enemies, both foreign and domestic, and that this management 
of death was central to the extension of government power, especially military power.  
While governments continued to kill and still do, during the transition to biopower, 
governments began to add a biopolitical management approach to their repertoires.   
As I have mentioned, this new approach was primarily concerned with investing in, 
interrogating, and controlling the biologies of all populations.  To explain the 
significance of this new political relationship relationship, Foucault writes “One 
might say that the ancient right to take life or let live was replaced by a [bio]power to 
foster life or disallow it to the point of death” (Foucault 1978: 138). 
A Marxist conception of power maintains that corporations exercise power to 
extract surplus value from the labor of workers.   In contrast, Foucault’s conception of 
biopower maintains that scientific institutions, governments, and corporations 
construct and deploy biological relationships for the regulation of populations.  In 
Foucault’s words, biopower was central to the development and success of capitalism 
because it enabled “the adjustment of the phenomena of population to economic 
processes” (Foucault 1978: 141).   Modern capitalism requires the control of large 
numbers of individual bodies, not only in terms of a need for a population of laborers, 
but with the health of bodies as objects of investment and sources of revenue in 
themselves.  The increasing commodification of health that comprises 
biomedicalization is good evidence of this treatment of bodies and their products as 




 A third and crucial theme of the framework of biopower is that it outlines a 
Foucauldian theory of race and racism.   Foucault’s recently published lectures at the 
College of France in 1975-1976, provide a unique elaboration of the concept of 
biopower and its connections to the emergence of the concept of race and the early 
formations of state racisms (Foucault 2003 [1976]).  In these lectures, Foucault argues 
that race emerged historically as a way to create a caesura, a break, within the 
biological and population phenomena addressed by biopower, a break used to 
separate out perceived biological risks to the health and vitality of the population 
(Foucault 2003 [1976]).  For Foucault, race serves as a transfer point between the 
production of biological knowledge about population health and the exercise of 
political power; race becomes a means of “transcribing a political discourse into 
biological terms” (Foucault 2003 [1976]: 266).  Thus, there existed a quick linkage 
between the exercise of biopower and nineteenth century biological theories of race.35  
 Relations of biopower both enable and justify the practices of racism that have 
taken place in the name of strengthening or improving population health (Foucault 
2003 [1976]: 258).  Modern racisms function in the context of biopower by 
establishing a perpetual relationship of war between the so called races in which 
racial categorization emerges as a way to identify biological enemies, again internal 
and external to a particular state government, and mark them for improvement, 
purification, or extermination.  Given this framework, it is clear how and why racial 
discourses were deployed to institutionalize ideas and practices of population 
eugenics, which were presumably aimed at improving the health of populations 




 In this section, I argued that Foucault’s framework of biopower contributes 
three important themes to this study.  The first core theme of the framework of 
biopower is a new emphasis on the relationships through which the life and health of 
populations become the objects of power and knowledge.   The second core theme of 
the framework of biopower is that institutions of power use these techniques in a 
polyvalent fashion to guarantee exploitive economic and political relationships by 
conforming bodies and populations to unequal political and economic arrangements.  
The third and crucial theme of the framework of biopower is that it specifies a 
Foucauldian theory of race and racism that emphasizes how biological and political 
relationships are deployed through racial categorization.  
  
Convergence, Divergence, and Synthesis 
 Thus far, I have presented critical race theory, biomedicalization (hereafter in 
this section called STS), and biopower as three distinct and independent bodies of 
scholarship that each offers unique contributions to this study.  However, sharp lines 
demarcating these areas are not so easily drawn as these areas have been shaped by 
and continue to influence each other in the broad context of sociological theory. 
While there are multiple points of convergence across these areas, they also diverge 
in meaningful ways that are germane to my synthetic interpretation of the 
relationships between the metabolic syndrome and race.   
 A primary point of convergence across critical race theory, STS, and 
biopower is a focus on the multiple linkages between bodies and populations and in 




targeted towards populations.   Yet, within this convergence, these three frameworks 
each treat this body-population link in different ways.  Historically in the United 
States, critical race theorists have been first and foremost concerned with the lived 
experiences of people of African descent living under unjust conditions of 
colonialism, slavery, and capitalism.   The idea of race itself provided a pseudo-
scientific pretext for enacting various forms of racial subjugation under European rule 
that operated by linking ideas about the inferiority of particular racial types to 
population-based exploitations.  In the same way, Foucault’s thinking about race as a 
system of biopower draws upon this understanding of race, but emphasizes how the 
operation of this new kind of power was enabled by a new focus on maximizing the 
life and health of dominant groups that emerged in the 1800s, nearly a century after 
the first racial taxonomies were codified in the European academy.  Scholars in the 
field of STS begin their analysis of the body-population link with Foucault, 
accompanied by a heavy reliance on feminist ideas about the gendered body, and 
examine the multiple ways that bodies and populations are constituted via new 
technologies in science and medicine.    
 This first point of convergence on the body-population link suggests a second 
key point of convergence across critical race theory, STS, and biopower—a shared 
focus on institutionally based forms of social stratification and inequality that 
predominate Western society.   Each of these bodies of knowledge draws upon a 
political orientation to the production of scholarship that recognizes that objective 
intellectual production does not, and cannot, occur in a just and fair society.   To the 




institutions like governments, corporations, and science shape the life chances of 
people and have worked to illuminate the social and political conditions necessary for 
the fostering of a more just society.  This shared focus on justice stems from a shared 
understanding about the nature of modern forms of power that have operated largely 
since the Enlightenment.  Major works in each of these areas have analyzed the role 
of scientists and scientific practices in the formation of unjust social arrangements 
and have deconstructed those forms of knowledge that undergird those arrangements.  
 A second point of convergence across these frameworks concerns the research 
methods utilized to answer research questions in each area.   Specifically, 
contemporary practitioners in critical race theory, biomedicalization, and biopower 
have all drawn upon discursive and historical methodologies to study different 
aspects of the relationships between power and knowledge.  For example, in her 
recent book (Panic Diaries: A Genealogy of Panic Disorder, 2006), sociologist Jackie 
Orr uses Foucault’s genealogical method to analyze the relationships of power and 
knowledge developed by a normalizing society to regulate the psychological life, 
health, and disorders of individuals and entire populations—a concept she calls 
pychopower (Orr 2006:11).  Drawing on Foucault’s formulation of biopower and the 
frameworks of technoscience and biomedicalization, Orr argues that psychopower has 
emerged since the late 19th century, but has gained new operational capacities with 
the rise of twentieth-century information and communication technologies.   Orr uses 
genealogy to identify three distinctive ways that the panic disorder serves as a site for 
the operation of psychopower.  First, psychopower disciplines individuals and entire 




public administration of the psychic realms of perception, emotion, and memory (Orr 
2006: 11).  Second, the techniques of public opinion polling, attitude measurement, 
and psychological testing both govern populations and have the additional effect of 
intensifying and multiplying the communicative feedback loops between governing 
bodies and the bodies they would govern (Orr 2006: 12).   Third, by utilizing these 
new techniques and knowledges focused on perception, emotion, and memory 
psychopower can blur the boundaries between the real and the unreal (Orr 2006: 13). 
 Through her articulation of psychopower, Orr contributes to a political 
understanding of how scientific practices and institutional relationships reproduce 
particular kinds of subjectivities and materialities.  Orr shows how U.S. government 
propaganda about nuclear annihilation during the Cold War was informed by and 
proactively informed the social psychology of group trauma, fear, and panic, which 
were themselves financed by the state.  Similarly, she makes a similar genealogical 
argument about clinical trials for the killer application Xanax.  The pharmacological 
effects of Xanax were tightly linked with the classificatory schema for panic disorder 
because of the new institutional relationships between biomedical psychiatry, the 
federal government (Department of Defense and FDA) and pharmecutical 
corporations (Upjohn), which were the institutional locations for the classification, 
administration, and treatment of panic disorder (Orr 2006: 255).   
 While serving as an exemplar of a way to synthesize a framework of biopower 
in the context of science and technology studies, Orr’s research also demonstrates a 
first point of divergence with critical race theory.  While some critical race scholars 




of science and technology studies (e.g. Troy Duster), precious few Foucauldian 
and/or STS scholars draw upon the insights of critical race theory to address 
questions of race and racism in direct terms.  Stated differently, these frameworks do 
not share equally across each other’s domains of inquiry.   A counterexample to this 
point of divergence is the work of Melbourne Tapper, whose 1999 book In the Blood: 
Sickle Cell Anemia and the Politics of Race draws upon ideas about African 
American citizenship, medicalizing discourses about disease, and the operation of 
biopower to explore how sickle cell anemia became an object of scientific 
intervention targeted on people of African descent.   
 A second point of divergence across these areas concerns the use of different 
theoretical vocabularies to describe what I increasingly see as analogous social 
practices and arrangements regarding the reproduction of race and racism.   For 
example, critical race theorists Michael Omi and Howard Winant advance the 
construct of racial formation to describe the processes by which racial categories are 
created, transformed, and destroyed.  Racial formation, in their way of speaking, 
consists of the integration of the discursive meanings of race and the institutionalized 
practices of racism that function based on that meaning.   In comparison, Michel 
Foucault advances a similar idea that race is reproduced through the convergence of 
the (racial) disciplining of bodies and the regulation of (raced) populations and that 
this reproduction takes place in order to propagate the unequal power/knowledge 
arrangements that comprise modern racisms.   While it is likely that Omi and Winant 




popularized by Foucault, nonetheless, these two frameworks ostensibly describe the 
same social process using different linguistic formulations.   
 Taken together, critical race theory, biomedicalization, and biopower provide 
a powerful synthetic framework that I use to interpret the politics of metabolism.  
These frameworks are synthetic because they speak to the similar social process and 
institutional relationships of these politics of metabolism.  Table 2.2 presents a 
summary of the core themes I developed in this chapter and positions them relative to 
the core components of the politics of metabolism.    
 
[Insert Table 2.2. Summary of Core Themes & the Politics of Metabolism] 
 
Column one summarizes the elements the politics of metabolism that are germane to 
the guiding questions of this study: social processes, institutional relationships, and 
the constructions of racial meaning and the metabolic syndrome.  Recall the three 
questions that shape this study: First, how did the metabolic syndrome emerge as a 
new discursive formation in the politics of metabolism?  Second, how are current 
conceptions and meanings of race constructed through the discourses of the metabolic 
syndrome?  Third, what are the implications of this emerging relationship between 
the metabolic syndrome and race for understanding the construction of racial 
meanings in the politics of metabolism?   
 Columns two, three, and four summarize the frameworks I developed in this 
chapter that shape my analysis of the emergence of the metabolic syndrome and the 




biomedical scientists, the government, and corporations through which the metabolic 
syndrome has emerged as a racialized phenomenon.   This table arrays these core 
elements of these frameworks against the principle components of the politics of 
metabolism.  Namely, the social processes and institutional relationships of the 
politics of metabolism structure the emergence of the metabolic syndrome and the 
construction of racial meaning. The social processes of racial formation and 
biomedicalization illustrate the combined use of racial categorization and 
biotechnologies to enact relations of biopower.  The framework of biopower helps to 
reframe the institutional relationships between biomedical scientists, the government, 
and corporations that are involved in racial formation and biomedicalization.   
 In the next two chapters, I use the main ideas summarized here to explore how 
the metabolic syndrome emerged as a new discourse of biopower by tracing the social 
processes and institutional relationships that are involved in the production of new 
racial meanings.  In the concluding chapter of the study, I will address how my 
interpretation of the relationships between the metabolic syndrome and race speak 




Table 2.1. Office of Management and Budget (OMB) racial and ethnic categories, 
1997. 
(1) American Indian or Alaska Native: 
A person having origins in any of the original peoples of North and South America 
(including Central America), and who maintains tribal affiliation or community 
attachment. 
(2) Asian: 
A person having origins in any of the original peoples of the Far East, Southeast Asia, 
or the Indian subcontinent including, for example, Cambodia, China, India, Japan, 
Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. 
(3) Black or African American: 
A person having origins in any of the black racial groups of Africa. Terms such as 
"Haitian" or "Negro" can be used in addition to "Black or African American". 
(4) Hispanic or Latino: 
A person of Cuban, Mexican, Puerto Rican, Cuban, South or Central American, or 
other Spanish culture or origin, regardless of race. The term, "Spanish origin," can be 
used in addition to "Hispanic or Latino”. 
(5) Native Hawaiian or Other Pacific Islander: 
A person having origins in any of the original peoples of Hawaii, Guam, Samoa, or 
other Pacific Islands. 
(6) White: 
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Chapter 3:  The Racial Formation of the Metabolic 
Syndrome 
 
 In chapter one, I introduced the metabolic syndrome as a concept that has 
been used to describe the co-morbidity of several prominent chronic metabolic 
conditions.  I noted that I would use the term “metabolic syndrome” to refer to a 
larger group of terms that encapsulate these new relations.  In chapter two, I outlined 
the theoretical vocabulary from critical race theory, biomedicalization, and biopower 
that I would use to analyze the relationships between the metabolic syndrome and 
race.  In this chapter, I analyze the emergence of the metabolic syndrome by 
examining the central ways it is involved in the production of new racial meanings.  
In the genealogical analysis of emergence, the metabolic syndrome appeared in 
multiple sites of knowledge production in biomedicine and has taken different forms 
in these various sites over time.37  I demonstrate that the phenomena that came to be 
called the metabolic syndrome had several different names and empirical definitions 
that each represents disjunctures that have differential implications for the production 
of racial meanings and the interpretation of racial inequality. 
 One way to frame the puzzle that race has presented for metabolic syndrome 
researchers is how to measure and interpret metabolic differences, both in terms of 
bodies and populations, in ways that were consistent with prevailing ideas about 
racial differences between bodies and populations.  In this chapter, I show how the 
emergence of the metabolic syndrome forged a technoscientific process for the 
production of biomedical and genetic conceptions of race.  Stated differently, I argue 




metabolic syndrome, in turn, serves as dynamic new site for the production of race 
and racial meaning.  Yet, by using the construct of disjunctures I described in chapter 
one, which represent the structure of discursive possibilities, I showed how these 
processes of emergence and racialization did not result from conscious and obvious 
choices on the part of biomedical scientists working in their respective fields.  To the 
contrary, the social processes and institutional relationships that comprise the politics 
of metabolism seem to be more open ended and heterogeneous, and have created a set 
of possible conditions through which the metabolic syndrome could emerge as a 
racial phenomena in some historical moments, and apparently non-racial in other 
moments.    
     I have divided this chapter into two main parts, each of which is further 
divided into three subsections.   While these subsections appear to be organized 
according to chronological time, each of these moments represents arbitrary 
disjunctures in the attempt to establish the metabolic syndrome as a biological clinical 
disease as a legitimate object of biomedical knowledge production and intervention.  
In Part I, I trace the emergence of the metabolic syndrome across three thematic 
moments in American biomedicine: Technical and Conceptual Foundations (1947-
1986); From Syndrome X to Dysmetabolic Syndrome X  (1987-2000); and The 
Ascendance of the Metabolic Syndrome (2001-present). In the first section, Technical 
and Conceptual Foundations, I highlight the early biotechnical and theoretical work 
on bodies and populations, molecular processes, and clustering that shaped early 
discourses and practices of the metabolic syndrome.   The second section, From 




syndrome through a second moment, where researchers continued to advance new 
ideas about the definition and causes of the syndrome focusing on the bodily 
measurement of insulin resistance.  The third section, The Ascendance of the 
Metabolic Syndrome, chronicles a third turning point in the emergence of the 
syndrome, namely, when in 2001 the syndrome comes under federal biomedical 
jurisdiction through the National Cholesterol Education Program and then accelerates 
out into the vast network of biomedical disciplines and research specialties.  
In Part II of the chapter, I retrace the production of racial meaning during the 
three thematic periods that I described in Part I.  For the first moment, Sampling 
Normal Subjects, I show how researchers’ approaches to the study of human 
metabolism both explicitly and/or implicitly targeted bodies and populations based 
upon prevailing racial categorizations that marked the metabolic processes of white 
male bodies as normal.  For the second moment, Is Race Really To Blame?, I 
examine how race was constructed as reflecting a genetic causation of the metabolic 
syndrome.   For the third moment, I use the notion of the “special populations” to 
show how race becomes fully incorporated into the technological measurement, 
scientific definition, and causal theories of the metabolic syndrome.  In the 
contemporary moment, all people who could be classified with the metabolic 
syndrome and all racial and ethnic minorities now seem to comprise high-risk 
populations that require permanent forms of examination, surveillance, and 
regulation.  
 Cutting into the emergence of the metabolic syndrome in these ways allows 




to shape the unfolding of the relationships between the syndrome and race.  The two 
main parts reflect my effort to sift the ostensibly non-racial features of the metabolic 
syndrome from the racial ones.  In fact, the production of racial knowledge related to 
the metabolic syndrome in and of itself suggests an important and organizing 
disjuncture in its emergence.  It was not always obvious that the metabolic syndrome 
could emerge as a biomedical construction that relied so heavily on racial distinction 
and administrative classification.  In addition to each of the main parts of chapter 
three representing a major disjuncture, I have divided each of the subsections in parts 
I and II according to a particular historical periodization that maps onto important 
disjunctures within the non-racial and racial narratives of the emergence of the 
syndrome.   In other words, while these subsections are organized according to a 
Western notion of continuous and linear time, I intend for them to represent arbitrary 
disjunctures where the emergence of the syndrome shifted in important ways that 
mattered for the production of racial meaning.  
 
Part I: The Emergence of the Metabolic Syndrome  
Technical and Conceptual Foundations, 1956-1987 
 During 1956-198738, the technical and conceptual foundations of the 
metabolic syndrome were tightly linked to three main sets of ideas and practices that 
operated in polyvalent fashion. Taken together, these polyvalent discourses and 
practices comprise the technical and conceptual frameworks through which the 
metabolic syndrome would emerge as a new technique of biopower.   They were (1) 




molecular level of a body; (2) the institutionalization of measuring the metabolic 
processes of populations; and (3) the increasing focus on the clustering of metabolic 
problems and risk that resulted from these new practices.   By interpreting these 
technical and conceptual foundations of the metabolic syndrome as technologies of 
biopower, I explore how the syndrome emerged as a result of the synergy of 
molecularization and the risk factor paradigm in biomedicalization.   In the sections 
that follow, I explain each of these technical and conceptual foundations in greater 
detail, highlighting how they each contributed to the emergence of the metabolic 
syndrome.   
 The development of a range of techniques to measure molecular processes 
constitutes a first development during these moments that shaped the emergence of 
the metabolic syndrome.  In the late 1800s and early 1900s, new scientific theories 
and concepts were developed and new technologies deployed to understand the 
body’s metabolic processes at the molecular level.  The creation of new technologies 
that would be used to study metabolism in terms of molecular processes, such as the 
discovery of insulin in 1920, helped to reinforce the early scientific imperative to 
know more about how bodies metabolized molecular structures like lipids, glucose, 
and insulin.   The technical development of the physical examinations and laboratory 
tests that comprise the metabolic syndrome occurred mostly prior to this first period, 
thus making it technically and discursively possible to construct a metabolic 
syndrome of any kind in this period.  Table 3.1 lists selected technical developments 





[Insert Table 3.1 Selected technical developments contributing to the metabolic 
syndrome, 1896-1985] 
 
 Not only did these technologies structure the content of biomedical knowledge 
about metabolic processes of bodies at the molecular level, they also opened up and 
closed off particular possibilities in terms of the emergence of the syndrome.  Once 
each of these technologies was in use, the conceptual foundations of the metabolic 
syndrome could be readily forged in laboratories and doctor’s offices.  Yet, the 
creation of technologies in a given historical moment delimits the technical 
aggregation of the various elements of the syndrome at later moments.  In other 
words, the technical and conceptual foundations in this early period form a set of 
disjunctures that continue to structure the range of discursive possibilities for the 
metabolic syndrome in the contemporary moment. 
 A growing focus on measuring various aspects of the body and the 
construction of certain ideas about particular populations based on these bodily 
measurements constituted a second important development during this period that 
enabled the subsequent development of the metabolic syndrome.  Take, for example, 
the work of University of Marseilles physician Jean Vague, who proposed an 
alternative anthropometric method that “traces the thickness of the fatty tissue on the 
surface of the body” (Vague 1956: 20).  Vague becomes a central figure in this period 
and is routinely cited as one of the primary so-called fathers of the metabolic 
syndrome concept39 because of his investigation of the causal relationships between 




 Vague articulates two hypotheses that illustrate the way he defined, measured, 
and conceptualized the IMD in relationship to sex difference.  His anthropometric 
method required the measurement, enumeration, and tabulation of the fatty tissue 
found at ten points on the trunk and limbs of the body.  The first hypothesis is that 
“the relationship of the thickness of the fold of the nape of the neck to that of the 
sacral fold is much greater than unity in the normal male, but much less in the 
female” (Vague 1956: 21).   The second hypothesis is that the brachio-femoral adipo-
muscular ratio, a comparison of the adipo-muscular ratio [the relationship between fat 
and muscle tissue] on the arm compared to the thigh, is above unity [greater than 
zero] in the normal adult female, while the inverse is true in the male” (Vague 1956: 
21).    He uses these measurements to construct a statistical representation on sex-
differentiated obesities, an index of masculine differentiation (IMD).  The IMD is “the 
average of the nape:sacrum ratio and the brachio-femoral adipo-muscular ratio” 
(corrected in terms of the total thickness of the fat in the two regions)  (Vague 1956: 
21).  This information is significant because Vague developed a body of conceptual 
and technical language that emphasized the measurement of the body, and the 
statistical comparison of different parts of the body, that were essential to his ideas 
about bodily difference.   
Vague’s hypothesis proposes that men and women are essentially different if 
measured and compared at these locations.   Based on his analysis of 600 subjects, 
Vague constructs five mutually exclusive groups, standardized around a value of “0” 
for the standard male body, comprising the following categories: “hyperandroid” 




(-45 to -75 IMD), and “hypergynoid” (+75 IMD).   These categories are meant as 
descriptions of the different types of distributions of obesity typically found in 
women and men, with android referring to men and gynoid to women. The binary 
logic of sex drives Vague’s interpretations of his statistics.  In this regard, he notes 
“fat distribution is very definitely a sexual characteristic, but there is a high 
percentage of overlapping between one sex and the other, especially at the two 
extremes of life” (Vague 1956: 24).   In other words, while the categories gynoid are 
meant to refer to a particular statistical construction of populations, men can exhibit 
with gynoid forms of obesity and women with android forms of obesity.  
 Vague concedes the non-exclusive nature of his gendered categories as 
demonstrated by Figures 3.2 and 3.3.  The text of Vague’s paper was published along 
with several tables and figures, as well as eight photographs of four of his research 
subjects, whose bodies are fully exposed to show the distributions of their obesities.   
Figure 3.2 shows one woman and one man, both classified with gynoid obesity, 
whereas Figure 3.3 shows one woman and one man both classified with android 
obesity.  
 
[Insert Figures 3.2 and 3.3] 
 
The images of Vague’s subjects and the captions that accompany them represent the 
visual forms of bodily evidence that Vague used to present ideas.  The captions note 
specific information about the subject’s metabolism including age, height, weight, 




including hair, the status of genitals and noted sexual practices, and the subjects’ 
value for the index of masculine differentiation.  Undoubtedly, disciplinary 
conventions about publishing photographs of nude research subjects in professional 
biomedical journals have changed somewhat since the 1950s, but the visual 
representation of these subjects shows the ease with which physicians might have 
differentiated between gynoid and android forms of obesity. 
 Vague’s work illustrates the growing emphasis of measuring the body, but it 
also points to how specific ways of interpreting the bodily measurements begin to 
make the metabolic syndrome possible.  In particular, one important ways Vague’s 
ideas preview the emergence of the metabolic syndrome lies in his claims about 
android obesity as a common cause of heart disease and diabetes.  In this brief 
passage, he describes how android obesity is the common cause of atherosclerosis 
and diabetes: 
The inconstancy of diabetes in the course of atherosclerosis 
when the islets of Langerhans40 offer a sufficient genetic 
resistance to the overwork imposed by the pituitary-adrenal 
overactivity, in contrast to the constancy of atherosclerosis in 
adult diabetes and its relative independence to the degree of 
hyperglycemia, cease to surprise us if we regard arterial legions 
and diabetes as the consequences of an identical cause [android 
obesity] acting against a backdrop which may suffer from a 





In other words, Vague posited that heart disease and diabetes share android obesity as 
a cause.  According to Vague, the development of diabetes, gout, uric calculous 
disease, and atherosclerosis is “very strongly favored by android obesity, especially 
when weight and the index of masculine differentiation are very high” (Vague 1956: 
29).  In contrast, gynoid obesity “does not exercise any direct influence on the 
metabolic disorders” (Vague 1956: 29).   In Vague’s thinking, genetic differences 
between bodies caused the differential development of android obesity, and 
consequently, diabetes and heart disease.   
 A second important way Vague’s ideas preview the syndrome lies in the 
predictive power Vague attaches to the IMD for classifying bodies that will develop 
metabolic disease.  By the 1956, Vague proposed that a particular combination of 
bodily measurements results in the best statistical predictor of android obesity.  Stated 
differently, Vague’s method was significant because it represented an important shift 
from diagnosing the body through physical examination to compiling the results of 
physical examinations to construct statistical ideas about population-based risk.  In 
other words, the IMD is a statistical construction that successfully identifies obese 
bodies that are predisposed to diabetes and to heart disease because of a common 
genetic mechanism.   He states that the index of masculine differentiation has “always 
indicated to us the exact position of these forms [of obesity] in our classification and, 
in addition, has provided prognostic data” (Vague 1956: 24).   His hope was that 
physicians would calculate the IMD and use it to predict, with great accuracy in his 




 Increasing reliance on the notion of clustering to guide biomedical research on 
metabolism constitutes a third important development during this period that enabled 
the subsequent emergence of the metabolic syndrome.  Clustering refers to the 
observation that several different metabolic conditions are more likely to occur 
together in one individual than would be expected by chance alone.  The notion of 
clustering is significant because the production of knowledge about the metabolic 
syndrome is made possible by the physical examination and biochemical surveillance 
of bodies and the aggregation of that individual level biological data to the level of 
populations. These conceptual developments in epidemiology are directly linked to 
the technical and conceptual foundations of the metabolic syndrome because of the 
widespread use of the metabolic syndrome as statistical predictor of heart disease and 
stroke in federally funded biomedical research. 
 By the early 1920s, several European physicians were the first to document 
and publish research about the clustering of metabolic problems they observed in 
their patients, and the potential risks such clustering could pose to metabolic health 
(Hitzenberger 1922; Kylin 1923; Maranon 1922).  While none of these physicians 
explicitly codified a syndrome, they had similar theoretical ideas about how different 
metabolic processes worked together in the body. For example, in his 1936 study of 
insulin action, endocrinologist H.P. Himsworth created the distinction between 
insulin sensitivity and insensitivity, the latter being most likely to precede and then 
accompany the development of type II diabetes (Himsworth 1936).  
 While the focus on the measuring the body’s metabolic processes in terms of 




conditions, it also formed the basis of later struggles to subsume the metabolic 
syndrome under different disciplinary specialties.  For example, Himsworth’s 
research on insulin metabolism in the 1930s anchored the structure of contemporary 
endocrinology, and the efforts of contemporary endocrinologists to study the 
metabolic syndrome make sense given this technical and conceptual anchor.  Early 
scholars, like Vague, drew explicitly upon notions of risk-based clustering in their 
theories about the nature of metabolic problems, but it was not always with respect to 
the same outcome. Whatever the outcome, these notions of clustering formed the 
logic upon which risk-based syndromes, like the metabolic syndrome, would be 
constructed in later decades.  Different clusters of conditions drew the attention of 
newly developing medical specialties like endocrinology and cardiology. In this early 
period, endocrinologists were concerned mostly with glucose metabolism, insulin, 
and diabetes; cardiologists were concerned with heart disease and the processes 
underpinning vascular function; rheumatologists were concerned with gout and so on. 
Increasingly, over this thematic period, physicians would continue to conduct clinical 
research on the interrelationships between basic metabolic processes with a growing 
list of new molecular compounds and physical examinations.  
 While many of these early metabolic researchers developed and used 
statistical methods of analysis in their clinical research, in the late 1940s, the federal 
government assumed a new role in producing information about the metabolic health 
of populations.  Indeed, the incorporation of a population-approach to metabolism 
represents a major disjuncture in the emergence of the metabolic syndrome.  In 




possible only through the numerical comparison of individuals within a defined 
population. In 1948, the National Heart Institute41 provided funding for the 
Framingham Heart Study, the first population heart study to include all of the 
physical exams and laboratory tests required to make a classification of the metabolic 
syndrome in the United States (Kannel, McGee, and Gordon 1976).42  The 
Framingham Study is also noteworthy for its role in identifying cholesterol as a so-
called risk factor in the development of coronary heart disease.  Following the 
successes of the Framingham Study at identifying risk factors for heart disease, the 
U.S. Congress passed the National Health Survey Act of 1956, which authorized “a 
continuing survey and special studies to secure accurate and current statistical 
information on the amount, distribution, and effects of illness and disability in the 
U.S. and the services rendered for such conditions.”43  According to the National 
Health Survey Act of 1956, the empirical data for these new government studies 
would be drawn from at least three sources: (1) the people themselves by direct 
interview, (2) clinical tests, measurements, and physical examinations on sample 
persons, and (3) places where persons received medical care such as hospitals, clinics, 
and doctor’s offices. 
 This law was significant because it mandated that the US government now 
conduct routine surveillance of its populations by use of physical examinations and 
laboratory tests that had hitherto been focused on individual bodies.  This act led to 
the creation of the National Health Interview Survey (NHIS), first conducted in 1957, 
the National Health Examination Survey (NHES) beginning in 1960, and the National 




NHANES study is the study upon which the National Cholesterol Education Program 
would later base its construction of the metabolic syndrome in 2001.   These 
government epidemiological studies have been and still are the largest population 
health surveys conducted in the United States each year.   Thus, population health 
studies over the next five decades were designed using the Framingham study as 
gold-standard model.44  
 These conceptual and technical developments at the level of bodies and 
populations converge in risk-based-syndromes.  Risk-based syndromes are sites 
where ideas and practices about molecular processes, bodies and populations, and 
clustering come together in a polyvalent fashion.   For example, the International 
Diabetes Federation (IDF) published their own version of the metabolic syndrome 
and draw upon a definition of syndrome from a 1995 dictionary of epidemiology 
(Last 1995), which states that what distinguishes syndromes from diseases is their 
lack of a clearly defined cause.  They note: 
“A syndrome is defined as a recognizable complex of symptoms and 
physical or biochemical findings for which a direct cause is not 
understood. With a syndrome, the components coexist more frequently 
that would be expected by chance alone.  When causal mechanisms are 
identified, the syndrome becomes a disease” (Alberti, Zimmet, and 
Shaw 2006: 473).   
Currently, the National Library of Medicine’s online medical dictionary defines a 
syndrome as “a group of signs and symptoms that occur together and characterize a 




  Throughout the 1960s and into the 1970s, given the increasing proliferation of 
laboratories across the US, and the increasing availability of epidemiological data, 
more researchers would have access to the technologies and interpretive frameworks 
required to produce knowledge about risk-based syndromes.  In the 1960s, there are 
several noteworthy contributions to the emergence of the metabolic syndrome, but 
still unresolved was the little issue of what to call the syndrome.  First, in 1966, 
French researcher Camus theorized that gout, diabetes, and hyperlipidemia comprised 
“a metabolic trisyndrome” (Camus 1966).  The following year in 1967, two Italian 
researchers advanced the notion of a “plurimetabolic syndrome” that included 
diabetes, obesity, and hyperlipidemia (Avogaro, Crepaldi, Enzi, and al 1967).46  And 
finally, in 1968, Dutch researchers Mehnert and Kulmann published an article in a 
prominent Dutch medical journal about the relationships between hypertension and 
diabetes (Mehnert and Kuhlmann 1968).  
 It was during the 1970s that the term “metabolic syndrome” would first appear 
in the biomedical research literature.  In 1976, Gerald Phillips, drawing heavily on 
Vague’s earlier work, theorized that the “constellation of abnormalities” that 
comprised increased heart disease risk could be explained by sex hormones (Phillips 
1978; Phillips, Jing, and Heymsfield 2003).  In 1977, three studies were published 
that each codified specific formations of “the metabolic syndrome” into the 
biomedical literature for the first time (Haller 1977; Singer 1977; Ziegler and Briggs 
1977).   A few years later, in 1981, two German researchers were also among the first 
to publish research on the “the metabolic syndrome” (Hanefeld and Leonhardt 1981).   




years, the increasing scientific focus on the clustering of condition in bodies and 
populations that was newly possible with new biomedical technologies, made that 
change possible.  
 The different names, definitions, and disciplinary homes for the metabolic 
syndrome represent central disjunctures in the emergence of the syndrome.  The 
incommensurability of the syndrome across cardiology, endocrinology, and 
epidemiology meant that there would continue to be struggles over its meaning in 
biomedicine.  At the same time, the technologies and conceptual developments that 
undergird the syndrome in polyvalent fashion made it possible for the syndrome to 
travel across these disciplinary boundaries with remarkable ease.  For example, 
medical practitioners and biomedical researchers regardless of specialty area utilize 
measurements of blood pressure and obesity.  Yet, when these same researchers study 
the metabolic syndrome within the confines of their own respective areas, it becomes 
possible for them to include and/or omit particular features of human metabolism that 
are deemed relevant or irrelevant to their biomedical perspective.  In the next section, 
I explore how the search for a cause of the metabolic syndrome inside of 
endocrinology reflects this kind of struggle.  
 
From Syndrome X to Dysmetabolic Syndrome X, 1988-2000 
 
 In a binomial equation, the letter “X” stands for an unknown variable that 
bears a measurable relationship to another variable “Y”. In order to solve for Y in 
such an equation, the value of X must be known, and vice versa.   This simple logic 




efforts to take existing observations about the clustering of multiple risk factors and 
use them to construct new forms of knowledge about the interrelationships between 
these risk factors.  Specifically, this period consisted of professional physicians, 
mostly endocrinologists, trying to advance new theories of what caused the metabolic 
syndrome.  Such theories were intended to help galvanize the syndrome as a 
biological disease and formal clinical diagnosis.   Perhaps by discovering the cause of 
the metabolic syndrome (“X”), their logic suggested, researchers might then be able 
to discern the real value and meaning of the metabolic syndrome (“Y”).   During this 
period, different research groups hoped to explain the statistical associations between 
heart disease risk factors with causal theories focused on the metabolic syndrome.  In 
other words, researchers made continued efforts to establish the causes of the 
metabolic syndrome.  
 One major event in this process occurred in 1988, when Dr. Gerald Reaven 
accepted the Banting Award, named in honor of Sir Fredrick Banting who 
synthesized human insulin in 1920, and gave the Banting Lecture to the American 
Diabetes Association based on his research on the role of insulin resistance in the 
development of heart disease (Reaven 1988).47  In this lecture, Reaven defined 
“syndrome X” as a series of six related variables that tend to occur in the same 
individual—resistance to insulin-stimulated glucose uptake, hyperglycemia, 
hyperinsulinemia, an increased plasma concentration of VLDL triglyceride, a 
decreased plasma concentration of HDL-cholesterol, and high blood pressure (Reaven 
1988).  In his 2000 “Syndrome X: Overcoming the silent killer that can give you a 




subtle reference to the paradox that while the syndrome has no visible symptoms, he 
argues that it may be responsible for up to 50 percent of heart disease in the United 
States (Reaven, Strom, and Fox 2000). 
 Reaven’s hypothesis is that insulin resistance is the common cause of the five 
other components of syndrome X, and therefore is a primary cause of heart disease.   
This framing of insulin resistance as the cause of syndrome X stands in stark contrast 
to Vague’s earlier theory that android obesity was the cause of heart disease and 
diabetes.  While the notion of syndrome X would not acquire the cache of similar 
terms, due to his omission of obesity in its definition, Reaven’s influence on the 
science of the metabolic syndrome is noteworthy.  Reaven’s hypothesis was that 
insulin resistance was responsible for up to 50% of heart disease.   Despite the 
existence of multiple methods for measuring insulin resistance, none of them have 
been institutionalized in population survey research to the extent that other biological 
measurements of diabetes have, like fasting blood glucose, in large part due to their 
expense.48  
 Dr. Reaven’s book or his 1988 lecture surprisingly do not include technical 
definitions of syndrome X.  Whereas Vague went to great lengths to include highly 
specific physiological measurements and statistical procedures in his codification of 
the metabolic syndrome, Reaven’s omission of these details represents a disjuncture 
in the emergence of the syndrome.   Specifically, whereas clustering was the central 
conceptual anchor in the earlier thematic moment, in this moment, the cultural power 
of biological causality serves to anchor and promote the truth properties of the 




new statistical concept in the biomedical landscape.  Instead, his introduction and 
reference to syndrome X is more of a passing reference to the unknown nature of 
these metabolic processes. He writes:  
Based on available data, it is possible to suggest that there is a series of 
related variables—syndrome X—that tends to occur in the same 
individual and may be of enormous importance in the genesis of 
coronary artery disease. These changes include resistance to insulin-
stimulated glucose uptake (insulin resistance), hyperglycemia (glucose 
tolerance), hyperinsulinemia, increased of very low-density lipoprotein 
(VLDL) triglyceride, a decreased plasma concentration of HDL-
cholesterol, and high blood pressure (Reaven 1987: 1605).  
While in 1988 Reaven’s hypotheses about syndrome X were more tentative, by 2000, 
he was calling it “the silent killer.”   Since his book seems to have been written for a 
general audience, it includes a “Self-Assessment for Risk of Syndrome X” rather than 
a formal scientific definition.49   
 After Reaven’s original hypothesis, what remained unknown, or at least 
unsettled, about the pathophysiology of the metabolic syndrome, was more than made 
up for with the growing list of heart disease risk factors that were correlated with the 
syndrome.  By the end of the 1990s, other groups of researchers advanced several 
similar constructions that aimed to encapsulate these hidden physiological 
relationships and to challenge Reaven’s syndrome X.  These constructions all draw 
upon the early conceptual and technical foundations and propose different iterations 




syndrome (DeFronzo and Ferrannini 1991), the multiple metabolic cardiovascular 
syndrome (Hjermann 1992), and the chronic cardiovascular risk factor clustering 
syndrome (Zimmet, Collins, Dowse, Alberti, Tuomilehto, Knight, Gareeboo, Chitson, 
and Fareed 1994), and multiple metabolic syndrome (Liese, Mayer-Davis, and 
Haffner 1998).  
 Perhaps the hope for each of these constructions was that they could derail 
and shift the subsequent development of a science of the metabolic syndrome. In 
2000, the American Association of Clinical Endocrinologists secured a petition to 
have a diagnosis code assigned to “dysmetabolic syndrome X” in the World Health 
Organization’s International Classification of Disease (ICD-9-CM) (Dickey 2000).  
This meant that physicians could now use a specific code, 277.7, to specify a 
diagnosis of the dysmetabolic syndrome X in their patients.  According to the new 
diagnostic criteria, dysmetabolic syndrome X is “a multifaceted syndrome 
characterized by hyperinsulinemia; dyslipidemia (hyperlipidemia); essential 
hypertension; abdominal obesity; and glucose intolerance in individuals with insulin 
resistance.50  With the codification of the dysmetabolic syndrome X in the ICD, what 
had started out for Reaven as an unknown with syndrome X, could now be known 
through classification with a simple diagnostic code.  
 
The Ascendance of the Metabolic Syndrome, 2001-Present 
 The third moment, which began in 2001 and continues into the present, is 
characterized by continued institutional and scientific battles over what the metabolic 




culmination of past disjunctures directly impacts the structure of contemporary 
institutional power struggles over the authority to produce a science of the metabolic 
syndrome.   In the broadest terms, whereas Vague had been fundamentally concerned 
with obesity and its multiple effects on metabolic health, and Reaven’s work puts 
insulin resistance at the center of the analysis of syndrome X, the effort to establish 
the metabolic syndrome as a derivative of cholesterol metabolism represents a 
defining disjuncture of the emergence of the metabolic syndrome.  In this section, I 
explore this institutionalized effort and analyze how earlier disjunctures shaped the 
subsequent ascendance of the metabolic syndrome as a formalized object of 
biomedical knowledge.  
 In 2001, what began as a multi-year, multi-agency government effort to study 
cholesterol, turned into a pivotal shift in the emergence of the metabolic syndrome.  
The National Cholesterol Education Program (NCEP) began in 1985 as part of a 
National Heart, Lung, and Blood Institute effort to examine the dynamics of high 
cholesterol among American adults.  The NCEP brought together experts from across 
the government, academy, and professional medicine.  Stated differently, the National 
Cholesterol Education Program was an example of an industry-academy-government 
collaboration that, given its centrality in defining the metabolic syndrome during this 
period, wielded significant influence in biomedical research on cholesterol and its 
relationship to heart disease.  
 In addition to publishing aggressive new standards for the clinical 
management of cholesterol, the NCEP defined the metabolic syndrome by calling it a 




metabolic syndrome as a secondary target of intervention, the NCEP argued that 
clinicians could not adequately address the heart disease risk from cholesterol without 
acknowledging the role these additional risk factors played in the causes of heart 
disease.  Under this logic, codifying the construct of the metabolic syndrome was 
intended to make practicing physicians aware of the need to address the clustering of 
risk factors for heart disease.   
 According to the NCEP, in order to be classified with the metabolic 
syndrome, a research subject would have to submit a blood sample (for analysis of 
cholesterols, fasting blood sugar, and other molecules) and submit to a physical 
examination including measurement of blood pressure, height, weight, and abdominal 
circumference.   If the subject’s levels met or exceeded three of five predetermined 
empirical cutpoints, the individual was said to “have” the metabolic syndrome.  The 
five components and their values for the NCEP definition are: (1) blood pressure 
(higher than 130/85); (2) fasting blood sugar (higher than 110 mg/dl); (3) LDL or 
“bad” cholesterol (higher than 150 mg/dl); (4) HDL or “good” cholesterol (lower than 
40 mg/dl for men and 50 mg/dl for women); (5) abdominal circumference (greater 
than 40 inches for men and 35 for women).    
 However, the move of framing the syndrome as a secondary target of 
intervention seems to have had the unintended effect of signaling to the biomedical 
research community, pharmaceutical corporations, and to the government itself that 
the metabolic syndrome required special attention as a primary object of knowledge.  
In a 2003 meeting at the National Institutes of Health on the metabolic syndrome, Dr. 




“concerned that the NCEP guidelines would be seen as only drug treatment guidelines 
for LDL [cholesterol], they decided to define a set of medical conditions related to 
obesity, physical inactivity, and nutrition and define these conditions as a metabolic 
syndrome” (NIH 2003: 9).  In other words, the NCEP’s action to define the metabolic 
syndrome seems to have been a way to cloak the practice of setting cholesterol 
control standards to drug regimes in a scientific garb. 
The additional significance of this disjuncture is that, through the NCEP’s 
codification of the metabolic syndrome, the syndrome came under the province of 
government scientific authority.  Whereas in earlier periods, the syndrome has been 
debated among practicing physicians who specialized in endocrinology and 
cardiology, the syndrome, however conceptualized, would now be understood as 
falling under government biomedical jurisdiction.   This moment is also significant 
because, despite the earlier ICD-9-CM classification for dysmetabolic syndrome in 
2000, as a result of the NCEP action, the metabolic syndrome increasingly came to 
acquire significant currency across biomedicine.  Table 3.4 shows the citation counts 
for major definitions of the metabolic syndrome.51 
 
[Insert table 3.4 citation counts of major definitions] 
 
 The NCEP’s definition of the metabolic syndrome also created both 
controversy and opportunities for more research in the biomedical community.  Partly 
in response to the NCEP definition of the metabolic syndrome, two years later the 




Endocrinology, including Dr. Reaven, began a renewed campaign to use the construct 
“insulin resistance syndrome” over the NCEP’s metabolic syndrome (Einhorn, 
Reaven, Cobin, Ford, Ganda, Handelsman, Hellman, Jellinger, Kendall, Krauss, 
Neufeld, Petak, Rodbard, Seibel, Smith, and Wilson 2003).  Dr. Reaven has 
continued to be a critical voice in the debates about the metabolic syndrome and 
similar concepts, despite being a key member of the National Cholesterol Education 
Program, and has advocated for the use of different terms at different times (Reaven 
1999; Reaven 2004a; Reaven 2005a; Reaven 2004b; Reaven 2005b). 
 To add to the ongoing struggles to name and define the syndrome, funded by 
an educational grant from AstraZeneca pharmaceuticals52, the International Diabetes 
Foundation (IDF) convened a 2004 workshop in London consisting of 21 experts in 
the fields of diabetes, public health, epidemiology, lipidology, genetics, metabolism, 
nutrition, and cardiology.  The workshop aimed to establish a new unified definition 
of the metabolic syndrome that could be used specifically to compare different 
populations around the world (Alberti, Zimmet, and Shaw 2006).  They present 
several different hypothetical causes of the metabolic syndrome: insulin resistance, 
obesity, genetic profile, physical inactivity, aging, and a proinflammatory state.53    
 In 2005, the NCEP and the American Heart Association (AHA) published an 
official statement affirming the metabolic syndrome as a useful and valid construct 
(Grundy, Cleeman, Daniels, Donato, Eckel, Franklin, Gordon, Krauss, Savage, Smith, 
Spertus, and Costa 2005).  The NCEP/AHA ground this affirmation in their view that 
the metabolic syndrome clinically identifies a person at increased risk for 




However, what is significant about their defense of the syndrome is that they argue 
that the clinical significance of the metabolic syndrome comes through its power as 
an indicator of statistical risk of disease, not through its existence as a disease with a 
unique pathogenesis.  Yet, the authors argue that getting “a better understanding of 
the cause(s) of the syndrome may provide an improved estimate for developing 
ASCVD or type 2 diabetes for individuals” (Grundy et al 2005: 2737).    
These discourses about the metabolic syndrome signal that the long-standing 
cultural power attached to diseases with known biological causes has accompanied, 
and perhaps in some was supplanted by, the increasing influence of risk-based 
syndromes with predictive power.  The disjuncture in this discursive moment is that 
after risk-based syndromes are identified via statistical manipulation, then scientists 
work to uncover the assumed-to-exist biological causes of those manufactured 
associations.  In this context, the authors of the NCEP update assume that the 
syndrome has a pathogenesis that can be discovered by studying genetics, molecular 
biological, and cellular signaling:  
Moreover, a lack of understanding of the genetic and metabolic 
contributions to the causation of the syndrome stands in the 
way of developing new therapeutic approaches.  The need 
exists, therefore, for additional basic and clinical research 
designed to better understand [the] pathophysiology [of the 
metabolic syndrome] from the standpoint of genetics, 





The implication of their argument is that proof of a cause for the metabolic syndrome 
will help improve its prediction of which groups will develop diseases, not to help 
establish it as a disease in and of itself.   Here, the effort to establish the metabolic 
syndrome as a disease with a cause in a body seems to be combined with, or perhaps 
supplanted by, the need to use the metabolic syndrome as an indicator of risk across 
populations. 
Nonetheless, it was precisely these types of arguments about the metabolic 
syndrome that encouraged the American Diabetes Association (ADA) and the 
European Association for the Study of Diabetes (EASD) to publish an eight point 
critique of the metabolic syndrome that called into question its legitimacy within 
biomedical science and use within clinical practice (Kahn, Buse, Ferrannini, and 
Stern 2005).  While the ADA/EADS authors believe that the metabolic syndrome 
may have been useful for educational purposes—to educate doctors about the 
clustering of risk factors for chronic disease—in the final analysis the metabolic 
syndrome has “taken on meaning and import greater than is justified by our current 
knowledge” (Kahn et al 2005: 2299).    A citation count of this study as of April 30, 
2009, shows that 672 authors have cited this ADA critique of the metabolic syndrome 
(see Table 3.4 for more information) 
In the paper, the ADA/EASD advance a critique that lists the top eight reasons 
to be concerned about the metabolic syndrome 
 





The authors also raise a new issue about the metabolic syndrome namely, that 
because of the ways that some definitions of the syndrome use race to determine 
statistical cutpoints of obesity, these definitions classify different proportions of racial 
and ethnic minority groups.  For example, the prevalence of metabolic syndrome in 
Mexican Americans varied up to 24% between the WHO and NCEP definitions of the 
syndrome (Kahn et al 205: 2291).54  Despite raising this issue, which I take up in 
greater detail later in this chapter, the ADA/EASD missed an opportunity to frame 
any broader implications for race and ethnicity as one of the top reasons to challenge 
the legitimacy or meaning of the metabolic syndrome.   
Since the NCEP codified the metabolic syndrome in 2001, different agencies 
within the government have published information about the metabolic syndrome on 
their websites.  Medline Plus, the web-based medical library provided by the National 
Library of Medicine55 and the National Institutes of Health, both define the metabolic 
syndrome and its causes.  Currently posted on the National Heart, Lung, and Blood 
Institute’s website, is the following claim: “Genetics (ethnicity and family history) 
and older age are other important underlying causes of metabolic syndrome.”56 The 
next section addresses how, in 2009, it is possible for the federal government to 
construct race and ethnicity as a genetic cause of the metabolic syndrome.  
 
Part II: The Production of Race 
 In this section, I interpret the metabolic syndrome as a racial project, an 
unfolding representation of bodily and population difference that continually draws 




race to classify bodies and populations.  In other words, I reconstruct the emergence 
of the metabolic syndrome as a polyvalent process of racial formation and 
biomedicalization.   I also use the construct of disjunctures to show how in some 
moments, this process of racial formation was explicit, and in other moments, it 
seems to be implicitly woven into the everyday practice of doing biomedical research 
in the United States.   In the broadest and most generous terms, the specific 
approaches to race within metabolic syndrome research were consistent with the 
broader treatment of race in biomedical research and clinical medicine.  Yet, the 
metabolic syndrome also becomes a new way that researchers can construct 
molecular and genetic discourses about racial difference.  In the three sections that 
follow, I show how biomedical researchers used and produced conceptions of race in 
metabolic syndrome discourse that affirmed essentialist, biological, and genetic 
conceptions of race.    By organizing part II using the same thematic schema I 
developed in part I, I aim to demonstrate how the racialization of the syndrome itself 
represents a major disjuncture in the emergence of the metabolic syndrome.  
 
Sampling Normal Subjects, 1956-1987 
 As World War II ended and the horrors of the Holocaust were revealed in 
public sight, the range of scientific ideas and practices that had supported white 
supremacy, racial superiority, and eugenics lost their normalcy.  The pronouncements 
of the United Nations’ Education, Scientific, and Cultural Organization (UNESCO) 
that scientific conceptions of race used to justify Nazi extermination policies had no 




approaches to race towards a population approach to race.  As I described earlier in 
my critical race theory framework, in the post-War period, population-based 
approaches to race began to accompany and supplant a view of race as reflecting 
natural human types.   As I describe in this section, this disjuncture was apparent in 
research on the metabolic syndrome.  However, the early period of emergence of the 
metabolic syndrome (1956-1987) still contained the seeds of typological race 
thinking.   
The physical examinations and laboratory tests that comprised the early 
technological foundations of the metabolic syndrome were developed using white 
European research subjects. Thus, the European body comprised the empirical data 
for the construction of early ideas about the metabolic syndrome.  In other words, the 
metabolism of the European allegedly normal body became the norm, against which 
other bodies would be compared, in the total absence of any explicit discourse on 
race.  None of the samples of these early studies contained any visible racial 
minorities, and there was no explicit or implicit reference to whether the observed 
clustering varied across population groups classified according to race (Hitzenberger 
1922; Kylin 1922; Maranon 1922, Vague 1956).  Rather, the assumption seemed to 
be that knowledge produced with white research subjects was valid and would apply 
universally to all bodies.   
 Jean Vague’s (1956) article on the index of masculine differentiation provides 
a good example of how race was present by virtue of its absence. The ways in which 
Vague’s core concept, the index of masculine differentiation, overlays the socially 




conceptual blueprint for how the metabolic syndrome would overlay sex and race 
categories over standardized biochemical and anthropometric data.   However, from a 
contemporary perspective, the unmarked and yet unremarkable white skin of his 
subjects is also noteworthy.57  
 In contrast to this implicit racial discourse in Vague’s published research, race 
and ethnicity were explicit organizing principles of population research beginning in 
the late 1970s and through the 1980s.   As I described earlier, beginning in the 1940s 
the federal government took on a new role in monitoring the metabolic health of the 
population of the United States.  While epidemiological studies like the Framingham 
Study provided the empirical basis for biomedical information about risk factors for 
heart disease in white populations, it was not until the 1980s that the US government 
began to fund population studies on non-European population groups specifically in 
terms of metabolic health problems (Pollock 2008).  This more explicit focus on race, 
and use of race to sample populations, was in part a response to community-studies of 
diabetes, heart disease, and stroke that showed rates of disease on the rise in 
communities of color beginning in the 1960s and 1970s (Williams and Collins 1995).  
This new focus on race, and new use of race, was also a consequence of broader 
efforts to include racial and ethnic minorities in clinical and biomedical research 
(Epstein 2004).   
 Population studies were instrumental for the emergence of the metabolic 
syndrome because they provided institutional mechanisms by which and a discursive 
framework through which conceptions about race and ethnicity could become 




frameworks of four of the earliest of these federally funded studies, which were all 
modeled after the 1948 Framingham Study.58  These four studies were significant for 
at least three main reasons: 1) they each included examinations and laboratory tests; 
2) they sampled and collected data from populations they conceptualized as racial; 
and 3) their data has been used to analyze the metabolic syndrome.   The timing of 
these studies from the mid-1980s through the present is significant because they 
would provide the racial data to study the metabolic syndrome in later years.  
 The first study, the San Antonio Heart Study, 1979-1988, was a longitudinal 
cohort study that sampled 5,000 residents of three areas of San Antonio, TX—from 
low SES ‘Mexican American’, middle SES ‘Mexican and White’, high SES ‘White’ 
(Gardner, Stern, Haffner, Relethford, and Hazuda 1982; Hazuda, Stern, Gaskill, 
Hoppe, Markides, and Martin 1981).  The study was designed to determine factors 
beyond obesity that contribute to diabetes and cardiovascular risk in Mexican 
immigrants and Mexican Americans as compared to whites.  The physical 
examination of this study included “blood pressure, obesity, body fat distribution, 
[and] skin color, the latter to estimate percent Native American genetic admixture.”59  
Measurements of insulin resistance were compared to skin color to test the hypothesis 
that at any given level of adiposity Mexican Americans will be more insulin resistant 
than Anglos and that the insulin resistance in Mexican Americans is proportional to 
the degree of Native American ancestry.”60  The San Antonio Heart Study is 
important because it was the first major study after Framingham to measure all of the 
components of the metabolic syndrome and to focus on a particular ethno-national 




 A second study, the Coronary Artery Risk Development in Young Adults 
Study (CARDIA), 1985-2006, was a prospective longitudinal, multi-site, cohort study 
that sampled 5,115 black and white men and women aged 18-30 in Birmingham, 
Chicago, and Minneapolis (Hughes, Cutter, Donahue, Friedman, Hulley, Hunkeler, 
Jacobs, Liu, Orden, Pirie, Tucker, and Wagenknecht 1987).   The CARDIA Study has 
been used to evaluate the relationship between racial discrimination and blood 
pressure (Krieger and Sidney 1998), as well as the relationships between dairy 
consumption and the insulin resistance syndrome (Pereira, Jacobs, Van Horn, 
Slattery, Kartashov, and Ludwig 2002). This study is significant because an explicit 
effort was made in the sampling strategy for CARDIA to achieve approximately 
balanced subgroups of race, gender, and education across age and geographic 
groups.61   
 The Atherosclerosis Risk in Communities Study (ARIC), 1987-1998, 
constituted a third study that was significant because it also was designed to 
“investigate the etiology and natural history of atherosclerosis, the etiology of clinical 
atherosclerotic diseases, and variation in cardiovascular risk factors, medical care and 
disease by race, gender, and location.”62   ARIC was a prospective longitudinal study 
that sampled 15,792 individuals (aged 45-62) across Minneapolis, MN; Washington 
County, MD; Forsyth County, NC; and Jackson, MS (Williams 1989) (Schmidt, 
Duncan, Watson, Sharrett, Brancati, and Heiss 1996).  
 The fourth study is the Jackson Heart Study (JHS) (1987-2003), the largest 
prospective study ever of the “inherited (genetic) factors that affect high blood 




Americans.”63  JHS initially began as one site of the aforementioned ARIC study.  It 
sampled 6,500 African Americans, aged 35-84, living in Jackson, MS (Taylor, Liu, 
Wilson, Golden, Crook, Brunson, Steffes, Johnson, and Sung 2008).  According to 
the study description at the NHLBI website, the Jackson Heart Study included an 
extensive examination including a questionnaire, physical assessments, and 
laboratory measurements of conventional and emerging risk factors that may be 
related to CVD.   The physical assessment of subjects in JHS includes height, weight, 
body size, blood pressure, electrocardiogram, ultrasound measurements of the heart 
and arteries in the neck, and lung function.  The laboratory measurements collected 
from subjects in JHS includes cholesterol and other lipids, glucose, indicators related 
to clotting of the blood, among others.  With these techniques, the Jackson 
investigators have been able to examine the “physiological relations between 
common disorders such as high blood pressure, obesity, and diabetes, and their 
influence on CVD.”64 
[Insert Table 3.6] 
 These four studies are significant because they produced forms of racial data 
that emerged in polyvalent locations and were then incorporated into subsequent 
research on the metabolic syndrome.65 Table 3.6 presents the citations for selected 
research articles based on data from these four studies.  For example, according to the 
study’s website, the ARIC study data have been used to publish at least eighteen 
studies on the metabolic syndrome, metabolic syndrome X, and multiple metabolic 




list of publications on the study website shows that as of February 2009 at least 16 
studies have used CARDIA data to analyze the metabolic syndrome and race.  
 
Is Race Really to Blame? 1988-2000 
 While population studies would come to produce the majority of data used in 
published studies of the metabolic syndrome in the 1990s and into the millennium, 
clinical researchers continued to use racial categorization in their research on 
metabolic syndrome.   In fact, the data that emerged out of race-based population 
studies provided a basis upon which practicing physicians might treat patients 
differently based upon their racial classification.  From the epidemiological 
perspective that shaped government funded race-based population studies, there was a 
need to understand whether and to what extent risks for metabolic health problems 
might differ across the major population groups of the nation.   As will become 
apparent in this next section, these questions about the distribution of metabolic 
health problems across racially categorized groups began to intersect with new 
questions about the causes of metabolic health problems.   
 Gerald Reaven’s early and later publications constitute a useful documentary 
case to examine how scholars conceptualized race and ethnicity in relationship to the 
population dynamics and individual-level causes of the syndrome X.  Along side of 
Jean Vague, who I discussed early in this chapter, Reaven is revered as a second so-
called father of the contemporary metabolic syndrome, and for this reason his ideas 
about race warrant detailed scrutiny.  Perhaps because it was delivered as a public 




special racial/ethnic distinctions in the syndrome X construct nor in the etiological 
theories that he proposed connected insulin resistance, cholesterol, blood pressure, 
and heart disease risk.  For that matter, he did not mention his sample population at 
all in the lecture.   
 In his early research on insulin resistance during the 1970s, Reaven seems to 
have drawn upon mostly European research subjects when he was part of a group of 
medical researchers in the Department of Medicine in the Stanford University School 
of Medicine.  Different members of the group (both including Reaven) published two 
studies in the Journal of Clinical Investigation, one in 1970 that tested a new 
technique for measuring insulin-mediated uptake (Shen, Reaven, and Farquhar 1970), 
and another in 1975 that demonstrated that this new method of insulin resistance 
tends to identify subjects with diabetes (Ginsberg, Kimmerling, Olefsky, and Reaven 
1975).  Both studies seemingly use of one of the samples upon which Reaven built his 
later research on Syndrome X.   The first and last initials of one of the research 
subjects (“L.K.”) are printed in both articles, thus strongly suggesting they are using 
the same sample.  The descriptions of the sample, which contains people with 
diagnosed diabetes and those without diabetes, are different in each paper in one 
exceptional case.  In the 1970 paper, the authors describe how the diabetics in the 
sample were selected from their patient referral group, matched by weight, age, and 
percent adiposity with the normal control group.  In this brief passage, they describe 
the sampling procedure for the normal population, which is notably absent from the 




Normal individuals were selected after interviews with a group of 
volunteers who had recently been discharged from a local minimum-
security prison.  Volunteers responded to a notice asking for assistance 
in a research project which would furnish their living expenses during 
a 2 week hospital stay (Shen, Reaven, and Farquhar 1970: 2151).  
In the 1975 paper, the recently released inmates who likely participated in the study 
in order to get shelter are described simply and neatly as “healthy adult male 
volunteers.”   While neither study reveals or refers to the race or ethnicity of its 
subjects, both the age and sex of each subject is noted in printed tables.   Without any 
evidence one way or the other, the only safe assumption is that Reaven’s subjects 
were predominantly white.  
 In a book on syndrome X in 2000 (Syndrome X: overcoming the silent killer 
that can give you a heart attack), Reaven argues that “ethnicity” plays a role in 
causing syndrome X, with people of non-European origin being at a much greater risk 
for the syndrome (Reaven, Strom, and Fox 2000: 20).  In the introductory chapter of 
the book, the reader is confronted with a section labeled “Who is likely to develop 
syndrome X?”   Here, Reaven lists the people who are likely to develop syndrome X: 
1) people with genetic abnormalities; 2) people of non-European origin; 3) people 
with a family history of diabetes, heart attack, and hypertension; 4) and people who 
eat poorly and exercise little.  Why does Reaven believe that people of non-European 
origin are more likely to develop syndrome X?   
 The answer to this question about how Reaven conceptualizes the relationship 




Genes Really to Blame?”   This was my inspiration for the title of this section because 
Reaven’s central argument in this passage is that ethnicity identifies genetic 
differences between individuals and populations.   In adjudicating the respective role 
of genes in the development of syndrome X, Reaven cites three lines of genetic 
evidence, two of which are drawn from research in which he participated, that taken 
together treat race and ethnicity as genetic categories.    
 For the first line of evidence, Reaven cites a 1985 study that he co-authored 
that compared fifty-five Pima Indian men living near Phoenix to thirty-five Caucasian 
men living in California (Bogardus, Lillioja, Mott, Hollenbeck, and Reaven 1985).66  
The investigators measured the levels of obesity, physical fitness, and insulin 
resistance in the two groups (who are not explicitly labeled as racial groups in any 
way) and used statistical techniques to determine the degree to which differences in 
their levels of obesity and physical fitness contributed to the variability of their 
insulin action (Reaven, Strom, and Fox 2000: 56).   Reaven, writing now in 2000, 
claims that this 1985 study showed that “half of the variability of insulin action was 
due to lifestyle, the other half presumably to our genes.  Of the 50 percent attributed 
to lifestyle, half was due to fitness, half to obesity” (Reaven, Strom, and Fox 2000: 
57).  Here, the authors claim that the other half was due to racial differences in 
genetics because their operating assumption about race is that by comparing Pima 
Indians and Europeans, they were uncovering underlying genetic differences between 
them.   
 The second line of genetic evidence upon which Reaven draws to claim that 




Pima Indians (Lillioja, Mott, Zawadzki, Young, Abbott, Knowler, Bennett, Moll, and 
Bogardus 1987).  This study compared levels of insulin resistance within Pima 
families to levels of insulin resistance across families and demonstrated, again 
according to Reaven in 2000, that the clustering of insulin action is greater within 
families than it is across families.67  In effect, this claim constructs familial 
heritability and genetic susceptibility as the same biomedical phenomenon when it 
plays out within a tribal group known to have high rates of intermarriage.   
 The third line of evidence that Reaven cites to substantiate the role he sees for 
genetics in causing syndrome X is not as well cited, making it more difficult to 
analyze his claims about race in great detail, but the implications of his argument are 
clear.  According to Reaven’s theory, genetics play a role in the development of 
syndrome X, and whatever the guilty genes might be, people of non-European 
ancestry are more likely to have them (Reaven, Strom, and Fox 2000: 58).    How can 
Reaven make such a claim?  He refers to a body of population studies that 
purportedly shows that American Indians, South Asian Indians, Japanese-Americans, 
African-Americans, Mexican-Americans, Australian Aboriginals, and various Pacific 
Islander populations are more insulin resistant compared to those of European 
ancestry (Reaven, Strom, and Fox 2000: 57).   Reaven does not cite any studies after 
making these sweeping claims, but instead inserts a parenthetical statement after 
listing these group differences that crystallizes his ideas about the causes of racial 
difference: the observed differences in insulin resistance reflect genetic differences 
between racial groups.  The authors argue that while its possible that some racial 




several studies [again, not cited in the book] did take group differences in all known 
factors into account, the differences in insulin resistance found as a result of these 
comparisons result from heritable genetic differences between groups (Reaven, 
Strom, and Fox 2000: 58). 
 At the conclusion of the section, Reaven writes that the comparison of a racial 
group with insulin resistant genes to one that does not have these genes is a way to 
test the hypothesis about non-European ethnicity as a genetic cause of syndrome X 
(Reaven, Strom, and Fox 2000: 58).   With reference to a comparative study of South 
Asian Indians and Europeans living in the United Kingdom, Reaven argues that 
despite the fact that the South Asian Indian individuals ate little fat and had lower 
cholesterol levels than the Europeans, they had fifty percent higher incidence of 
diabetes and heart attacks.  “Clearly,” Reaven concludes, “genes played a major role 
in the development of insulin resistance and Syndrome X in these South Asian 
Indians” (Reaven, Strom, and Fox 2000: 58).    
 
The New Special Populations, 2001-Present 
 In the contemporary period, the uses and conceptions of race in biomedical 
research on the metabolic syndrome seemingly have expanded in ways reminiscent of 
earlier periods and extended in new and unanticipated directions.  These expansions 
and extensions have taken place through the increasing interaction between new 
forms of clinical biomedicine and government public health research, both of which 
are focused on racial health disparities.  Due to these converging forces, there is no 




populations is used specifically within government biomedicine to refer to pregnant 
women, children, racial/ethnic minorities, elders, and any other population group that 
is not white/European and male.   In the contemporary moment, people who are 
classified with the metabolic syndrome or who think they have it comprise a new 
special population that is constructed out of and produces race.  In this final section, I 
describe some of the central ways that race is taken up in contemporary research on 
the metabolic syndrome and discuss a special focus on African Americans as a 
special population that has been organized around the metabolic syndrome.  
 The 2001 National Cholesterol Education Program (NCEP) approach to race 
was to acknowledge existing racial inequalities in heart disease risk, and to advocate 
an approach to managing cholesterol that treated all groups as if they were the same, 
but otherwise to leave questions about race unasked.  In a section titled “Special 
Considerations for Different Population Groups”, the authors of the 2001 NCEP 
report imply that the high presence of the metabolic syndrome among African 
Americans is a partial explanation of racial inequalities in heart disease risk: 
African Americans have the highest overall CHD [coronary heart 
disease] mortality rate and the highest out-of-hospital coronary death 
rates of any ethnic group in the United States, particularly at younger 
ages.  Although the reasons for the excess CHD mortality among 
African Americans have not been fully elucidated, it can be accounted 
for, at least in part, by the high prevalence of coronary risk factors.  
Hypertension, left ventricular hypertrophy, diabetes mellitus, cigarette 




all occur more frequently in African Americans than in whites 
[emphasis added] (NCEP 2001: 2495).   
What this is saying is that African Americans have higher risk for heart disease 
because, as a group, they experience multiple heart disease risk factors more often 
than do whites.  Despite making this claim, the NCEP concludes that there was 
insufficient evidence to make racial and ethnic-specific recommendations for studying 
or treating cholesterol for African Americans or other ethnic population groups.  They 
continue,  
Other ethnic groups and minority populations [other than African 
Americans] include Hispanics, Native Americans, Asian and Pacific 
Islanders, and South Asians.  Although limited data suggest that racial 
and ethnic groups vary somewhat in baseline risk for CHD, this 
evidence did not appear sufficient to lead the ATP III panel to modify 
general recommendations for cholesterol management in these 
populations (NCEP 2001: 2495). 
And while it is technically true that there are groups other than European and African 
Americans living in the United States, this has nothing to do with cholesterol 
management per se.  By not addressing the potential implications of their new 
definition of the metabolic syndrome for racial and ethnic groups in the context of the 
ongoing dialogue about racial health disparities, the NCEP helped to establish the 
epistemic conditions for race and ethnicity in contemporary metabolic syndrome 




 Since 2001, despite the claims about race (and not made) in the NCEP 
definition of metabolic syndrome, scientists have increasingly raised questions about 
the use, measurement, and interpretation of the metabolic syndrome construct across 
different racial and ethnic populations.  These new questions about the relationship 
between race and the metabolic syndrome have several disjunctive features.  For one, 
since the World Health Organization recommended standardizing obesity 
measurements in different racial and ethnic groups in first 1997 (WHO 1997) and 
again in 2004 (WHO 2004), race and ethnicity are explicitly used in the practice of 
validating group-specific empirical cutoff points (endpoints) for the physical 
examinations and laboratory tests (biomarkers, for short) that comprise the syndrome.  
The argument for using race-based endpoints is that they improve the generalizability 
and validity of comparisons of disease risk across individuals and populations.  
Statistical validity is determined with respect to the outcome, the metabolic 
syndrome, by evaluating whether the syndrome successfully identifies all of the 
individuals at increased risk within specific populations groups.  For example, the 
body mass index for an individual who is classified “African American” would be 
statistically adjusted for two reasons:  first, to account for the differential relationship 
between obesity and CVD risk in African Americans as compared to other groups.  
These standardizations construct statistical norms against which racial and ethnic 
populations can be validly compared to one another.  
 A second feature of the relationships between race and the metabolic 
syndrome concerns how research institutions use new conceptions of the metabolic 




insulin resistance syndrome, the American Association of Clinical Endocrinologists 
and the American College of Endocrinology provided optional standardizations of 
obesity for different ethnic groups (Einhorn 2003).  They also repeat the thesis that 
“Non-Caucasian ethnicity (e.g. Latino/Hispanic American, African American, Native 
American, Asian American, Pacific Islander)” is a “risk factor” for the syndrome, 
reaffirming Reaven’s earlier racial hypotheses from the 1980s.   
 Three years later in 2006, the International Diabetes Federation incorporated 
racial and ethnic measurements of waist circumference because “…there are clear 
differences across ethnic populations in the relationship between overall adiposity, 
abdominal obesity, and visceral fat accumulation” (Alberti, Zimmet, and Shaw 2006: 
473)..  The authors elaborate a list of country/ethnic-specific values for waist 
circumference for “Europids,” “South Asians,” “Chinese,” and “Japanese” 
populations.  Several other groups do not yet have their own standardized values: 
“Ethnic South and Central Americans,” “Sub-Saharan Africans,” and “Eastern 
Mediterranean and Middle East.” In the meantime, the authors advocate that the 
South and Central American ethnic groups should use “South Asian” values, the 
Africans and the “Arab populations” should use “European” values until “more 
specific data are available.”   The authors provide special instructions for applying 
these “country/ethnic specific values” in clinical and epidemiological research.  They 
write,  
It should be noted that the ethnic group-specific cut-points should be 
used for people of the same ethnic group, wherever they are found. 




expatriate Japanese communities, as would those for South Asian 
males and females regardless of place and country of residence 
(Albert, Zimmet, and Shaw 2006: 476).  
These recommendations imply that these standardizations are not country-specific 
values, but racial ones that transcend “place and country of residence.”   
 Since 2005, these institutional practices have resulted in a new line of 
biomedical research that investigates the implications of using the metabolic 
syndrome to compare heart disease risk across different racially categorized groups 
(Banerjee and Misra 2007; Unwin, Bhopal, Hayes, White, Patel, Ragoobirsingh, and 
Alberti 2007).  Scholars in this emerging field of research have investigated racial and 
ethnic differences in the relationships between obesity and heart disease risk (Zhu, 
Heymsfield, Toyoshima, Wang, Pietrobelli, and Heshka 2005), body composition and 
metabolic risk factors (Desilets, Garrel, Couillard, Tremblay, Despres, Bouchard, and 
Delisle 2006), the power of trigycerides to predict insulin resistance (Bovet, Faeh, 
Gabriel, and Tappy 2006; Sumner, Finley, Genovese, Criqui, and Boston 2005; 
Sumner and Cowie 2008), and the relationship between HDL cholesterol levels and 
CVD risk (Amarenco, Labreuche, and Touboul 2008).  
 African Americans, and theories of African American health, occupy a 
prominent place in special populations research that links race and the metabolic 
syndrome.  A review article on the metabolic syndrome in African Americans was 
published in the journal Ethnicity & Disease in 2003.68   All of the authors of this 
review article are members of the African-American Lipid and Cardiovascular 




from an unrestricted educational grant from Bristol-Myers Squibb Company, and 
many of them have published widely on the metabolic syndrome and African 
Americans.69 Like the NCEP, Hall and colleagues (2003) situate their review of 
metabolic syndrome and African Americans in the context of the epidemiological fact 
that African Americans have the highest overall CHD mortality and out-of-hospital 
coronary death rates of any racial group in the United States.  Yet to explain the racial 
disparities in the metabolic health between “Native Americans”, “Mexican 
Americans”, and “African Americans” compared to “European Americans”, the 
group advances a “genetic admixture theory” (Hall et al 2003: 415).70  
 Theories of genetic admixture assume that individual level susceptibility to 
disease is related to their shared genetic admixture with populations known to be 
susceptible to the disease.  According to this theory, before the 1960s, European 
Americans had historically had higher rates of diabetes than African Americans, 
Hispanics, and Native Americans but increasing racial miscegenation that has 
occurred since the colonialism explains the increasing rates of diabetes in these racial 
and ethnic minority groups (Tull and Roseman 1995: 614).   The central assumption 
of this theory is that racial groups at an earlier moment were pure and segregated and 
it is their intermingling since the “discovery” of race that explains racial disparities in 
modern times.  They argue that the degree of genetic admixture is related to the 
“susceptibility” of different racial groups to the risk factors that constitute metabolic 
syndrome.  They write  
Whites of European origin appear to have greater predisposition to 




whereas Blacks of African origin are more prone to HBP [high blood 
pressure], type 2 diabetes and obesity.  Native Americans and 
Hispanics are less likely to develop HBP than Blacks, but appear 
particular susceptible to type 2 diabetes. Of particular note is the 
considerable genetic admixture among Native Americans and 
Mexican Americans (Hall et al 2003: 415).  
Also like the authors of the NCEP report, the authors homogenize all non-white 
population groups in terms of recommendations for treating the metabolic syndrome. 
They write that most of the discussion and recommendations for African Americans 
probably also apply to Native Americans, Mexican Americans, and South Asians 
(Hall et al 2003: 415).    
 
Conclusion 
 In part I of this chapter, I demonstrated that the metabolic syndrome emerged 
through the technoscientific integration of molecularization and the risk factor 
paradigm, two social processes that were increasingly focused on understanding 
metabolism from a biomedical perspective.  Based on this analysis, I argue that the 
extension of legitimate government authority over the metabolic syndrome marks the 
emergence of a new discourse of biopower.   This emergence created a context in 
which the molecular processes of the body were used to constructed risk-based 
syndromes of populations that social institutions like professional biomedicine and 
the federal government could deploy to understand and improve metabolic health, 




social processes and institutional relationships involved in the racial formation of the 
metabolic syndrome.    
 
[Insert Table 3.7. Summary of social processes and institutional relationships in the 
racial formation of the metabolic syndrome] 
 
 In part II, I argued that the emergence of the metabolic syndrome created a 
discursive and institutional context for the production of race.  In other words, the 
constructions of the metabolic syndrome have changed over time, but they emerge 
out of processes that consistently draw upon and produce racial meaning.   The 
construction of racial meaning that accompanied the emergence of the metabolic 
syndrome was consistent with broader biomedical ideas about race.  In the first 
moment between 1956 and 1988, the science of metabolism became a site for the 
integration of typological and population-based approaches to the study of race and 
racial difference.  This process would continue to inform the emergence of the 
metabolic syndrome.  For example, in the second moment between 1988 and 2000, 
discourses that constructed race as genetic shaped the biomedical debate about the 
genetic causes of the metabolic syndrome.  In the third moment since 2001, the 
metabolic syndrome has become a new site of special populations research in which 
racially categorized groups are compared using standardized biological, genetic, and 




 In the next chapter, I explore how constructions of the metabolic syndrome 
and meanings of race are taken up in new special populations research on prescription 







Table 3.1 Selected technical developments contributing to the metabolic syndrome, 
1896-1985. 







(1896) Riva-Rocci develops the mercury manometer.  
(1897) Hill and Bernard develop the aneroid manometer. 
(1906) Janeway publishes “The Clinical Study of Blood Pressure” which 
influences the medical director Northwestern Mutual Life Insurance 
Company, Dr. J.W. Fisher, to include blood pressure in its physical 
examinations.  By 1918, most insurance companies measured blood 
pressure in their examinations.  
(1917, 1921, and 1927) the American Bureau of Standards published major 
reports on the improvement and standardization of blood pressure 






(1929) Horgaard and Thayssen develop what they call the insulin-tolerance 
test. 
(1983) DeFronzo and colleagues develop the “Eeuglycaemic 
hyperinsulinaemic clamp technique”-- the proverbial ‘gold standard’ for 
measuring insulin resistance in vivo (Defronzo, Ferrannini, and Koivisto 
1983). 
(1985) Mathews and colleagues construct the homeostasis model 
assessment-insulin resistance index.  
(1998) Belfiore and colleagues develop the oral glucose tolerance test 





LDL and VLDL 
triglycerides, HDL 
lipoprotein analysis 
The history of the science lipid metabolism originates in the late 1800s.  
(1948-present) The Framingham Heart Study was central to the 
establishment of the risk factor paradigm, especially the role of total 
cholesterol in the development of cardiovascular disease (Kannel, McGee, 
and Gordon 1976).  
(1964) Konrad Bloch and Feodor Lynen were awarded the Nobel Prize in 
Physiology or Medicine for their discoveries concerning the mechanism and 
regulation of the cholesterol and fatty acid metabolism. 
(1985) Goldstein and Brown also win a Nobel for their research on the 
cellular synthesis of cholesterol. 
Obesity 
Body Mass Index 
(weight in kg/ 
height in meters2) 
(1942) Metropolitan Life Insurance Company issues weight-for-height 
tables that measure the “ideal weight” for men (Metropolitan Life Insurance 
Company 1942). 
(1959) MetLife includes women in its weight-for-height schema 
(Metropolitan Life Insurance Company 1959) 
(1980) The USDA Dietary Guidelines for Americans attempts to 
standardize the measurement of body mass index, although the 
measurement of obesity would continue to undergo significant revision in 













Figure 3.2. Photograph scanned from Vague (1954) showing gynoid obesity in male 





Figure 3.3. Photograph scanned from Vague (1954) showing android obesity in male 






Table 3.4. Selected major definitions of the metabolic syndrome and citation counts 












































plus two or more 
of the following 
biomarkers 
3 of 5 of any of 
the following 
biomarkers 






Insulin resistance  Elevated glucose 
>= 110 mg/dl 
Elevated glucose 
> 110 mg/dl 
*excluding 
type 2 diabetes 





















>=150 mg/dl  
or  
HDL < 35 
mg/dl 
LDL triglycerides 
> 150 mg/dl 
LDL triglycerides 
> 150 mg/dl 
 
LDL triglycerides 
>= 150 mg/dl 
or   









Decreased HDL  See above panel 
HDL cholesterol 
men < 40 mg/dl 
women < 50 
mg/dl 
HDL cholesterol 
men < 40 mg/dl 
women < 50 mg/dl 
 
HDL cholesterol 
men < 40 mg/dl 









Blood pressure > 
160/90 or  
drug treatment for 
hypertension 
Blood pressure > 
130/85 
Blood pressure > 
130/85 
Blood pressure >= 
130 systolic or 85 












ratio > .90 or 






men > 40 inches 
women > 35 
inches 
See below panel 
Abdominal 
circumference 
men >= 102 cm 









Body mass index 
(BMI) adjusted by 
ethnicity, waist 
circumference, and 
family history of 
type 2 diabetes  
 





Table 3.5. American Diabetes Association & European Association for the Study of 
Diabetes Critique of the metabolic syndrome, 2005 (cited 672 times, April 2009). 
 
 
Eight Challenges to the Metabolic Syndrome 
1) The criteria for metabolic syndrome are ambiguous or 
incomplete and the rationale for threshold values of specific 
biomarkers are ill defined 
2) The value of including diabetes in the definition is questionable 
3) Insulin resistance as the unifying etiology of metabolic 
syndrome is unclear 
4) There is no clear basis for including/excluding other CVD risk 
factors 
5) CVD risk value is variable and dependent on the specific risk 
factors present 
6) The CVD risk associated with the syndrome appears to be no 
greater than the sum of its parts; 
7) Treatment of the syndrome is no different than the treatment for 
each of its components; and 





Table 3.6. Selected articles on metabolic syndrome based on population studies. 
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Chapter 4: The Racial Pharmacology of Killer Applications 
In chapter one, I stated that pharmaceutical corporations are interested in 
developing prescription drugs that could be sold to people who might be classified 
with the metabolic syndrome and that this research has a new racial dimension.  In 
chapter three, I argued that the emergence of a discourse about the metabolic 
syndrome involved social processes and institutional relationships that accompanied 
and produced new racial meanings.   Specifically, I suggested that the emergence of 
the metabolic syndrome is a racialized process of biomedicalization that has drawn 
upon the techniques of biopower that are focused on disciplining and regulating the 
metabolic health of individuals and groups.  In chapter three, I also used the term 
special populations as a way of referring to the biomedical study of population 
groups who are not white men.  This term has added significance in the context of 
drug research and development because just as biomedical research needed to include 
these non-white and male groups, drug manufacturers are now required to study the 
safety and efficacy of prescription drugs in these groups.   
The metabolic syndrome and race are deployed at the intersection of an 
increasingly technological, biomedical, and racially organized approach to the study 
of prescription drugs and drug metabolism.  In this chapter, I analyze the genealogical 
descent of race and the metabolic syndrome in biomedical research on the metabolism 
and use of prescription drugs among African Americans.72  This new biomedical 
research encompasses three distinctive elements that connect race, the metabolic 
syndrome, and prescription drugs.  First, researchers use conceptions of race and the 




American populations.  Second, physicians and clinical decisions play a role in terms 
of the differential diagnoses in health conditions that lead to differential forms of 
pharmacological treatment of health problems in African Americans.  Third, this new 
special populations research is a potential site for the deployment of biological and 
genetic explanations of racial differences in the metabolism of prescription drugs 
among African Americans. 
 To investigate these issues, I divide this chapter into three sections.  In the 
first section, I develop the metaphor of killer applications to examine how 
prescription drugs operate in the politics of metabolism.  Recall that the politics of 
metabolism encompasses the discourses, social processes, and institutional 
relationships that structure the metabolic health of individuals and groups.  Killer 
applications is a metaphor for novel combinations of human and non-human 
technologies that structure bodily practices in a wide range of social, commercial, and 
scientific contexts.  The metaphor of killer applications is especially well suited for 
examining how prescription drugs operate in the politics of metabolism by 
transforming the ways that pharmaceutical corporations design and market drugs for 
racially categorized groups.  Stated differently, the search for and research on killer 
applications have seemingly incorporated the metabolic syndrome and race. 
In the second and third sections, I compare the different racial meanings in the 
pharmacological study of two potential killer applications: atypical antipsychotics and 
statins.  Statins and atypical antipsychotics are prescribed for the treatment of 
schizophrenia and high cholesterol, respectively, and each has a unique relationship 




to treat dyslipidemias, which are fundamental to the construction of the metabolic 
syndrome.73 Second, atypical antipsychotics are a class of drugs that mental health 
practitioners prescribe to treat the collection of symptoms known as schizophrenia, 
but that produce the negative side effects of weight gain, hyperglycemia, and 
dyslipidemia—side effects that together comprise the metabolic syndrome.74  After 
describing the metaphor of killer applications and the field of racial pharmacology, I 
elaborate on the specific comparisons made in this chapter.  
 
The Metaphor of Killer Applications 
 A biomedical-government-industry collaboration formed in 2002 focused on 
the relationships between diabetes and heart disease.75  At this meeting, a 
pharmaceutical company representative encouraged a new line of pharmaceutical 
research on what he called “killer applications.”  He argued that so called killer 
applications research on the metabolic syndrome was needed because patients, like 
those with metabolic syndrome, are taking multiple drugs for multiple health 
problems and a new killer application in this area might obviate the need for multiple 
drug regimens, or replace existing therapies by increasing efficacy or decreasing side 
effects.  What is a killer application and what does it have to do with prescription 
drugs and the metabolic syndrome?  
 Donna Haraway suggests that killer applications constitutes a useful metaphor 
for novel combinations of human and non-human technologies that structure bodily 
practices in a wide range of social, commercial, and scientific contexts (Haraway 




superiority and maintain market supremacy over their competitors (Downes and Mui 
1998).  As Larry Downes and Chunka Mui point out, killer applications are a new 
good or service that “establishes an entirely new category and, by being first, 
dominates it, returning several hundred percent on the initial investment” (Downes 
and Mui 1998: 4).  For example, killer applications structure the social practices of 
technology users, as was the case of the iPod.  Within a few short years, the iPod 
revolutionized how people listen to music, interact with each other, and as a result of 
being the first of its kind, it still enjoys widespread popularity and brisk sales.  In 
other words, killer applications enact the power to change modes of cultural and 
economic organization.  Moreover, because of the myriad ways that killer 
applications impact our social lives, they have the potential to change our bodies and 
identities in profound ways.  
This metaphor of killer applications suits prescription drugs in four central 
ways.  First, prescription drugs fit the classic definition of killer applications, namely, 
they are technoscientific commodities that combine non-human and human elements.  
The non-human element of prescription drugs consists of the drugs themselves.  
Prescription drugs are mostly synthetic chemical compounds and fillers that have 
been mass-produced in laboratories and factories since the 1950s.  The human 
elements of prescription drugs as killer applications can be seen in the field of clinical 
pharmacology, the branch of biomedical science that studies the intended and 
unintended effects of drugs on the body. These human elements of prescription drugs 
consist of the relationships between medical professionals, typically doctors, who 




The interaction of these non-human and human elements of prescription drugs qua 
killer applications represents a network of technoscientific and commercial 
relationships that fundamentally change human bodies.  In this sense, prescription 
drugs are “applied” to bodies through a formalized process that involves drug 
companies, federal regulatory agencies, medical professionals, and consumers. 
Second, because prescription drugs have revolutionized how American 
medicine treats illness and disease, the search for killer applications has taken on new 
cultural meaning within the pharmaceutical industry.  As the pharmaceutical industry 
has grown in scope and reach over the past fifty years, taking prescription drugs has 
become Americans’ preferred practice for treating illness. When Americans get sick, 
they turn to their doctors and pharmacists for help, assuming that they have access to 
doctors and pharmacists and the financial means to pay them.  If one is not feeling 
well, often the first question people ask is “Are you taking anything?”  When 
individuals develop illnesses, all they need to do is ask their doctors for a 
prescription.  Every day, Americans are bombarded with television and print 
advertising from the pharmaceutical industry that encourages them to ask their 
doctors about taking new drugs to treat what ails them.  
Third, risk management is the central tool for creating successful and 
profitable killer applications.  The production of knowledge about risk was central to 
the emergence of the metabolic syndrome and no less has risk influenced a 
biomedical and statistical approach to population-based drug development and 
research.  Some prescription drugs like Lipitor acquire market supremacy by doing 




whereas other prescription drugs become successful because they do the best job of 
minimizing the risk of experiencing side effects from other drugs.   The better a drug 
is at managing different kinds of risk in bodies and populations, the more likely it will 
become a killer application.  Recently, the term comparative efficacy has emerged in 
the current debate over the future of the US health care system as a way to make 
America’s health care system more cost efficient (Malozowski 2008).  Comparative 
efficacy refers to a process through which researchers compare possible treatments 
for a health problem in order to determine which treatment, or combinations of 
treatments, is most likely to be effective at treating the problem.   
 Fourth, because of the rise of metabolic health problems in the American 
population, the pharmaceutical industry has a special interest in killer applications.  
The health problems encapsulated by the metabolic syndrome currently account for 
one fifth of all health care spending in the United States and much of that money is 
spent on prescription drugs.  In 2005, Americans spent $200.3 billion dollars on 
prescription drugs, five times more than they spent in 1990 (KFF 2007).   The 
pharmaceutical industry has been the most profitable industry in the United States for 
years, in large part due to prescription drugs that are sold to the millions of 
individuals who suffer from metabolic conditions like heart disease and high 
cholesterol.  In 2004, four of the top ten most dispensed drugs treat hypertension or 
high cholesterol, two central pillars of the metabolic syndrome (KFF 2007).77  
Globally, the biggest selling drug is Lipitor, a cholesterol drug, which brought in sales 




pharmaceutical industry has sixty million new potential customers and, potentially, 
some new challenges, some of which are centered on race.   
 
Defining Racial Pharmacology 
In recent years, numerous scholars have raised a series of questions about how 
drug researchers use race to develop, study, and market prescription drugs (Jones and 
Perlis 2006; Kahn 2006; Lynch, Lynch, and Dubriwny 2006; Sankar and Kahn 2005).  
Many of these new questions about race in pharmaceutical research have emerged in 
response to the controversy over BiDil, the first drug approved by the FDA in June 
2005 for specific use among African Americans.  BiDil (isorbide 
dinitrate/hydralazine hydrochloride) is a not a new chemical compound—rather it is a 
new patented combination of two existing generic drugs.   As these scholars have 
identified, one of the central questions in the BiDil case was how industry researchers 
used racial categories to frame their investigation of whether subpopulations varied 
with respect to drug response and metabolism.  Thus, the central challenge race poses 
for killer applications is this: If race is a socially constructed category, then how can 
biomedical researchers use race to identify which bodies and populations need 
particular killer applications, or particular doses of killer applications?  
 These developments are part of what I refer to here as racial pharmacology, or 
the biomedical study of prescription drugs, their effects, and their metabolism in 
racially categorized bodies and populations.   Clinical pharmacology is the branch of 
biomedicine that studies the intended and unintended effects of drugs on the body.   




study: pharmacokinetics, pharmacodynamics, and pharmacogenomics.  Each of these 
fields of clinical pharmacology has a racial structure that shapes the research and 
development of killer applications.  Pharmacokinetics studies the biological processes 
by which bodies absorb, distribute, metabolize, and excrete drugs.  
Pharmacodynamics studies the effects of drugs on bodies, the mechanisms of drug 
action, and the relationships between drug concentration and effect.  
Pharmacogenomics investigates the relationships between drug pharmacokinetics, 
pharmacodynamics, and genetics. 
I argue that the racial pharmacology of killer applications is a central feature 
of the politics of metabolism.  Three interrelated developments comprise the central 
questions in this emerging field of racial pharmacology.   First, as illustrated in the 
BiDil case, pharmaceutical companies are interested in creating racially 
circumscribed markets for their killer applications.  Because the pharmaceutical 
industry is part of an economic system that exploits human health as a commodity, 
constructions of racially categorized risk groups are easily adopted into drug research 
and marketing strategies that seek to profit from presumed forms of racial difference 
that are thought to have a meaningful relationship to individual-level differences in 
drug metabolism.  Second, in 2005 the Food and Drug Administration published new 
guidelines the use of racial classifications in clinical trials advocate that 
pharmacologists use the Office of Management and Budget (OMB) racial categories 
in clinical trials in order to study group differences in these metabolic processes that 
may be related to variability in drug responses (Food and Drug Administration 




pharmacokinetic, pharmacodynamic, and pharmacogenomic differences between 
individuals map onto racial categorizations that organize groups of individuals.  
In the following sections, I compare and contrast the racial meanings that 
emerge from the racial pharmacology of two potential killer applications, 
antipsychotics and statins, that are both associated with the metabolic syndrome, yet 
in different ways.   Specifically, I compare these two killer applications across four 
central dimensions of racial pharmacology.  First, I ask how scientists use race to 
study the underlying health conditions that are related to each potential killer 
application.   In the case of antipsychotics, the underlying health condition is 
schizophrenia and in the case of statins, the underlying condition is high cholesterol.  
The racial dynamics of each of these conditions is linked to how race is taken up in 
killer applications research.  Second, given the treatment of race in the study of the 
underlying condition, I ask how race is used to organize clinical trials for these killer 
applications.   How well are African Americans represented in clinical research on 
these drugs and what are the implications of this participation?  Third, I ask how race 
is used to organize the routes of administration and consumption of these killer 
applications.  Are African Americans underprescribed or overprescribed particular 
killer applications?  How might ideas about race shape these practices?  Fourth, I ask 
how race is deployed to frame questions about group differences in African 
Americans’ drug metabolism.   How do assumptions about genetic meanings of racial 
difference shape the science of drug metabolism?  By comparing antipsychotics and 
statins along these four dimensions, I hope to gain a richer understanding of how race 





Prescribing Antipsychotics: Schizophrenia and the Metabolic Syndrome 
 In this section, I analyze antipsychotics as a potential killer application that is 
a site for the descent of the metabolic syndrome and race in clinical pharmacology. 
Analyzing the side effects of atypicals using the discourse of the metabolic syndrome 
has become a new focus of schizophrenia drug research.  Specifically, in the context 
of atypicals, the metabolic syndrome has become a way of measuring whether 
racially categorized bodies require different modes of antipsychotic therapy because 
of the risks of weight gain and type II diabetes associated with their consumption.   
 A diagnosis of schizophrenia is traditionally a prerequisite for the prescription 
of any antipsychotic medicine.  And, like the category metabolic syndrome, the 
diagnostic category “schizophrenia” must be understood in relationship to the 
knowledge-making practices that have produced psychiatric illness taxonomies since 
the 1800s.  According to the Diagnostic and Statistical Manual of Mental Disorders-
IV (DSM-IV), an individual can be classified with schizophrenia if he/she reports the 
following:  
…a disturbance lasting at least 6 months and […] including two or 
more of the five symptom groups: (1) delusions; (2) hallucinations; (3) 
severely disorganized speech; (4) grossly disorganized or catatonic 
behavior, or (5) negative symptoms (e.g. affective flattening, 
alogia/poverty of speech, and avolition/inability to initiate and 




The contemporary professional psychiatric model understands mental illnesses like 
schizophrenia as, “a spectrum of syndromes that are classified by clusters of 
symptoms and behaviors considered clinically meaningful in terms of course, 
outcome, and response to treatment” (Bruce 1999).  Based on this technical and 
conceptual understanding of mental illness, schizophrenia is a mental illness that 
defines one percent of the American population—roughly four million people (Keith, 
Regier, and Rae 1991).  
 In the 1950s, a biological view of schizophrenia gained prominence before the 
publication of the Diagnostic and Statistical Manual.  The biological model of mental 
illness maintains that psychiatric symptoms, and the taxonomies they are used to 
construct, reflect undetected biochemical and genetic processes in the body.  In 
contrast contemporary social constructionist models of mental illness argue that 
illness categories, like schizophrenia, represent cultural definitions applied to 
different types of bodies and behaviors, and whose contours and meanings change 
over time (Foucault 1965; Horowitz 1999).  
 Beginning in the 1950s, based on a biological view of psychiatric illness, 
psychiatrists began to treat schizophrenia using powerful new medications called 
antipsychotics.  The first generation, or so-called typical antipsychotics, instantly 
became the killer applications for schizophrenia.  However, typical antipsychotics had 
a series of undesirable side effects: they caused significant weight gain, elevated risk 
for developing type II diabetes, and increased cholesterol levels (Remington 2006).   




dyskinesia, a disorder that causes involuntary movements including tongue thrusting, 
repetitive chewing, jaw swinging, and facial grimacing.79   
 In the 1990s, pharmaceutical companies began to develop a second-generation 
of antipsychotics called “atypical” that were supposed to avoid these metabolic and 
neuromuscular side effects.   The six atypicals and their year of FDA approval are: 
Clozaril® (clozapine) in 1990; Risperdal® (risperdone) in 1994; Zyprexa® 
(olanzapine) in 1996, Seroquel® (quetiapine) in 1997, Geodon® (ziprasidone) in 
2001, and Abilify® (ariprazole) in 2003.  Since their introduction in the 1990s, 
atypical antipsychotics have become the new killer applications for the treatment of 
schizophrenia and have become a major source of profit for pharmaceutical 
companies by costing as much as 10 times more than typical antipsychotics (Daumit, 
Crum, Guallar, Powe, Primm, Steinwachs, and Ford 2003: 121).  In 1999, the status 
of atypicals as killer applications was affirmed when professional psychiatric 
treatment guidelines were modified to name atypical antipsychotics as “first-line drug 
therapy” in the treatment of schizophrenia (McEvoy, Scheifler, and Francos 1999).   
 Atypicals continue to dominate the antipsychotics market, yet they, too, create 
serious side effects. In November 2003, a biomedical-government-industry 
collaboration, led by the American Diabetes Association and the American 
Psychiatric Association, met to discuss the causes and consequences of the observed 
correlations between atypical therapy and diabetes (Barrett, Blonde, Clement, David, 
Devlin, Kane, Klein, and Torrey 2004). The conference, titled “Consensus 
Development Conference on Antipsychotic Drugs and Obesity and Diabetes,” 




American Psychiatric Association, the American Association of Clinical 
Endocrinologists, the North American Association for the Study of Obesity, the FDA, 
and AstraZeneca, Bristol-Myers Squibb, Janssen, Lilly, and Pfizer pharmaceutical 
companies.  A consensus view emerged that psychiatrists should closely monitor their 
patient’s metabolic biomarkers because of the known metabolic side effects of 
atypicals. The 2003 ADA/APA group also urged researchers to determine whether the 
risks of therapy are increased in certain ethnic groups (e.g., African Americans) 
(Barrett et al. 2004: 600).  It is in this context that two noted schizophrenia 
researchers, Wayne Fenton and Mark Chavez, claim the metabolic syndrome is 
emerging as the tardive dyskinesia of the second-generation antipsychotics (Fenton 
and Chavez 2006).  
 In 2004, the FDA issued a warning that atypical antipsychotics increased the 
risk of developing diabetes on its “news show”—FDA Patient Safety News.80  The 
FDA asked drug manufactures of atypicals to add new warnings to their labels 
informing patients of these risks; they also recommended that patients taking 
atypicals have their blood sugar levels checked periodically.  At the same time in 
2004, a group of psychiatrists issued specific recommendations for monitoring the 
metabolic health of people diagnosed with schizophrenia (Marder, Essock, Miller, 
Buchanan, Casey, Davis, Kane, Lieberman, Schooler, Covell, Stroup, Weissman, 
Wirshing, Hall, Pogach, Pi-Sunyer, Bigger, Friedman, Kleinberg, Yevich, Davis, and 
Shon 2004).  For instance, one study found that African Americans may be more 
likely to gain weight while taking atypicals (Basson, Kinon, Taylor, Szymanski, 





Slow Metabolizers: Treating African Americans With Schizophrenia  
 Since the rise of professional psychiatry in the nineteenth century, 
psychiatrists have assumed, asserted, and eventually accepted that African Americans 
were more likely to suffer from schizophrenia (Adebimpe 2003; Adebimpe 1994; 
Adebimpe 1981; Keck, Arnold, Collins, Wilson, Fleck, Corey, Amicone, and 
Adebimpe 2003; Strakowski, Flaum, and Amador 1996).  One major reason for this 
prevailing view about African Americans and schizophrenia had to do with the 
statistical methods that were widely used to produce knowledge about population 
rates of mental illness.  Prior to the 1980, the treated-case-method was the preferred 
method for psychiatric epidemiology, which only counted subjects who received 
inpatient treatment in mental health institutions (Grob 1985).  During this period, 
African Americans comprised a disproportionate portion of those individuals who 
were institutionalized for schizophrenia, especially during the era of mass 
institutionalization of the mentally ill, between 1900 and 1940 (Dowdall 1999).  
Because psychiatrists assumed that African Americans were more likely to have 
schizophrenia, they institutionalized them at higher rates.  Because African 
Americans were overrepresented among the institutionalized, the treated-case method 
produced inflated estimates of group illness, which reaffirmed the prevailing view of 
African Americans’ mental inferiority.   
 By the 1990s, community based studies, like the Epidemiologic Catchment 
Area (ECA) Study and the National Comorbidity Survey (NCS) were established as 




Siewart, Takeuchi, and Pangan 2003).  These population studies showed that African 
Americans did not have higher rates of schizophrenia or other affective disorders 
when compared to Whites, nor were there other significant racial or ethnic group 
differences in other mental illness (Kessler and Zhao 1999).  Nonetheless, these 
epidemiological studies used the diagnostic categories for schizophrenia provided by 
the first edition of the DSM, which was published in 1980.  
 Despite the fact that racist ideas about the prevalence of schizophrenia among 
African Americans had been successfully challenged, the emerging field of racial 
pharmacology created new problems and new questions.   Beginning in the 1980s, 
scholars began to study group differences in access to and use of antipsychotics as a 
drug class.   In the 1980s and 1990s, researchers found that psychiatrists prescribed 
typicals at higher rates and in doses to African Americans in both inpatient and 
outpatient psychiatric settings (Chung, Mahler, and Kakuma 1995; Rudorfer and 
Robins 1982).  More recently, scholars have documented group differences in the 
route of administration of antipsychotics: African Americans categorized with 
schizophrenia are more likely to receive atypicals via injection as opposed to pill 
therapy (Kuno and Rothbard 2002; Segel, Bola, and Watson 1996; Walkup, 
McAlpine, Olfson, Labay, Boyer, and Hansell 2000; Woods, Sullivan, Neuse, Diaz, 
Baker, Madonick, Griffith, and Steiner 2003).  Several groups of scholars have 
documented that African Americans with schizophrenia are less likely to receive 
atypicals (Daumit et al. 2003; Herbeck, West, Ruditis, Duffy, Fitek, Bell, and 
Snowden 2004; Mark, Dirani, Slade, and Russo 2002; Wang, West, Tanielian, and 




 Researchers also documented patterns between African Americans’ access to 
and use of atypicals compared to other racially categorized groups.  A 2001 Surgeon 
General Report titled “Mental Health: Culture, Race, and Ethnicity” included a listing 
of the representation of racially categorized groups in twenty-five randomized 
controlled trials for the treatment of schizophrenia that took place between 1986 and 
1996.  While sixteen of the twenty-five studies collected and reported data on the race 
and/or ethnicity of their research subjects, none of these conducted (or at least 
reported) analyses by race or ethnicity.  The remaining nine studies did not collect 
information on the race or ethnicity of research subjects, and did not conduct analyses 
by race or ethnicity (DHHS 2001).81  In other words, there is a lack of statistical 
information about the safety and efficacy of antipsychotics in African Americans.  
 The 2001 Surgeon General’s report on Mental Health and Race also advanced 
a biological explanation of the different pharmacokinetics, or the processes by which 
bodies absorb, distribute, metabolize, and excrete drugs, of antipsychotics in African 
Americans: more of them are “slow metabolizers.”  Citing a 1977 study (Ziegler and 
Briggs 1977), a 1982 study (Rudorfer and Robins 1982), and a 1998 study (Bradford, 
Gaedigk, and Leeder 1998), the report claims “a greater percentage of African 
Americans than whites metabolize some antidepressants and antipsychotic 
medications slowly and might be more sensitive than whites” (DHHS 2001: Chp. 3).  
They offer two contrasting arguments about the clinical significance of race in the 
pharmacological treatment of schizophrenia.   On one hand, they argue “biological 
similarities between African Americans and whites are such that effective 




hand, they cite recent that suggests that “African Americans and white Americans 
sometimes have different dosage needs” [emphasis added] (DHHS 2001)  
 The Surgeon General’s report mentions the P450 system as a possible genetic 
source of observed racial pharmacokinetic differences among schizophrenic patients 
taking atypicals.   Relling and colleagues found racial differences between “American 
black and white subjects” in debrisoquin hydroxylase (P450IID6) activity, a 
biochemical and genetic process that is implicated in drug metabolism (Relling, 
Cherrie, Schell, Petros, Meyer, and Evans 1991).   Walkup and colleagues (2000) 
explain the slow metabolizer theory of racial group difference in the P450 system in 
the following manner:  
Drug metabolism is mediated through the cytochrome P450 
micosomal enzyme system.  Small numbers of individuals lack the 
P450 microsomal enzyme and, consequently, are “poor metabolizers.”  
Their plasma levels tend to be high.  Recent studies have identified a 
larger group who are genotypically heterogeneous “slow 
metabolizers.”  Recent estimates suggest that the prevalence of slow 
metabolizers of antipsychotic medications is higher among African 
Americans and Asian groups than whites (Walkup et al. 2000: 346). 
In their conclusion, the authors insinuate, it is logically possible that unmeasured 
physical differences in pharmacokinetics might be responsible for differences in the 
metabolism of antipsychotics between white and African American or Hispanic 
individuals (Walkup et al. 2000: 346).   




Selling Statins: Cholesterol and the Metabolic Syndrome  
 In this section, I analyze statins as a second potential killer application that is 
a site for the descent of the metabolic syndrome and race.  Statins have become the 
killer application for the treatment of cholesterol problems (dyslipidemias), a central 
component of the metabolic syndrome. Statins are a class of cholesterol drugs that 
were first approved for sale in the United States in 1986 and went on the market in 
1987 (Junod 2007).82  As of 2004, there were seven statins available in the United 
States for the treatment of dyslipidemia (Gotto 2004).83 
 The first statin approved by the FDA in 1987, lovastatin, introduced the 
practice of treating “surrogates” into the FDA drug approval process and private drug 
research and development (Greene 2007).  A surrogate is a biological marker that is 
transformed into a statistical stand-in for a hypothesized disease process or outcome.  
So, LDL cholesterol is a surrogate for the development and growth of plaque in the 
arteries and in the heart.84  Rather than needing to demonstrate that lovastatin reduced 
the incidence of heart attacks or strokes in a long-term prospective clinical trials, the 
investigators only needed to show that the drug agent effected the surrogate in 
expected (and desirable) ways in order to gain FDA approval (Junod 2007).  The 
pharmacological treatment of cholesterol as a means of reducing heart disease risk is 
an outgrowth of the so-called “lipid hypothesis,” namely, that lowering LDL 
cholesterol alone will stop or slow the development of heart disease. 
 Formal clinical guidelines for the pharmacological management of cholesterol 
identify statins are used to determine the adequacy and equitability of patient care. As 




Education Program stand as the expert recommendations for the management of 
cholesterol (Ito, Cheung, Gupta, Birtcher, Chong, Bianco, and Bleske 2006; NCEP 
2001).   Given the stringent nature of these recommendations, many individuals with 
dyslipidemia will not be able to achieve optimal LDL cholesterol levels without 
pharmacological therapies, even with adequate exercise and changes in dietary 
practices (Grundy et al. 2004) 
 
Race-Based Therapies: Treating African Americans with High Cholesterol  
 Crestor™ is one of the newest statins made by the AstraZeneca that lowers 
LDL cholesterol and raises HDL cholesterol.  Just one year after its FDA approval in 
2003, 15 million individuals filled prescriptions for Crestor™, spending $908 million 
dollars. Crestor™ (rouvastastin) is a member of a class of drugs called statins that are 
prescribed primarily to treat forms of hyperlipidemia (they are prescribed to people 
who have high LDL cholesterol and low HDL cholesterol, two criteria of the 
syndrome).  In August 2008, AstraZeneca began marketing Crestor™ a new clinical 
finding that, along with diet and exercise, it can slow the progression of 
atherosclerosis.  
 Cholesterol researchers use the metabolic syndrome and race as ways to 
identify which bodies and populations are most likely to benefit from statin therapy.  
Are the makers of Crestor, a new statin, framing the racial pharmacology of statins in 
order to be able to market them to racially categorized groups?  In 2003, the 
pharmaceutical giant AstraZeneca started the Galaxy Programme™ Studies, which 




research initiative designed to address unanswered questions in statin research and to 
investigate the impact of Crestor™ on cardiovascular risk reduction and patient 
outcomes.”85 The Galaxy Programme™ funded three six-week randomized, 
controlled, open label, multi-center clinical trials were designed to evaluate the safety 
and efficacy of Crestor™ in populations with hyperlipidemia—populations that were 
sampled using racial and ethnic categories.86   
 To organize these trials, AstraZeneca followed the FDA’s guidelines for 
including racially categorized groups in its clinical trials; however, they divided the 
groups into single race trials.  For example, the African American Rosuvastatin 
Investigation of Efficacy and Safety (AIRES) trial is a randomized, controlled, open-
label, multi-center trial designed to evaluate the efficacy of Crestor® in 774 African 
American subjects by comparing it to Lipitor® (Ferdinand et al. 2006).87  In this 
study, Dr. Luther T. Clark and his colleagues evaluated so-called ethnic differences in 
the achievement of cholesterol treatment goals in a sample of African Americans and 
non-Hispanic Whites.  The rationale for the study is that racial and ethnic differences 
in cholesterol management may partially account for the excess risk and mortality 
experienced by racial and ethnic minority groups.   The study’s cholesterol treatment 
goals were based on the 2001 National Cholesterol Education Program (NCEP) Adult 
Treatment Panel III definitions for dyslipidemia, the same risk category criteria that 
are included in the metabolic syndrome.  Subjects were classified into risk categories 
based on the NCEP criteria.  
 The ARIES patient sample consisted of non-Hispanic Whites and African 




from the description of the study’s methodology.88  The investigators found that body 
mass index (BMI), total cholesterol, and LDL cholesterol were higher in African 
American subjects (which confers higher disease risk), but HDL and triglycerides 
biomarkers were better (which confers lower disease risk).  African Americans were 
significantly less likely to meet ATP III LDL-C treatment goals within each risk 
category and overall.  African Americans were less likely to be taking statins than 
whites (75.7% versus 70.6%) and less likely to be taking high-efficacy statins (54.8% 
versus 45.6%).89  Even among subjects taking statins and high efficacy statins, fewer 
African Americans reached ATP-III targets for LDL-C.  
 According to the researchers, the explanations for the alleged ethnic disparity 
in cholesterol management were “not immediately apparent” (Clark et al. 2006: 324).  
The disparity cannot be explained by differences in dyslipidemia diagnoses or access 
to health care because both the African Americans and non-Hispanic Whites in the 
sample were recruited because they were receiving treatment for dyslipidemia.  Fewer 
African American subjects were taking statins and received treatment from lipid 
specialists less frequently.  Therefore, less aggressive treatment on the part of treating 
physicians may partially explain the disparity.  However, the statistical association 
between ethnicity and cholesterol goal achievement remained after controlling for 
these differences.  
 Group differences in rates of drug compliance may also account for these 
differences in cholesterol management.  The authors cite three studies published since 
2000 that suggest that African Americans are less compliant with statin drug therapy 




Chong, Tzallas-Pontikes, Seeger, and Stamos 2000; Williams, Morris, Ahmad, 
Yousseff, Li, and Ertel 2002).  The authors conclude, “It is likely that the explanation 
for lower frequencies of treatment goal achievement among African American 
patients for lipids and other therapies is multifactorial” (Clark et al. 2006: 324). The 
authors cite socioeconomic status, educational level, and type of medical and 
prescription drug coverage as the multiple other factors affecting goal achievement, 
but their data did not permit the analysis of these other factors.    
 Clark and colleagues (2006) cited evidence that serum lipid (cholesterol) 
responses to lifestyle modifications and drug therapies are “generally similar” in 
African American and non-Hispanic White subjects (Clark, Maki, Galant, Maron, 
Pearson, and Davidson 2006).  However, three of the four studies that they cite 
analyzed samples that only consisted of African Americans, including the ARIES 
trial, and thus could not have compared racial and ethnic groups (Ferdinand et al. 
2006; Jacobson, Chin, Curry, Miller, Papademetriou, Schlant, and Larosa 1995; 
LaRosa, Applegate, Crouse, Hunninghake, Grimm, Knopp, Eckfeldt, Davis, and 
Gordon 1994; Prisant, Downton, Watkins, Schnaper, Bradford, Chremos, and 
Langendorfer 1996).  In the conclusion of the paper, the authors cite these same four 
studies again and state that data from clinical trials of lipid-lowering drug therapies 
suggest that African American and non-Hispanic White subjects exhibit similar 
physiological responses (Clark et al 2006: 324).   Because the effects of lifestyle 
intervention and drug therapy do not vary across African American and non-White 
Hispanic populations, the authors hypothesize that the lower rates of cholesterol 




management by treating physicians, b) suboptimal compliance by African American 
patients, or c) some combination of these factors.   
 In a 2007 article titled “Metabolic Syndrome in African Americans: 
Implications for Preventing Coronary Heart Disease,” Drs. Luther T. Clark and Fadi 
El-Atat review several therapeutic approaches to metabolic syndrome in African 
Americans.  While the magnitude of LDL-C reduction with statins appears to be 
similar in blacks and whites, the authors cite data from the Antihypertensive and 
Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) study 
showed that statin therapy lowered the risk of CHD death and non-fatal heart attacks 
more in black than in non-black subjects, but did not decrease the mortality gap 
overall between the two groups (Clark and El-Atat 2007).  
 In 2008, Dr. Karol E. Watson, an Associate Professor at the Geffen School of 
Medicine at UCLA and Director of the UCLA Center for Cholesterol and Lipid 
Management, published a review article in the Journal of the National Medical 
Association entitled “Cardiovascular Risk Reduction among African Americans: A 
Call to Action” (Watson 2008).  As a member of the speaker’s bureau for 
AstraZeneca, Merck, Schering-Plough, and Sanofi Aventis, Dr. Watson reviews 
evidence that the major risk factors for cardiovascular disease require special study 
and intervention in the African American population.  She argues that while data on 
racial and ethnic differences in response to lipid-lowering drugs are limited, two 
studies have shown that statins are not as effective at lowering African Americans’ 
LDL levels compared to European Americans (ALLHAT 2002; Simon, Lin, Hulley, 




 Towards the end of her review article, Dr. Watson has a subsection titled 
“Race-Based Therapeutics,” which is in quotation marks.  The section begins “The 
development and use of so-called “Race-based therapeutics” remains controversial.  
Results of some clinical trials indicate that racial/ethnic differences in vascular 
function may have implications for the treatment of CVD risk factors” (Watson 2008: 
22).  Here, she makes the argument that African Americans may have a different 
endothelial response to ACE inhibition that European Americans (see also (Ferdinand 
2007); and 
Individual response to the pleiotropic effects of statins, such as their 
beneficial effects on renal function independent of lipid lowering, may 
also be affected by race.  In one study of short-term rosuvastatin 
treatment, estimated glomerular filtration rate increased by >3-fold in 
African American patients compared with the overall study population 
(Watson 2008: 24).   
To substantiate this second claim, she cites the study (Vidt, Harris, McTaggart, 
Ditmarsch, Sager, and Sorof 2006).  She then argues that “the fact that African 
Americans and European Americans appear to exhibit differences in endothelial and 
vessel wall response suggests that alternative strategies may be needed to customize 
therapy appropriately for patients of different races/ethnicities” (Watson 2008: 24).  
For Watson, the case of BiDil serves as an exemplar of these alternative strategies for 
race-based therapeutics.   She concludes this section by rejoining that BiDil may work 
equally well in other racial/ethnic groups and that more research is needed in this area 






  The convergence of racial pharmacology, killer applications, and the 
metabolic syndrome created an important synergy that is the focus of this chapter. 
The racial pharmacology of killer applications has several distinguishing features in 
the politics of metabolism.   Table 4.1 presents a summary of the social processes and 
institutional relationships that comprise the racial pharmacology of killer applications.  
 
[Insert Table 4.1. Summary of social processes and intuitional relationships in the 
racial pharmacology of killer applications] 
 
The analysis presented in this chapter suggests that racial pharmacology, the 
biomedical study of prescription drugs, their effects, and their metabolism in racially 
categorized bodies and populations, is an emerging site for the production of racial 
meaning.  First, pharmaceutical companies and drug researchers use constructions of 
race are used to organize clinical trials, the study of killer applications, and the 
genetics of drug metabolism.  In the case of antipsychotics, researchers use the 
metabolic syndrome as a discourse about the undesirable side effects of killer 
applications like antipsychotics. African Americans have historically received 
differential diagnoses of schizophrenia, have been under represented in clinical trials, 
are over prescribed antipsychotic injection therapies, and are said to differ genetically 




schizophrenia have become racialized, the diagnostic category of schizophrenia 
becomes racialized through the deployment of killer applications.  
 In contrast, in the case of statins, researchers use the metabolic syndrome as a 
discourse about potentially broader uses of existing killer applications like statins. 
African Americans are constructed as having differential rates of high cholesterol, are 
the primary subjects in new clinical trials, are under prescribed the most effective 
statin therapies, and are said to differ genetically from other groups in terms of statin 
metabolism.   In order to justify race-based treatments, high cholesterol is being 
framed as a new racial disparity that requires new studies in drug efficacy and safety.   
 Second, race and the metabolic syndrome intersect in different ways in the 
racial pharmacology of antipsychotics and statins that matter differently for African 
Americans.  African American bodies are deployed in unique ways in the racial 
pharmacology of antipsychotics and statins.  Yet, in both cases, assumptions about 
unobserved genetic differences across racially categorized groups shape the racial 
pharmacology of killer applications.   Drug scientists are using the metabolic 
syndrome to study the interactions Black bodies and drugs, and are seeking to 
produce pharmacological knowledge that can be translated into profits for drug 
companies.   
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Chapter 5:  The Politics of Metabolism 
 In the previous two chapters, I explored how the metabolic syndrome and race 
emerged as features of biopower by tracing the social processes and institutional 
relationships that are involved in the production of new racial meanings.  In this 
concluding chapter, I provide the central interpretations, implications, and 
significance of this study.  First, I summarize the main interpretations of this study in 
terms of how they might contribute to a more robust understanding of how race 
shapes the politics of metabolism.   Second, I discuss the implications of this study 
for the critical social theory and for the theoretical frameworks that shaped this study.  
Third, I discuss the sociological significance of the metabolic syndrome in the 
broader struggle for social justice. 
 
Understanding the Politics of Metabolism 
 In chapter one, I asked what are the implications of this emerging relationship 
between the metabolic syndrome and race for developing a more robust 
understanding of race in the politics of metabolism?  The sociological relationships 
between the metabolic syndrome and race in the United States seem to have emerged 
at the intersection of scientific racism—a set of scientific discourses and practices that 
served to ignore, explain away, and/or justify racial inequalities—and the practices of 
an increasingly biological and technological approach to the study of human 
metabolism. Because the metabolic syndrome emerged in 20th century American 




 Here, I develop two central interpretations that emerge from this study that 
can inform a richer understanding of the politics of metabolism.  First, understanding 
the politics of metabolism requires that we shift our thinking from an epidemic 
perspective to one that embraces an endemic perspective of metabolic health 
problems.  Second, developing a more robust understanding of the politics of 
metabolism also involves further analysis of the biomedical-government-industry 
collaborations that lie at the center of biomedical knowledge production in the United 
States.  Taken together, these interpretations underscore both the importance of ideas 
and institutional practices in the politics of metabolism.  
Shifting from an epidemic to an endemic perspective 
 Developing a more robust understanding the metabolic syndrome and race in 
the politics of metabolism requires that we shift our thinking from an epidemic 
perspective to one that embraces an endemic view of metabolic health problems.   
Recent public scientific discourse about the metabolic problems that comprise the 
metabolic syndrome refers to each of them as epidemics in their own right (Grundy 
2008; Kereiakes and Willerson 2003; Zimmet, Alberti, and Shaw 2001).  While it is 
true that most Americans will most likely experience, and/or die from one or more 
metabolic problems over the course of their lives, these conditions are not epidemics 
in the historical meanings of the term.  In this historical context, epidemics killed 
nearly every individual living within a circumscribed geographic region both quickly 
and indiscriminately.   Therefore, the historical response to controlling and 
eradicating epidemics has been to rapidly target individuals who are most likely to 




 In stark contrast, the politics of metabolism are characterized by endemic 
problems.  According to Foucault, endemics are discriminating, widespread, and 
long-term population-level phenomena that weaken societies’ energy because treating 
them is expensive and they lead to the decreased economic productivity of working 
populations (Foucault 2003 [1976]: 244).     Because endemics represent both a 
political problem for those who govern, endemic problems quickly become objects of 
scientific knowledge and commodification.  In the context of biopower designed to 
make the population more productive and healthier, this problematization of endemic 
phenomenon is required to excise as much scientific discipline, economic profit, and 
political utility from populations as possible.  According to data published by leading 
authorities, the direct and indirect healthcare costs from heart disease, diabetes, and 
stroke exceed one trillion dollars per year (ADA 2003; Finkelstein, Ruhm, and Kosa 
2005; Thom 2006).90   
 Shifting our perspective from an epidemic to endemic view is critical for 
understanding the how the biological realities, political rationalities, and economic 
opportunities of the politics of metabolism shaped the emergence and descent of the 
metabolic syndrome.  While the metabolic syndrome may not exist as a biological 
reality in precisely the same ways that cancers exist, the metabolic syndrome emerged 
in the context of a massive biomedical, government, and corporate response to the 





Analyzing biomedical-government-industry collaborations 
 Developing a more robust understanding of the politics of metabolism also 
involves further analysis of the biomedical-government-industry collaborations that 
lie at the center of biomedical knowledge production in the United States.  
Throughout this study, I showed how biomedical-government-industry collaborations 
on the metabolic syndrome shape the production of racial meanings.   The discourses, 
technologies, and practices of these social institutions are the tools with which 
researchers construct the metabolic syndrome and race in the contemporary United 
States.  Here, I briefly highlight how these discourses, technologies, and practices are 
linked across biomedical, government, and corporate contexts.   
 First, biomedicine is a term that denotes the centrality of a biological approach 
to the ideas and practices that comprise contemporary medicine.   Biomedical 
researchers and institutions combine new forms of molecularization and risk 
assessment surveillance to produce the construction of the metabolic syndrome.  
Whether the metabolic syndrome construct will be widely adopted by practicing 
physicians to diagnose patients is not clear.   However, the inclusion of a diagnostic 
code for the metabolic syndrome in the International Classification of Disease 
certainly signals that physicians and health care institutions would be operating 
within accepted guidelines if they started classifying patients using this new category.   
Also not clear is what a diagnosis of the metabolic syndrome would actually mean for 
patients, physicians, and the practice of medicine.   What is clear is that the metabolic 




and investigates metabolic health problems.   As the biomedical discourses and 
practices of the metabolic syndrome continue to unfold, they intersect with the ways 
in which race shapes the theories and practices of medicine in terms of disease 
surveillance, diagnosis, and treatment.  
Second, the federal government plays several important roles in the 
production of the metabolic syndrome and race.   The federal government enforces 
the racial categorizations used in biomedical research on the metabolic syndrome, 
funds and produces research on the metabolic syndrome, and regulates the labeling 
and safety of prescription drugs related to the metabolic syndrome.  In chapters three 
and four, I analyzed the institutional practices of government that are central to the 
production of discourses about the metabolic syndrome and race.  For example, in 
chapter three, I documented the moments when the government institutionalized the 
measurement of the metabolic processes of Americans at the molecular level.  As 
these new technologies were incorporated into the routine practices of epidemiology, 
they became integral to the establishment of the risk factor paradigm that operates 
today.  
Third, the relationships between the metabolic syndrome and race cannot be 
understood without analyzing the pharmecutical industry as a central actor in the 
politics of metabolism.   The metabolic syndrome and race are used to study and 
target killer applications produce toward racially categorized individuals and groups.  
In chapter four, I examined how government racial categories are used to structure 




antipsychotics and statins has taken place in a commercial context where 
administrative racial categories are invested with pharmacological uses and meanings.   
   
Implications for Critical Social Theory and Social Justice  
 
 In chapter two, I outlined the core concepts from three critical social theories 
that shaped the questions and analysis in this study.  Critical social theories can 
provide several unique insights as to how the metabolic syndrome and race might 
operate together in the politics of metabolism.  Patricia Hill Collins defines critical 
social theory as bodies of knowledge and sets of institutional practices that actively 
grapple with the central questions facing groups of people differently placed in 
specific political, social, and historical contexts characterized by injustice (Collins 
2005).  Critical social theories are committed to producing ideas and engaging in 
practices that serve the interests of social justice.  In the context of this study, this 
commitment to a social justice context involves linking an analysis of institutional 
racism and racial health disparities to the analysis of racial meaning in biomedical 
constructions of health.  As a way of framing the contribution of this study for critical 
social theory, in this section I explore the implications of this study for these ideas 
and practices. 
 
What are the implications for critical race theory?   
The metabolic syndrome appears to be a new site of racial formation, the 




meaning.  As I argued in chapter two, critical race theory has long recognized the 
centrality of science and medicine to the construction of racial concepts and meanings 
that in turn influence the practices of social institutions.  In other words, the metabolic 
syndrome is an emerging site for the reproduction of race and racism in American 
society.   
Drawing on this critical race framework, I have argued that the metabolic 
syndrome represented a new way that biomedical researchers could construct 
scientific knowledge about racial difference.  In chapter three, I documented how the 
metabolic syndrome became a racial project, an unfolding process that drew upon 
different racial meanings to make sense of human metabolic difference, and 
simultaneously used race to classify bodies and populations.  Based upon this 
analysis, I believe that the metabolic syndrome seems to draw upon earlier formations 
of race that link racial inequality to the essential properties of purportedly biologically 
and genetically meaningful groups.91  As I argued in chapters three and four many of 
the biomedical theories of metabolic differences across racially categorized 
populations can rely on assumptions about color-coded predispositions, 
susceptibilities, and genetic admixture.92    
These practices and theories are reminiscent of historical formations of 
scientific racism that explained racial inequalities as biological, natural, and 
immutable.  Racial health disparities have long constituted a major site of struggle 
over the meaning of race and explanations of racial inequality in the United States.  
When analyzed in the specific context of racial health disparities in the United States, 




significance in the history of comparative racial biology and eugenics.  Racial 
essentialism is central to the operation of scientific racism, a set of discourses and 
practices that served to explain and justify racial inequalities using the tools and 
authority of science.  For example, critical race theorist Tukufu Zuberi analyzed how 
the field of biometrics, an 19th century science that applies the methods of social 
statistics to biological problems, was used to justify the practices of the American and 
European eugenics movements (Duster 2003 [1990]; Zuberi 2001).   
 More recently, other critical race theorists have described emerging 
developments in biomedicine and genomics as “the biological reification” or 
“biological rewriting” of race (Duster 2005; Fausto-Sterling 2004; Gannett 2004; 
Thompson 2006b).93  For example, Troy Duster argues racial categories are 
increasingly interpreted through the new genetic prism, a phrase he uses to describe 
the increasing centrality of genetics and genomics as the primary lens for 
understanding racial differences in so-called multifactorial diseases. Duster argues 
that social, economic, and political interests profoundly influence the production of 
scientific knowledge about race.  While biomedical researchers theorize that 
multifactorial diseases, like heart disease, are caused both environmental and genetic 
factors, through the new genetic prism, individual differences in disease are often 
explained as the consequence of inherent population-based genetic susceptibilities 
(Duster 2005: 1050).  Thus, understanding the relationships between sociopolitical 
processes, knowledge-making practices, and racial categorization is fundamental to 
understanding what remains contested and problematic about the concept of race in 




 Duster also reminds us that the first principle of knowledge construction is 
which question gets asked first in the research enterprise.  In the context of race and 
pharmaceuticals, a priori assumptions about biological differences between racially 
classified populations shape the kinds of questions that biomedical researchers ask 
about race.  Study samples are treated as populations in a narrow sense of the term, 
even when there is little evidence that they represent a geographically localized, 
reproductively isolated group.   These narrowly and scientifically defined populations 
are then analyzed in terms of existing racial taxonomies.  Alternatively, Duster argues 
that biomedical researchers should treat race as “a stratifying practice in societies that 
can lead to different frequencies of alleles in different modern populations but also to 
different access to health-related resources” (Duster 2005:1050).  So, not only do 
questions about racial difference create a context where disparities themselves are 
used as marketing tools, but they also may unwittingly reinforce biological and 
genetic explanations of racial inequality.  
 However, perhaps in part due to prevailing assumptions within critical race 
theories that familiar formations of scientific racism had been discredited, critical race 
theorists have been slow to recognize the productive power of biotechnologies to 
transform race in the contemporary moment.  While scholars like Troy Duster have 
been talking about the importance of biotechnologies for racial formation since 1990, 
this study makes a meaningful contribution to critical race theory by demonstrating 
two important ways that race and biotechnology intersect through the lens of the 
metabolic syndrome.  Specifically, I investigated how biotechnological developments 




racialized in the discourses on the metabolic syndrome.   Thus, new intersections of 
race and technology will require sustained attention from racial theorists going 
forward.  
 
What are the implications for biomedicalization?   
The framework of biomedicalization provides a set of powerful analytic tools 
through which to analyze the relationships of the metabolic syndrome and race.  The 
metabolic syndrome was also forged in the context of biomedicalization, which 
encompassed an increasingly biological and technological approach to the study of 
human metabolism.  Technoscience provides a way of understanding how the 
increasingly technological and scientific aspects of the metabolic syndrome come 
together in politics of metabolism.   Thus, in chapter three, I showed how the 
emergence of the metabolic syndrome was made possible through the technoscientific 
integration of molecular approach in clinical medicine and a risk factor approach in 
epidemiology.   This integration led to a new emphasis on the production of 
knowledge about disease risk and a new practice of targeting allegedly at risk 
populations for behavioral, pharmacological and social interventions.  Taken together, 
these practices resulted in the construction of raced bodies as inherently and always at 
risk and the very constitution of so-called at risk populations as always explicitly or 
implicitly racial.  
In a 2005 article published in the journal Science, sociologist Troy Duster 
cautions biomedical researchers of race against committing the fallacy of 




obdurate character of the empirical world (Duster 2005).  Duster questions how 
NitroMed, the producer of BiDil, presented statistical information about racial 
disparities in hypertension in ways that misrepresented the extent and etiology of the 
racial gap in the prevalence of hypertension between African Americans and Whites.  
This misrepresentation in the case of BiDil (and in the case of new forms of genetic 
criminology) comprises the reification of race by arguing that different racial groups 
have “genetically sufficiently distinctive features…which are used to explain health 
disparities between racially categorized populations” (Duster 2005: 1050).   As I 
discussed in chapter two, these types of essentialist discourses about race historically 
established an important justification for scientific racisms.  
 In another recent article, philosopher of race Lisa Gannett asks whether 
federally created and self-reported race, ethnicity, and ancestry are good proxies for 
genetic similarities in drug metabolism (Gannett 2005).  She argues that the debate 
about the use of racial categories in clinical trials and pharmacological research has 
often been framed in terms of realist versus social constructionist theories of race. 
The realist theory of race claims that our racial classifying practices identify things in 
nature, and that race is therefore a scientific and objective category.  The social 
constructionist theory of race asserts that race is not a genuine natural category, but 
an invention of racialist/racists societies, hence subjective. Gannett steps through this 
debate by noting that this framing of the epistemological status of race assumes that 
boundaries can be inserted between “the social and scientific, the cultural and natural, 




taxonomies of human groups, such as those used in pharmacological research, do not 
exist independently of social classifying practices in specific research contexts.   
 To analyze these emerging practices, Gannett advances a pragmatist 
epistemological framework that includes a normative ethical analysis of the use of 
group categories in pharmacogenomics research.   What this means is that scholars 
need to ask questions about the potential harms enacted upon racially categorized 
groups if the very categories designed to track and rectify the effects of systemic 
racism become biologized through their incorporation in scientific research, clinical 
practice, and the marketing of pharmaceuticals.  Rather, attention to health-related 
group differences need not perpetuate the racist history that has seen some 
communities shoulder a disproportionate share of the burdens associated with 
biomedical research while reaping fewer of the benefits.  
In chapter four, I analyzed how biomedical researchers use the metabolic 
syndrome and race to target different population groups in killer applications 
research.   I argued that the search for new killer applications has led pharmaceutical 
corporations to take greater advantage of the infrastructure for racialization in drug 
research and development.    
 
What are the implications for biopower?   
What can this study contribute to the ongoing evaluation of Foucault’s ideas 
about biopower to analyze contemporary social arrangements of knowledge and 
power?  In 2003, science and technology studies scholars Paul Rabinow and Nikolas 




relevant to contemporary social arrangements yet remains analytically 
underdeveloped (Rabinow and Rose 2003: 34).  A growing handful of scholars are 
using Foucault’s thinking on race in the context of biopower to understand racial 
formation and racism across different historical periods and social contexts.94  Since 
2000, scholars the science and technology studies have adopted and extended 
biopower to analyze the contemporary dynamics of biomedicalization in the life and 
human sciences.95  
 Biopower provides a way to think about how scientific disciplines like 
demography and epidemiology, and emerging biomedical specialties like cardiology 
and endocrinology, combined with government regulations on race and prescription 
drugs, to create a racial context through which the metabolic syndrome could emerge.  
The relations of biopower that encapsulate both the metabolic syndrome and race 
discipline bodies and regulate populations so that they can be more easily targeted for 
biomedical research, political utility, and economic exploitation.  
 In chapter three, I analyzed how ideas about race shaped the emergence of the 
metabolic syndrome in terms of the relationships between bodies and populations.  In 
chapter four, I examined how race and the metabolic syndrome operate together to 
establish a political, economic, and scientific context in which racial groups are 
targeted in killer applications research.  I argued that the metabolic syndrome is a new 
site where racial pharmacology shapes the deployment of killer applications in the 
politics of metabolism.    




The Sociological Significance of the Metabolic Syndrome  
Are we forever doomed to the politics of metabolism?  How might this study 
highlight ways to navigate and shift the politics of metabolism in ways that foster 
human health and undermine entrenched inequalities and the institutional practices 
that create them?  To conclude, I outline three contexts that I could not explore in 
depth in this study, but that highlight the broader sociological significance of the 
metabolic syndrome.  
Context of racial health disparities 
The first context for the significance of the metabolic syndrome is the use of 
the metabolic syndrome to represent and explain racial health disparities.  The scope 
and impact of chronic metabolic conditions has intensified in the United States, 
especially among America’s racial and ethnic minority groups.  Recent data from the 
Centers for Disease Control and Prevention (CDC), documents substantial and 
persistent racial disparities in the distribution of and complications from these major 
chronic metabolic conditions (CDC 2005).  Based on government data96, 27% of 
whites, 42% of African Americans, and 27% of Mexican Americans have 
hypertension or are currently taking anti-hypertensive medication 
This study suggests that the metabolic syndrome will continue to serve as a 
new way of representing and explaining racial inequalities in the politics of 
metabolism.  For decades social epidemiologists have documented substantial group 
disparities in the distribution of and complications from the major chronic metabolic 
health conditions that comprise the metabolic syndrome between America’s racial 




1995).  This research on racial health disparities reveals that African Americans and 
other racially categorized minority groups experience higher rates of death due to 
chronic metabolic diseases (Benjamin, Arnett, and Loscalzo 2005; Mokdad, Marks, 
Stroup, and Gerberding 2004; Zhang and Wang 2004) and higher rates of 
complications due for those diseases (Kington and Smith 1997), in large part due to 
the interactive dynamics of racism and social class on health (Clark, Anderson, Clark, 
and Williams 1999; Dressler 1993; Hayward, Crimmins, Miles, and Yang 2000; 
House 2001; House and Williams 1996; Krieger 1987; Krieger and Sidney 1998; 
Link and Phelan 1995; Marmot 2003; Smith and Hart 2002; Smith 1998; Williams 
1990; Williams and Collins 1995). 
This body of literature on racial health disparities has received less attention in 
terms of making a major theoretical contribution to critical race theory, science and 
technology studies, or political sociology, and instead has been more embraced in the 
fields of social epidemiology and public health. At its core, this research challenges 
the notion that racial health disparities are caused by natural and/or cultural 
differences between racially categorized groups.  These scholars have long argued 
that racial health disparities result from group-based inequalities in access to the 
economic and political resources necessary to maintain and improve health, like 
having access to affordable and adequate medical care.  
However, simply paying more attention to racially encoded health disparities 
in the context of the metabolic syndrome will not be enough.   Currently, scientific 
comparisons of racially categorized groups in the metabolic syndrome and its 




analysts often carry out their work with the purpose of devising better biomedical 
explanations for health disparities in heart disease, diabetes, and stroke.  Yet, the 
dubious theories of racial inequality and essentialist discourses of race that emerge 
from metabolic syndrome research on racial and ethnic groups have not been 
adequately addressed in the research literature on the metabolic syndrome.   
 
Context of colorblind racism 
A second important context for assessing the sociological significance of the 
metabolic syndrome is that of colorblind racism.   Colorblind racism is a new racial 
ideology that aims to explain racial inequality with reference to non-racial dynamics 
(Bonilla-Silva 2003; Brown et al. 2003; Guiner and Torres 2002).  Colorblindness is 
an ideology whose effect is to obscure the material practices of racism and racial 
structure.   Colorblind racism comprises four distinctive non-racial frames that social 
actors use to account for the effects of racially coded inequalities:  liberal 
individualism, cultural racism, and minimization of racism, and naturalization 
(Bonilla-Silva 2003).  Because the metabolic syndrome is constructed out of physical 
and biochemical markers, it is routinely interpreted as non-racial.  However, this 
study has shown how colorblind racism operates in the politics of metabolism by 
obscuring the multiple ways in which this ostensibly non-racial syndrome is, in fact, 
racialized.   
The discourse of the metabolic syndrome seems to draw upon each of these 
colorblind frameworks in specific ways.  First, liberal individualism is a political 




free-market economic system.  In terms of health, liberal individualism the stock 
stories (Guiner and Torres 2002) through which the role of individual responsibility is 
overemphasized in explaining group rates of chronic disease.  The millions of dollars 
spent on public health interventions in communities of color reflects the belief that 
causes of and solutions to racism in health is in people of color themselves (Guiner 
and Torres 2002).  The proliferation of techniques of examination and surveillance 
and the construction of risk-based syndromes for marking bodies becomes 
comprehensible only within this dominant ideological framework that views health an 
individual moral responsibility (Novas and Rose 2000).   
Second, cultural racism refers to the explanations of racial health disparities 
that reference to the “lifestyles” and corrupted cultures of racially categorized groups, 
without any reference to the broader systems of institutional power that structure 
access to health or opportunity (Satel 2000).  “Lifestyle” here explicitly refers to 
questions around individuals or groups’ patterns of daily life in terms of diet, 
nutrition, and exercise (Tesh 1988).   Third, minimization of racism is a frame that 
suggests that racism is no longer a reality that can impact the life chances of racially 
categorized minority groups.   While it is nearly impossible to maintain that racial 
health disparities do not exist, the metabolic syndrome can be constructed in ways 
statistically that seem to design racial health disparities in such a way as to minimize 
them wholesale.   As I described in chapter three, different definitions of the 
metabolic syndrome can produce different information about the prevalence of the 




scientists to construct so called racial differences in the metabolic syndrome in 
different ways for different purposes.    
Fourth, as I have described in detail in this study, naturalization is a 
framework of colorblind racism that explains racial inequality as an outcome of 
natural and inevitable processes.   The emergence of the metabolic syndrome 
represents an effort to naturalize a social and economic order that disproportionately 
increases rates of metabolic health problems in racially categorized groups.  Genetics 
research on racial disparities and the metabolic syndrome is one potent site where 
colorblind racism and naturalization seem to be operating in different forms. These 
interpretive practices reflect the long-standing assumption that race is essentially 
linked to natural, biological, and immutable differences through the attempt to map 
genetic differences onto racial difference, and vice versa.  This research often 
proceeds in the absence of any meaningful analysis of the economic and political 
arrangements that create racial health disparities.   
In the field of genetic epidemiology, which investigates the molecular 
underpinnings of common chronic diseases, conceptions of race are used as 
conceptual tools for categorizing and explaining different levels of population risk 
(Cooper, Kaufman, and Ward 2003). In a first example of naturalization, Loos and 
colleagues sampled genetic information from individual members of 105 self-
identified black and 99 white nuclear families in order to identify genomic regions 
harboring genes that may influence metabolic syndrome (Loos, Katzmarzyk, Rao, 




report their findings in a manner that strongly suggests that the black and white 
samples have mutually exclusive genomic profiles:  
Blacks and whites had no QTLs [quantitative trait loci] in 
common for PC1 or PC2 [the two principal components of a 
multivariate analysis of phenotypic characteristics].  Although 
this may be due to the lack of power in the black sample, it is 
also possible that the loci for blacks and whites are truly 
distinct. (Loos et al. 2003 :5941).  
A second example of naturalization comprises discourses of family history 
that construct race as scientifically valuable tool in the determination of genetic risks 
for heart disease without explicitly using discourses of race.  This family history 
approach argues that the systematic collection and interpretation of family history is 
the best technique for identifying individuals with genetic susceptibility to heart 
disease (Scheuner 2004).  This second genetic approach to the syndrome and race 
shifts the unit of analysis for assessing heart disease risk from the individual or 
population levels to the level of the nuclear family.  The discursive effect of this 
approach is that researchers use family and ethnicity as colorblind substitutions for 
race potentially in order to avoid charges of scientific racism.    
This method involves asking study participants specific questions concerning 
their nuclear and extended family’s burdens of chronic disease and classifying their 
responses into categories of risk.    This measure of family risk is then compared to 
the presence of the metabolic syndrome in a sample individual.  This technique has 




illnesses, like schizophrenia (Shih, Belmonte, and Zandi 2004).  The central 
assumption of this approach is that a family history of heart disease reflects the 
interaction of genetic, environmental, cultural, and behavioral risk factors that is 
shared among family members (Scheuner 2004 :2).  Despite Scheuner’s obvious care 
in not using race in his article, he believes the family history should include ethnicity 
and country of origin because certain conditions may be more prevalent in certain 
ethnic groups (Scheuner 2004:11).  
 A third colorblind approach of naturalization that is grounded in genetics 
involves tests of the theory of genetic admixture as an explanation for color-coded 
disparities in diabetes.  The theory of genetic admixture assumes that the genetic 
susceptibility of different populations to the risk factors that constitute the metabolic 
syndrome are determined by the extent of racial admixture in any given individual.  
The theory of genetic admixture maintains since Europeans have historically had 
higher rates of diabetes than racially categorized groups (e.g., African Americans, 
Latinos, and Native Americans), the increasing racial miscegenation that has occurred 
since the colonialism explains the increasing rates of diabetes in these minority 
groups (Tull and Roseman 1995).  The central assumption of this theory is that racial 
populations at an earlier moment in (pre) history were pure, distinctive, and 
segregated and it is their intermingling since the discovery of race that explains racial 
disparities in the contemporary moment times.  One way to think about this theory is 
of it as a reverse degeneracy theory, in which genetic intermingling with whites 
reduces the life chances of people of color, rather than having the normative effect of 





Context of intersectionality 
 A third important context for the significance of the metabolic syndrome is 
intersectionality.  Analyzing the politics of metabolism using an intersectional 
framework would investigate how systems of race, gender, age, social class, and 
nation operate together in shaping the biological realities, political rationalities, and 
economic opportunities presented by the emergence of the metabolic syndrome.  
Scholars like Janet Shim, Donna Haraway, Dorothy Roberts, and Laura Mamo have 
documented how science, medicine, and technology are involved in propagating 
systems of racial, gender, and sexual stratification.  For example, how did 
assumptions about gender shape the metabolic syndrome research of Jean Vague?   
The metabolic syndrome is associated with metabolic health conditions that 
disproportionately impact women of color especially heart disease, stroke, polycystic 
ovary syndrome, and or gestational diabetes.  The children of women with metabolic 
syndrome have become a new object of biomedical scrutiny because of research and 
theories linking gestational conditions prior to birth to the development of metabolic 
health problems later in life.  
 These interlocking systems of oppression are also important for another 
reason that directly relates to the interpretation of racial data on the metabolic 
syndrome.  Analysts have documented gender and class differences in the metabolic 
syndrome within racial and ethnic groups.  For example, African American women 
and poor African Americans are disproportionately classified with metabolic 




Metabolic syndrome researchers who are fixed on documenting and explaining racial 
and ethnic forms of difference while ignoring these important within-group 
differences may unwittingly interpret what are really gender or class differences as 
racial differences.  
 
Context of food and nutrition  
A final important context that highlights the significance of the metabolic 
syndrome is that of food politics and nutrition.  It is not possible to provide a critical 
interpretation of the politics of metabolism without recognizing and acknowledging 
the synergistic relationships between food politics and metabolic health problems.    
Not only are food politics critical to the politics of metabolism, Foucault argued that 
agricultural innovation is one of the central features of the emergence of biopower—
the power over food represents an emergent form of social control over life itself. The 
processed foods that are associated with the development of metabolic health 
problems have long been the objects of scientific study, government regulation, and 
corporate commodification within global capitalism.  The historical period during 
which time the metabolic syndrome emerged also brought radical global changes to 
the ways that food was produced, marketed, and distributed, which in turn, shape the 
distribution of metabolic health problems. Most prominently, in the 1930s, 40s, and 
50s, the privatization of food under conditions of global capital expansion led to the 
introduction of low-cost synthetic substitutes for raw sugar and vegetable oils.  
The significance of food politics is also apparent in stark contrast to the 




over people’s metabolic lives. Indeed, the economic interests of transgenic (which 
means both agricultural and pharmaceutical) corporations operate in our bodies and 
shape the politics of metabolism in ways that go beyond posing food and drugs as 
disconnected political issues.   If, as a society, we decided to invest in the sustainable 
production of foods that promote good metabolic health, as opposed to more and 
more killer applications, perhaps the politics of metabolism could begin to establish a 
context for human flourishing.  
 
The Metabolic Fetish 
Fetishism is about interesting “mistakes”—really denials—where a fixed 
thing substitutes for the doings of power-differentiated lively beings on 
which and on whom, in my view, everything actually depends. (Haraway 
1997: 135). 
 
The names, definitions, and theories of the metabolic syndrome have indeed 
changed over time, but the discursive formation of the metabolic syndrome has never 
been consistent with itself.  The category of the metabolic syndrome cannot contain 
the complexity and heterogeneity of its history and those social actors who 
participated in this complexity cannot contain its productive effects.  To conclude, let 
me reflect on the ontological and epistemological status of the metabolic syndrome.  
How can we know anything about the metabolic syndrome and in what ways does it 
exist?   Acting with the authority of scientific, state, and corporate power, social 
actors simply called the metabolic syndrome into existence within the government 
database, the corporate market report, and in the physiological substrata of bodies and 




hard for me to imagine at this point a more unabashedly constructed thing-in-itself.  
Any critical questions about the socially constructed nature of the syndrome and its 
implications for race and racism might be quickly subsumed in molecular, genetic, 
and biological discourses about its etiology and population distribution. If a person is 
classified and/or diagnosed with the syndrome, do they “have” it?  Of course, based 
upon this study the answer to this question is “no”.   
 My final interpretation centers on the fetishism of the syndrome--the denial, 
disavowal, and error that undergird its production in a racialized and biomedicalized 
politics of metabolism.  Situating the syndrome as a fetishized commodity helps to 
explain how this construct has become a new bright object in a biomedical gaze 
trained on metabolism.   The reified heat of the syndrome glows as brightly as an 
imploding star, and biomedical scientists, corporate benefactors, and government 
regulators shave been unable to avert their eyes from it.  In other words, while the 
metabolic syndrome does not exist as a thing-in-itself, scientists have constructed an 
epistemological framework in which claims about the metabolic syndrome have 
meaning for social actors and institutions that have an interest in the truth and validity 
of any such claims.  This study attempted to develop a critical relationship to the 
knowledge-making practices that have produced a viable epistemological framework 
for the metabolic syndrome that has afforded it a provisional legitimacy in the world 









Research methods, data sources, and procedures 
One of the main practical challenges of executing this study was how to 
transform the seemingly obtuse method of genealogical historiography into a set of 
procedures that I could follow consistently to analyze different kinds of documents 
and construct a critical narrative that demonstrated some of the relationships between 
the metabolic syndrome and race.   Indeed, Foucault was not forthcoming with a 
codified checklist of procedures a researcher might follow to conduct a genealogy, 
and since his death, his interpreters have continued to struggled to do the same.97   
With this challenge in mind, this appendix restates my genealogical approach to 
discourse analysis and elaborates on the data sources I drew upon to construct this 
genealogy.   I also use this appendix as a space to reflect on methodological roads not 




As I stated earlier, rather than only analyzing the meaning of a discourse, 
discourse analysis also analyzes the structure of the discursive themes by which a 
particular discourse is produced.  Specifically, discourse analysis asks three core 
questions about the production of discourses: (1) who produced the discourses and 
with what resources? (2) Under what political, economic, and historical conditions 
were the discourses produced? (3) How are the meanings of the discourse shaped by 




the discourse of metabolic syndrome emerged in ways that draw upon constructions 
of race in service of producing new meanings of race.  In each document I analyzed, 
my goal was to identify the explicit and implicit assumptions about race that 
structured the discourses, practices, and technologies of the metabolic syndrome.   
It is worth nothing that the theoretical frameworks that informed the study 
consistently shaped my thinking about which documents were important and the 
analytic procedures I used to highlight what might be important about a document. In 
other words, the multiple connections between theory, method, and data were 
exceptionally important in this case.  At different points throughout the study, 
particular ideas in critical race theory, biomedicalization, and biopower informed my 
interpretation of the discursive themes that were important to document in the 
genealogical narrative.  For example, from a critical race perspective, I was 
consistently interested in documenting any naturalizing discourses that constructed 
race as biological and genetic.   However, naturalization is also an important theme in 
the frameworks of biomedicalization and biopower.   Because naturalization is 
theoretically important within each of these frameworks, my analysis of the theme of 
naturalization took on greater significance as the study unfolded.  Consequently, I 
increasingly focused on discourses within documents that suggested this theme, and 
then tried to analyze those discourses in a consistent manner.  
 
Data Sources 
As I described in chapter one, I employed three basic strategies to traverse and 




overall purpose of this three-step process was to identify the primary documents that 
formed the evidentiary bedrock of my study.  As Table 1.1 suggests, thousands of 
research articles have been published on the metabolic syndrome, and while it was 
not possible or perhaps desirable to analyze all of the documents about the metabolic 
syndrome, it was important to establish a subset of this universe of documents to 
analyze in this study.   
 
Biomedical Research Documents 
First, I conducted extensive searches of multiple biomedical research 
databases in order to compile a comprehensive bibliography of documents pertaining 
to the metabolic syndrome and race.  This group of documents consists of peer-
reviewed research, reviews and commentaries on the metabolic syndrome and its 
connections to race published in academic and professional biomedical journals.  
Specifically, I repeatedly searched three prominent databases in this first strategy: (1) 
www.science.gov, the federal government’s central search engine for published 
scientific research both within and outside the purview of the government and its 
scientific agencies; (2) Medline and PubMed™ Central, the premier bibliographic 
databases for the National Library of Medicine of the National Institutes of Health; 
and (3) ISI Web of Science, Science Citation Index.  As my research continued, I also 
created publication alerts for the metabolic syndrome, which are search tools that 
emails the user when a document is published that makes reference to a particular set 
of search terms.    This tool was extremely useful, as I was able to reference many 




A second strategy was to use the ISI Web of Science cited citations index to 
conduct citation counts on the published documents I found on the metabolic 
syndrome and race to determine the extent to which a particular document has 
traveled and gained scientific currency throughout biomedicine.  I employed this 
strategy in the full recognition that some sites of biomedical knowledge production 
have more political and scientific influence than others, and that not all journals are 
included in the ISI science citations index.  For instance, a document published by 
one of the National Institutes of Health wields more influence than a document 
published in a relatively obscure biomedical journal that deals with a narrow subject 
matter.  When appropriate, I made reference to this information throughout the study.   
However, I do not feel that this technique was as useful as I had thought it 
might be because the production and consumption of a discourse are not one and the 
same process.  For example, a document that is published in a specialized biomedical 
journal may not have been widely cited, but specialists in that subfield may consume 
and use the ideas contained in the document in ways that do not involve academic 
citation (e.g. practicing physicians may use that information in their practice, but 
never publish any research that cites that usage).  One way to frame the limitations of 
this particular method is that citation counts are not meant to account for the 
polyvalence of discourses—they only assume one valid and legitimate usage of 






 A third strategy was to place special emphasis on the relatively smaller 
number of government and corporate documents.  The corporate documents consist of 
published documents pertaining to AstraZeneca’s Galaxy Program, Crestor™, 
including published clinical trial research, study documentation, regulatory 
submissions and letters to the FDA on behalf of AstraZeneca.   I also collected 
documents that pertained to the research and development of antipsychotics.   While I 
monitored and collected corporate documents relating to corporate practices relating 
to the metabolic syndrome and race that emerged over time, my analysis of racial 
pharmacology and killer applications focused more on published research articles in 
pharmacology and psychopharmacology journals.   Because my study increasingly 
focused on the construction of racial meaning, published biomedical documents were 
a more useful kind of data for this kind of analysis.    
 
Government Documents 
 The third group of primary documents consists of U.S. federal science 
policies, regulatory documents, administrative guidelines, and scientific documents 
that pertain to the conduct of biomedical research and clinical trials in the U.S.  I 
analyzed these government documents in so far as they provide the overall regulatory 
context for the collection, standardization, and reporting of racial and biomedical data 
in all federal research on the metabolic syndrome.  I considered the regulatory impact 
of four specific federal policies.  The first policy is the National Health Survey Act of 




and current statistical information on the amount, distribution, and effects of illness 
and disability in the U.S. and the services rendered for such conditions.98  This act led 
to the creation of the National Health Interview Survey (NHIS), first conducted in 
1957, the National Health Examination Survey (NHES) beginning in 1960, and the 
National Health and Nutrition Examination Survey (NHANES), which began in 1967.   
These government studies have been and still are the largest population health 
surveys conducted in the U.S., while the government has also funded many smaller 
yet still influential population health surveys over the past 50 years.99  
 The second policy is the 1997 Office of Management and Budget (OMB) 
regulations for the collection and presentation of federal data on race and ethnicity 
(Office of Management and Budget 1997). This regulation applies to all federal data 
collection efforts, including clinical and biomedical research sponsored by the NIH 
and FDA.  According to the regulations, the U.S. government and its agencies 
consider self-identification as the preferred means of obtaining information about an 
individual’s race and ethnicity.  The regulations provide the minimum number of 
racial categories that must be used to ensure compliance with various civil rights 
statutes. 100  The OMB stresses that the racial and ethnic categories it recommends 
represent social-political constructs, and are not anthropologically or scientifically 
based (OMB 1997). The federal regulation of race provides a uniform, standardized, 
and common language for defining the major population groups of the country (OMB 
1997).   
 The context and substance of the first two shapes the context and substance of 




Health guidelines on the inclusion of women and racial groups as subjects in clinical 
research (NIH 2001).   These guidelines mandate that women and members of 
minority groups and their subpopulations be included in all NIH-supported 
biomedical research projects involving human subjects, unless a clear and compelling 
rationale and justification establishes to the satisfaction of the relevant 
Institute/Center Director that inclusion is inappropriate with respect to the health of 
the subjects or the purpose of the research.   The fourth policy is the 2005 FDA 
guidance statement for the pharmecutical industry on the collection of race and 
ethnicity data in clinical trials (Food and Drug Administration 2005).   This 
regulatory guidance statement says that drug companies must follow the NIH 
guidelines on the inclusion of racial and ethnic groups and use the OMB definitions 
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Sciences 11:159-170; Mahon, Michael. 1992. Foucault's Nietzschean genealogy: 
truth, power, and the subject. Albany: State University of New York Press; May, 
Todd. 1993. Between Genealogy and Epistemology: Psychology, Politics, and 
Knowledge in the Thought of Michel Foucault: Pennsylvania State University Press; 
Meadmore, Daphne, Caroline Hatcher, and Eric McWilliam. 2000. "Getting tense 
about genealogy." Qualitative Studies in Education 13:463-476; Prado, C.G. 2000. 
Starting with Foucault: An introduction to genealogy. Boulder, CO: Westview Press; 




                                                                                                                                      
International studies in philosophy 22:129-141; Shiner, Larry. 1982. "Reading 
Foucault: Anti-Method and the Genealogy of Power-Knowledge." History and 
Theory 21:382-398; and Visker, Rudi. 1995. Michel Foucault: genealogy as critique. 
Translated by C. Turner. London: Verso..  
22 These are known as the prescriptive effects of the jurisdiction of power and the 
effects of the veridiction of truth, respectively. 
23 Foucault euphemistically calls this network of power/knowledge relationships the 
“hazardous play of dominations” (Foucault 2003[1971]: 357).  In his thinking, this 
play of dominations manifests itself in the rituals and practices of bodies and laws and 
regulations that impose various rights and obligations on bodies (Foucault, Michel. 
2003[1971]. "Nietzsche, Genealogy, History." Pp. 351-369 in The Essential Foucault 
edited by P. Rabinow and N. Rose. New York: The New Press.) 
24 For the articulation of discourse analysis I use in this study, see (Clarke, Adele E. 
2005. Situational Analysis: Grounded theory after the postmodern turn. Thousand 
Oaks: Sage Publications.) 
25 Clinical pharmacology is the branch of biomedicine that studies the intended and 
unintended effects of drugs on the body.    
26 There is a voluminous body of knowledge about the history, philosophy, and 
politics of race in science over the past 20 years.  Some outstanding sources on these 
issues are: Duster, Troy. 2003 [1990]. Backdoor to Eugenics. New York: Routledge; 
Graves, Jospeh L. Jr. 2001. The Emporer's New Clothes: Biological Theories of Race 
at the Millenium. Brunswick, NJ: Rutgers University Press; Harding, Sandra. 1993. 




                                                                                                                                      
Indiana University Press; Paul, Diane. 1998. The Politics of Heredity: Essays on 
Eugenics, Biomedicine, and the Nature-Nurture Debate. Albany: SUNY Press; 
Stephan, Nancy Leys. 1982. The idea of race in science. Hamden, CT: Archon 
Books; and Zack, Naomi. 2002. Philosophy of Science and Race. London: Routledge. 
27 This is the shift that historian Elazar Barkan famously described as the retreat of 
scientific racism which refers to physical anthropology’s adoption of the concepts, 
methods and theories of population genetics (Barkan, E. 1992. The Retreat of 
Scientific Racism: Changing Concepts of Race in Britain and the United States 
between the World Wars) 
28 In a more lyrical way, Goldberg explains “the “primitive” is the romantic 
fabrication of and longing for an original human subjectivity, pristine in its 
representation” (Goldberg 2002: 202).  For more on scientific discourses of 
primitivism, see Haraway, Donna. 1989. Primate Visions: Gender, Race, and Nature 
in the World of Modern Science. New York: Routledge. 
29 At least since Omi and Winant, contemporary critical race theorists have 
recognized the centrality of the state to racial formation (see Goldberg, David Theo. 
2002. The Racial State. Malden, MA: Blackwell Publishers; Omi, Michael and 
Howard Winant. 1994. Racial Formation in the United States. New York: Routledge; 
and Stevens, Jacqueline. 2003. "Racial Meanings and Scientific Methods: Changing 
Policies for NIH-Sponsored Publications Reporting Human Variation." Journal of 
Health Politics, Policy and Law 28:1033-1087.) 
30 The 1790 census asked five questions: the number of free white males over 16 




                                                                                                                                      
31 I discuss these specific regulations in chapter three in the context of the metabolic 
syndrome.  
32 The Food and Drug Administration enforces similar guidelines regarding the 
inclusion of women and racial minorities in drug clinical trials.   I discuss these 
regulatory guidelines in chapter four.  
33  Several other scholars have examined the use of race and ethnicity in 
pharmacological research and development.  See Duster, Troy. 2005. "Race and 
Reification in Science." Science 307:1050-1051; Gannett, Lisa. 2005. "Group 
Categories in Pharmacogenetics Research." Philosophy of Science 72:1232-1247; 
Lee, Sandra Soo-Jin. 2005. "Racializing Drug Design: Implications of 
Pharmacogenomics for Health Disparities." American Journal of Public Health 
95:2133-2138; and Sankar, Pamela and Jonathan Kahn. 2005. "BiDil: Race Medicine 
Or Race Marketing?" Health Affairs: 54-55. 
34 I explore this dynamic of biopower in chapter four, when I examine prescription 
drugs as a means of extracting both knowledge and profit from bodies.   
35 Biological theories of race, produced as part of the disciplinary knowledges of 
biopower, were mobilized to rationalize the expansionism and exploitation that 
accompanied colonialism and slavery.  As I discussed in the critical race theory 
framework, scientific racism operated by deploying scientific justifications for racial 
conquest and domination. 
36 For more on the links between biological theory, eugenics, and race see Duster, 
Troy. 2003 [1990]. Backdoor to Eugenics. New York: Routledge, Graves, Jospeh L. 




                                                                                                                                      
Brunswick, NJ: Rutgers University Press, Paul, Diane. 1998. The Politics of Heredity: 
Essays on Eugenics, Biomedicine, and the Nature-Nurture Debate. Albany: SUNY 
Press, Weingart, Peter. 1998. "The Thin Line between Eugenics and Preventive 
Medicine." in Xenophobia in Germany and the United States, edited by N. Finzsch 
and D. Schirmer. Cambridge: Cambridge University Press, Zuberi, Tukufu. 2001. 
Thicker than Blood: An Essay on How Racial Statistics Lie. Minneapolis: University 
of Minnesota. 
37 The analysis of emergence situates the emergence of a practice or discourse within 
in a broader network of institutionally based power/knowledge relationships. For 
more on the genealogical analysis of emergence, please reference my discussion in 
chapter one.  
38 I have selected the year of 1956 as a way to mark the publication of the research of 
Jean Vague, a French physician whose work on metabolism is considered by many 
metabolic syndrome scientists to be foundational to the new field.  I discuss Dr. 
Vague’s work in several points throughout the chapter.  
39 Researchers at the Metabolic Syndrome Institute, a web-based organization of 
biomedical researchers whose primary goal is to promulgate the idea of the metabolic 
syndrome, attribute the concept to Dr. Vague.  Several prominent metabolic 
syndrome researchers belong this group, including Dr. Scott Grundy 
(http://www.metabolic-syndrome-institute.org/medical_information/history/#lien_a 
accessed December 20, 2006.).  Indeed many others note the centrality of Dr. 




                                                                                                                                      
40 The Islets of Langerhans are a part of the pancreas that is responsible for insulin 
production.  
41 The National Heart Institute is the institutional precursor to the National Heart, 
Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH).    
42 The Framingham study sample consisted of 5,209 ‘white’ men and women (30-62) 
living in Framingham MA; (1971) 5,124 of their children and spouses, and then their 
grandchildren in 2005. 
43 (www.cdc.gov/nchs/about/major/nhis/hisdesc.htm accessed on October 23, 2006). 
44 See my discussion of these population heart studies later in this section.  
45 (http://www2.merriam-webster.com/cgi-bin/mwmednlm) accessed on March 5, 
2009 at 4:25pm.  
46 In 1993, this construct gets revived by Descovich and colleagues in a book edited 
by Crepaldi himself (Descovich, G.C., B. Benassi, V. Canelli, S. D'Addato, G. De 
Simone, and A.  Dormi. 1993. "An epidemic view of the plurimetabolic syndrome." 
in Diabetes, Obesity, and Hyperlipidemia: The plurimetabolic syndrome, edited by G. 
Crepaldi, A. Tiengo, and E. Manzato. Amsterdam: Elsever Science.) 
47 The Banting Lecture is published annually in the journal Diabetes, which is the 
flagship journal of the American Diabetes Association.  As of August 19, 2008, 
Reaven’s published lecture had been cited 5,953 times.  
48 In the 1980s, three groups of researchers created three new techniques for 
measuring insulin resistance.  DeFronzo and colleagues developed the “euglycemic 
hyperinsulinemic clamp technique” in 1983, and it still is the gold-standard procedure 




                                                                                                                                      
Koivisto. 1983. "New concepts in the pathogenesis and treatment of noninsulin-
dependent diabetes mellitus." The American Journal of Medicine 74:52-81.)  Other 
noteworthy techniques include the “homeostasis model assessment-insulin resistance 
index” (Matthews, DR, JP Hosker, AS Rudenski, BA Naylor, DF Treacher, and RC. 
Turner. 1985. "Homeostasis model assessment: insulin resistance and beta-cell 
function from fasting plasma glucose and insulin concentrations in man." 
Diabetologia 28:412-419.) and the “oral glucose tolerance test” (Belfiore, Francesco, 
Silvia Iannello, and Giovanni Volpicelli. 1998. "Insulin Sensitivity Indices Calculated 
from Basal and OGTT-Induced Insulin, Glucose, and FFA Levels." Molecular 
Genetics and Metabolism 63:134-141.) 
49 In this simple schema, three points are awarded if your fasting glucose is greater 
than 11, or your glucose at two hours into the Glucose Tolerance Test is greater than 
140; fasting triglyceride level is greater than 200; fasting HDL-cholesterol levels is 
lower than 35; blood pressure is greater than 145/90.  You earn one point if your 
weight check reveals you are more than 15 pounds overweight; family has a history 
of heart disease, high blood pressure (hypertension) or diabetes; lifestyle is 
characterized by physical inactivity in both work and leisure hours. Your risk of 
having a heart attack triggered by syndrome X can be low (0-4 points), moderate (5-8 
points), high (9-12), and very high (13 or more). (Adapted from Reaven, Strom, and 
Fox 2000: 68). 
50 (http://www.icd9data.com/2009/Volume1/240-279/270-279/277/277.7.htm) 




                                                                                                                                      
51 Recall from chapter one that a second methodological strategy was to use the ISI 
Web of Science cited citations index to conduct citation counts on the published 
documents I found on the metabolic syndrome and race to determine the extent to 
which a particular document has traveled and gained scientific currency throughout 
biomedicine.  
52 I discuss AstraZeneca again in chapter four because they are the producers of 
Crestor, a cholesterol lowering medication that has been studied in populations 
classified with the metabolic syndrome.  
53 The proinflammatory state refers to elevated levels of C-reactive protein, another 
biochemical that has been associated with the metabolic syndrome.    
54 See the forthcoming section titled “The New Special Populations”.  
55 (http://www.nlm.nih.gov/medlineplus/metabolicsyndrome.html) accessed on 
February 13, 2009 at 10:23 am.  
56 (http://www.nhlbi.nih.gov/health/dci/Diseases/ms/ms_whatis.html) accessed on 
May 4, 2009 at 4:30pm.  
57 See Figures 3.2 and 3.3.  
58 Several other studies illustrate the general argument presented here. See, for 
example: MESA (Multiethnic Study of Athlerosclerosis)—Bild DE, Bluemke DA, 
Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jr. Jacob DR, 
Kronmal R, Liu K, Nelson JC, O'Leary D, Saad MF, Shea S, Szklo M, and Tracy RP. 
2002. "Multi-ethnic study of atherosclerosis: objectives and design." American 
Journal of Epidemiology 156:871-881; and IRAS (Insulin Resistance and 




                                                                                                                                      
Mykkanen, Russell P. Tracy, and Steven M. Haffner. 2000. "Chronic Subclinical 
Inflammation as Part of the Insulin Resistance Syndrome: The Insulin Resistance 
Atherosclerosis Study (IRAS)." Circulation 102:42-47. 
59 I will discuss the theory of genetic admixture in the final part of section two, The 
New Special Populations Research. (www.clinicaltrials.gov/ct/show/NCT00005146) 
retrieved on February 13, 2009.  
60 (www.clinicaltrials.gov/ct/show/NCT00005146) retrieved on February 13, 2009.  
61 (http://www.cardia.dopm.uab.edu/lad_info.htm) accessed on February 16, 2009 at 
2:08pm.  
62 (http://www.cscc.unc.edu/aric/) accessed on February 16, 2009 at 2:51 pm.  
63 (http://jhs.jsums.edu/jhsinfo/) accessed on February 16, 2009 at 3:23 pm.  
64 (http://www.nhlbi.nih.gov/about/jackson/2ndpg.htm) accessed on February 16, 
2009 at 2:59 pm.  
65 These four studies are not exhaustive of the population studies that incorporate 
measurements of the metabolic syndrome in racially categorized groups.  The 
Multiethnic Study of Atherosclerosis and the National Health and Nutrition 
Examination Study are two other studies that meet these criteria.  
66 According to an NIDDK website on the special role the Pima have played in 
government biomedical research on diabetes, “This cooperative search between the 
Pima Indians and the NIH began in 1963 when the NIDDK (then called the National 
Institute of Arthritis, Diabetes and Digestive and Kidney Diseases), made a survey of 
rheumatoid arthritis among the Pimas and the Blackfeet of Montana. They discovered 




                                                                                                                                      
Institute, the Indian Health Service, and the Pima community set out to find some 
answers to this mystery” 
(http://diabetes.niddk.nih.gov/dm/pubs/pima/pathfind/pathfind.htm) accessed on 
February 16, 2009.  
67 In chapter five, I briefly discuss how ideas about family intersect with race and 
ethnicity in the context of colorblindness, but I wanted to note their historical 
deployment here by Reaven. 
68 The International Society on Hypertension in Blacks (ISHIB), Inc, publishes 
Ethnicity & Disease. 
69 I will talk more about the published research of members of the AALCC in Chapter 
Four.  See Clark, L. T. and F. El-Atat. 2007. "Metabolic syndrome in African 
Americans: Implications for preventing coronary heart disease." Clinical Cardiology 
30:161-164; Ferdinand, KC, LT Clark, KE Watson, RC Neal, CD Brown, BW Kong, 
BO Barnes, WR Cox, FJ Zieve, J Ycas, PT Sager, and A Gold. 2006. "Comparison of 
efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in 
a six-week randomized trial." American Journal of Cardiology 97:229-235; Grundy, 
Scott M., James I. Cleeman, C. Noel Bairey Merz, H. Bryan Brewer, Jr., Luther T. 
Clark, Donald B. Hunninghake, Richard C. Pasternak, Sidney C. Smith, Jr., and Neil 
J. Stone. 2004. "Implications of Recent Clinical Trials for the National Cholesterol 
Education Program Adult Treatment Panel III Guidelines." Circulation 110:227-239; 
and Smith, Sidney C, Stephen R Daniels, Miguel A Quinones, Shiriki K Kumanyika, 
Luther T Clark, Richard S Cooper, Elijah Saunders, Elizabeth Ofili, and Eduardo J 




                                                                                                                                      
Health Summit 2003: report of the Obesity, Metabolic Syndrome, and Hypertension 
Writing Group." Circulation 111:e134-e139.    
70 Recall that the San Antonio Heart Study was designed to assess the degree of 
genetic admixture as well.  
71 I draw these highlights from several published articles and reports on these 
technologies.  Sarafidis, Panteleimon A. and Peter M. Nilsson. 2006. "The metabolic 
syndrome: a glance at its history." Journal of Hypertension 24:621-626. National 
High Blood Pressure Education Program, NHBPEP and Lung National Heart, and 
Blood Institute, NHLBI. 2002. "Summary Report: Working Meeting on Blood 
Pressure Measurement." National Institutes of Health, Bethesda, MD.  Kuczmarski, 
Robert J and Katherine M Flegal. 2000. "Criteria for definition of overweight in 
transition: background and recommendations for the United States." American 
Journal of Clinical Nutrition 72:1074-1081. 
72 Recall from chapter one that the analysis of descent traces the multiple sites of 
knowledge production by documenting the actual research instruments, procedures, 
and practices used in the study of the body. 
73 There are other candidate drugs that could be examined here as well.  The 
metabolic syndrome is increasingly used to refer to new drug targets, or new 
laboratory markers that reflect the efficacy of drug therapies.  See Giugliano, Dario, 
Antonio Ceriello, and Katherine Esposito. 2008. "Are there specific treatments for the 
metabolic syndrome?" American Journal of Clinical Nutrition 87:8-11; Grundy, Scott 
M., James I. Cleeman, C. Noel Bairey Merz, H. Bryan Brewer, Jr., Luther T. Clark, 




                                                                                                                                      
Stone. 2004. "Implications of Recent Clinical Trials for the National Cholesterol 
Education Program Adult Treatment Panel III Guidelines." Circulation 110:227-239; 
Grundy, Scott M. T. . 2006. "Drug therapy of the metabolic syndrome minimizing the 
emerging crisis in polypharmacy." Nature Reviews Drug Discovery 5:295-315; 
Jacobson, T. A., C. C. Case, S. Roberts, A. Buckley, K. M. Murtaugh, J. C. Y. Sung, 
D. Gause, C. Varas, and C. M. T. "Characteristics of U. S. adults with the metabolic 
syndrome and therapeutic implications." Diabetes, Obesity & Metabolism 6:353; and 
Lesko, L. J. and Aj T.  Atkinson. 2001. "Use Of Biomarkers in Development, 
Surrogate Endpoints In Drug Regulatory Decision Making: Criteria, Validation 
Strategies." Annual Review of Pharmacology & Toxicology 41:347-66. 
74  The case of antiretroviral drugs that treat HIV infection could have also been 
analyzed here.  Many HIV drugs have metabolic side effects and the metabolic 
syndrome is also being deployed to describe these effects.  See Hadigan, C., J. B. 
Meigs, C. Corcoran, P. Rietschel, S. Piecuch, N. Basgoz, B. Davis, P. Sax, T. Stanley, 
P. W. F. Wilson, R. B. D'Agostino, and S. Grinspoon. 2001. "Metabolic abnormalities 
and cardiovascular disease risk factors in adults with human immunodeficiency virus 
infection and lipodystrophy." Clinical Infectious Diseases 32:130-139; Murata, H., P. 
W. Hruz, and M. Mueckler. 2000. "The mechanism of insulin resistance caused by 
HIV protease inhibitor therapy." Journal of Biological Chemistry 275:20251-20254; 
and Safrin, S. and C. Grunfeld. 1999. "Fat distribution and metabolic changes in 
patients with HIV infection." Aids 13:2493-2505. 
75 On July 15, 2002, the Diabetes Mellitus Interagency Coordinating Committee, held 




                                                                                                                                      
Maryland to discuss “Macrovascular Disease and Diabetes: Translation Issues.”  The 
committee brought together representatives from various the Institutes of Health, the 
Centers for Disease Control, academic biomedicine, and the pharmaceutical industry 
to “determine the means and methods for translating the current scientific data from 
clinical trials and epidemiological studies to diabetes patients and the general public” 
(DMICC 2002:1).  The committee’s responsibilities are to tell Americans about “an 
increased relative risk of cardiovascular disease (CVD) for those individuals who 
have been diagnosed with diabetes or pre-diabetes” (DMICC 2002:1) and to propose 
ways that the government, biomedicine, and the pharmaceutical industry might work 
together to help in the translation effort.  
76 Haraway uses the term in the following manner.  She writes, “Software sufficiently 
powerful to revolutionize how computers are used—that is, how further hybrids of 
human and nonhumans take shape and act—are, unfortunately, called, killer 
applications.  Comparable only to the importance of the word-processor and 
spreadsheet software, Mosaic-like browsers are likely to be such “killer applications” 
that reconfigure practice in an immense array of domains.  Mosaic was about the 
power to make hypertext and hypergrahic connections of the sort that produce the 
global subject of technoscience as a potent form of historical, contingent, specific 
human nature at the end of the millennium.  Contesting how such subjects and 
hybrids are put together and taken apart is a critical feminist technoscientific practice” 




                                                                                                                                      
77  #1 Lipitor for cholesterol--74.8 million prescriptions; #4 Norvasc for hypertension 
and angina--38.3 million prescriptions; #5 Toprol-XL for hypertension 35 million; #7 
Zocor for hypertension 29.6 million.  
78 These FDA guidelines advocate the use of the Office of Management and Budget 
racial categories I discussed earlier in chapter two. 
79 (http://www.nlm.nih.gov/medlineplus/ency/article/00685.htm accessed on August 
23, 2008 at 11:26am).  
80 (www.fda.gov/fsn accessed on August 22, 2008—Show #28, June 2004) 
81 Data collected from Appendix A, Table A-2 of this document.  
82 The term “statins” refers to a class of drugs that are hydroxylmethl glutaryl 
coenzyme A (HMG CoA) reductase inhibitors. 
83 The six statins in order of their FDA approval are: Mevacor (lovastatin), Lescol 
(fluvastatin), Lipitor (atoravastatin), Zocor (simvastatin), Pravachol (pravastatin), and 
Crestor (rosuvastatin).  
84 LDL, or low-density lipoprotein, is the so called bad cholesterol that has long been 
considered a risk factor for heart disease and stroke.   
85(www.astrazeneca-us.com/modules/PRMS/display.asp?id-591959 accessed on 
October 23, 2006).  The Galaxy Program has included over 50,000 research subjects 
in 50 nations.  
86 The ARIES (2) The STARSHIP Study (Study Assessing Rosuvastatin in Hispanic 
Population) Lloret, R, J Ycas, M Stein, and SM Haffner. 2006. "Comparison of 




                                                                                                                                      
American Journal of Cardiology 98:768-773. and (3) The IRIS Study (Investigation 
of Rosuvastatin in South Asian Subjects). 
87 ARIES was conducted from March 2002-December 2003 at 76 academic and 
clinical research centers in the United States. 
88 Research subjects were recruited from the practices of physicians who participated 
in the study and all had been on either diet or drug therapy for high cholesterol during 
the previous three months.   The physician sample (n=401) was drawn from a larger 
pool of practicing doctors who represented the top 26% of statin prescribers who 
worked under the auspices of IMS Health (based in Westport, CT).  These doctors 
were responsible for 55% of prescriptions for lipid-lowering drugs in 2002.  The 
doctors included in the sample may be what the authors call “enthusiasts” who may 
manage lipids more aggressively than average. 
89 The investigators considered simvastatin and atoravastin “high-efficacy statins.” 
90 This is my estimate complied from these sources. Direct costs include the costs of 
physicians and other professionals, hospital and nursing home services, the cost of 
medications, home health care and other medical goods.  In direct costs refer to lost 
economic productivity due to premature disease and death.  
91 See my discussion of racial essentialism and naturalization in chapter two under 
framework of critical race theory.  
92 See chapter three for more on these genetic theories of race and the syndrome.     
93 The history and philosophy of race in science is an interdisciplinary body of 
scholarship from epidemiology, sociology, biology, philosophy, legal studies, and 




                                                                                                                                      
race in science and medicine are: Cooper, Richard S., Jay S. Kaufman, and Ryk 
Ward. 2003. "Race and Genomics." New England Journal of Medicine 348:1166-
1175; Duster, Troy. 2003a. "Buried Alive: The Concept of Race in Science." Pp. 258-
277 in Genetic Nature / Culture: Anthropology and Science Beyond the Two-Culture 
Divide, edited by A. H. Goodman, D. Heath, and M. S. Lindee. Berkeley and London: 
University of California Press; Duster, Troy. 2005. "Race and Reification in Science." 
Science 307:1050-1051; Fausto-Sterling, Anne. 2004. "Refashioning Race: DNA and 
the Politics of Health Care." differences: A Journal of Feminist Cultural Studies 15:1-
37; Gannett, L. 2001. "Racism and human genome diversity research: The ethical 
limits of "population thinking."" Philosophy of Science 68:S479-S492; Gannett, L. 
2004. "The biological reification of race." British Journal for the Philosophy of 
Science 55:323-345; Ossorio, Pilar and Troy Duster. 2005. "Race and Genetics: 
Controversies in Biomedical, Behavioral, and Forensic Sciences." American 
Psychologist 60:115;  Rabinow, Paul and Nikolas Rose. 2003. "Some Thoughts on 
Biopower Today." in Vital Politics: Health, Medicine, and Bioeconomics into the 
Twenty First Century. London School of Economics; Smedley, Audrey and Brian D. 
Smedley. 2005. "Race as Biology Is Fiction, Racism as a Social Problem Is Real." 
American Psychologist 60:16-26. 
94 See Feder, Ellen K. 2004. "Race, Biopower, and The Dangerous Individual." 
Radical Philosophy Review; McWhorter, Ladelle. 2004. "Sex, Race, and Biopower: A 
Foucauldian Geneaology." Hypatia 19:38-62; Rai, A. S. 2004. "Of monsters - 
Biopower, terrorism and excess in genealogies of monstrosity." Cultural Studies 




                                                                                                                                      
Foucault's History of Sexuality and the Colonial Order of Things. Durham: Duke 
University Press. 
95 For several examples of this scholarship in the field of science and technology 
studies, see Briggs, C. L. 2005. "Communicability, racial discourse, and disease." 
Annual Review of Anthropology 34:269-291; Franklin, Sarah and Margaret M. Lock. 
2003. "Remaking Life & Death: Toward an Anthropology of the Biosciences." in 
School of American Research Advanced Seminar Series; Haraway, Donna J. 1997. 
Modest_Witness@Second_Millennium. FemaleMan_Meets_OncoMouse. New York, 
NY: Routledge; Melbourne, Tapper. 1995. "Interrogating Bodies: Medico-Racial 
Knowledge, Politics, and the Study of a Disease." Comparative Studies in Society and 
History 37:76-93; Orr, Jackie. 2006. Panic Diaries: A Genealogy of Panic Disorder. 
Durham: Duke University Press; Reardon, Jennifer. 2005. Race to the Finish: Identity 
and governance in an age of genomics. Princeton, NJ: Princeton University Press; 
Rose, Nikolas. 2001. "The Politics of Life Itself." Theory, Culture, and Society 18:1-
13; and Shim, Janet K. 2000. "Bio-power and Racial, Class, and Gender Formation in 
Biomedical Knowledge Production." Research in the Sociology of Health Care 
17:175-195. 
96 I compiled these prevalence data from the third (1999-2002) National Health and 
Nutrition Examination Survey.  NHANES III (1988-94) is the seventh in a series of 
government epidemiological surveys designed to provide national estimates of the 
health and nutritional status of the civilian non-institutionalized population of the 
U.S.  The NHANES III included about 40,000 participants, including, for the first 




                                                                                                                                      
97 See my discussion of the challenges of defining genealogy in chapter two.  
Scholars and theorists from a range of disciplines, including Foucault himself, have 
struggled to craft a clear procedure for what a genealogy ought to entails.  
98 (www.cdc.gov/nchs/about/major/nhis/hisdesc.htm accessed on October 23, 2006). 
99 See Table 3.6.  
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